
<html lang="en"     class="pb-page"  data-request-id="7ae534ad-a810-489b-922f-0e840e9a52d8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b00933;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel" /></meta><meta name="dc.Creator" content="Eva  Caroff" /></meta><meta name="dc.Creator" content="Francis  Hubler" /></meta><meta name="dc.Creator" content="Emmanuel  Meyer" /></meta><meta name="dc.Creator" content="Dorte  Renneberg" /></meta><meta name="dc.Creator" content="Carmela  Gnerre" /></meta><meta name="dc.Creator" content="Alexander  Treiber" /></meta><meta name="dc.Creator" content="Markus  Rey" /></meta><meta name="dc.Creator" content="Patrick  Hess" /></meta><meta name="dc.Creator" content="Beat  Steiner" /></meta><meta name="dc.Creator" content="Kurt  Hilpert" /></meta><meta name="dc.Creator" content="Markus A.  Riederer" /></meta><meta name="dc.Description" content="Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause ..." /></meta><meta name="Description" content="Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 18, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00933" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00933" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00933" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00933" /></link>
        
    
    

<title>4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00933" /></meta><meta property="og:title" content="4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0018.jpeg" /></meta><meta property="og:description" content="Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y12 antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma. Herein we present the optimization steps that led to the discovery of clinical candidate ACT-246475 (30d). The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent molecules of the program. In addition, low in vivo clearance in rat and dog was achieved for the first time. Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45). Compound 30d showed efficacy in the rat ferric chloride thrombosis model when administered intravenously as parent or orally as its prodrug 45. Moreover, 30d displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00933"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00933">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00933&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00933&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00933&amp;href=/doi/10.1021/acs.jmedchem.5b00933" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9133-9153</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01375" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00928" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">4-((<i>R</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y<sub>12</sub> Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva++Caroff">Eva Caroff</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francis++Hubler">Francis Hubler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuel++Meyer">Emmanuel Meyer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorte++Renneberg">Dorte Renneberg</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carmela++Gnerre">Carmela Gnerre</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Treiber">Alexander Treiber</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus++Rey">Markus Rey</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Hess">Patrick Hess</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beat++Steiner">Beat Steiner</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kurt++Hilpert">Kurt Hilpert</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus+A.++Riederer">Markus A. Riederer</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Drug Discovery and Preclinical Research and Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland</span></div><div class="corresp-info"><strong>*</strong>Phone: +41 61 565 62 31. Fax: +41 61 565 65 00. E-mail: <a href="/cdn-cgi/l/email-protection#6f0a190e410c0e1d0009092f0e0c1b0a03060001410c0002"><span class="__cf_email__" data-cfemail="6a0f1c0b44090b18050c0c2a0b091e0f0603050444090507">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00933&amp;href=/doi/10.1021%2Facs.jmedchem.5b00933" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9133–9153</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 9, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 June 2015</li><li><span class="item_label"><b>Published</b> online</span>18 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00933" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00933</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9133%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEva%2BCaroff%252C%2BFrancis%2BHubler%252C%2BEmmanuel%2BMeyer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D23%26contentID%3Dacs.jmedchem.5b00933%26title%3D4-%2528%2528R%2529-2-%257B%255B6-%2528%2528S%2529-3-Methoxypyrrolidin-1-yl%2529-2-phenylpyrimidine-4-carbonyl%255Damino%257D-3-phosphonopropionyl%2529piperazine-1-carboxylic%2BAcid%2BButyl%2BEster%2B%2528ACT-246475%2529%2Band%2BIts%2BProdrug%2B%2528ACT-281959%2529%252C%2Ba%2BNovel%2BP2Y12%2BReceptor%2BAntagonist%2Bwith%2Ba%2BWider%2BTherapeutic%2BWindow%2Bin%2Bthe%2BRat%2BThan%2BClopidogrel%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9153%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00933"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2449</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">28</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00933" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Caroff&quot;},{&quot;first_name&quot;:&quot;Francis&quot;,&quot;last_name&quot;:&quot;Hubler&quot;},{&quot;first_name&quot;:&quot;Emmanuel&quot;,&quot;last_name&quot;:&quot;Meyer&quot;},{&quot;first_name&quot;:&quot;Dorte&quot;,&quot;last_name&quot;:&quot;Renneberg&quot;},{&quot;first_name&quot;:&quot;Carmela&quot;,&quot;last_name&quot;:&quot;Gnerre&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Treiber&quot;},{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;Rey&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Hess&quot;},{&quot;first_name&quot;:&quot;Beat&quot;,&quot;last_name&quot;:&quot;Steiner&quot;},{&quot;first_name&quot;:&quot;Kurt&quot;,&quot;last_name&quot;:&quot;Hilpert&quot;},{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;A. Riederer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9133-9153&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00933&quot;},&quot;abstract&quot;:&quot;Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y12 antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma. Herein we present the optimization steps that led to the discovery of clinical candidate ACT-246475 (30d). The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent molecules of the program. In addition, low in vivo clearance in rat and dog was achieved for the first time. Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45). Compound 30d showed efficacy in the rat ferric chloride thrombosis model when administered intravenously as parent or orall&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00933&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00933" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00933&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00933" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00933&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00933" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00933&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00933&amp;href=/doi/10.1021/acs.jmedchem.5b00933" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00933" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00933" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00933%26sid%3Dliteratum%253Aachs%26pmid%3D26550844%26genre%3Darticle%26aulast%3DCaroff%26date%3D2015%26atitle%3D4-%2528%2528R%2529-2-%257B%255B6-%2528%2528S%2529-3-Methoxypyrrolidin-1-yl%2529-2-phenylpyrimidine-4-carbonyl%255Damino%257D-3-phosphonopropionyl%2529piperazine-1-carboxylic%2BAcid%2BButyl%2BEster%2B%2528ACT-246475%2529%2Band%2BIts%2BProdrug%2B%2528ACT-281959%2529%252C%2Ba%2BNovel%2BP2Y12%2BReceptor%2BAntagonist%2Bwith%2Ba%2BWider%2BTherapeutic%2BWindow%2Bin%2Bthe%2BRat%2BThan%2BClopidogrel%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9133%26epage%3D9153%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recent post hoc analyses of several clinical trials with P2Y<sub>12</sub> antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y<sub>12</sub> antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma. Herein we present the optimization steps that led to the discovery of clinical candidate ACT-246475 (<b>30d</b>). The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent molecules of the program. In addition, low in vivo clearance in rat and dog was achieved for the first time. Since the bioavailability of <b>30d</b> was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, <b>45</b>). Compound <b>30d</b> showed efficacy in the rat ferric chloride thrombosis model when administered intravenously as parent or orally as its prodrug <b>45</b>. Moreover, <b>30d</b> displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following a lesion of the vascular wall, multiple signals will trigger activation of circulating platelets that subsequently adhere and aggregate at the site of injury, forming a seal to prevent blood loss. Similarly, rupture of an atherosclerotic plaque may lead to uncontrolled platelet thrombus formation. Vessel occlusion might occur followed by ischemia of the downstream located tissue with consecutive myocardial infarction (MI).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Inhibiting the activation and aggregation of platelets is the recommended therapeutic option to prevent atherothrombotic events in patients with atherosclerotic disease in the coronary, peripheral, or cerebrovascular circulation.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a></div><div class="NLM_p">The ADP receptor P2Y<sub>12</sub> is a key player in the process of activating platelets and aggregation.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Platelet activation is initially triggered by the interaction of glycoproteins on the surface of platelets with components of the subendothelial matrix or ruptured atherosclerotic plaque and is amplified by the release of soluble mediators, which also recruit new platelets. One of the most important soluble mediators is ADP, which is an agonist at the two G protein-coupled receptors (GPCRs), P2Y<sub>1</sub>, and P2Y<sub>12</sub>. Both P2Y<sub>1</sub> and P2Y<sub>12</sub> participate in the activation of integrin glycoprotein IIb/IIIa, which binds fibrinogen, contributing to the creation of the cross-linked aggregates that form a thrombus. Whereas P2Y<sub>1</sub> is important for the initial activation at low levels of ADP, it appears that P2Y<sub>12</sub> is required to amplify and sustain the responses leading to stable thrombus formation. The P2Y<sub>12</sub> receptor is a validated target in antiplatelet therapy for patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">In patients with ACS, the current guidelines recommend a dual antiplatelet therapy with acetylsalicylic acid and a P2Y<sub>12</sub> receptor antagonist, such as clopidogrel, prasugrel, or ticagrelor.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> Clopidogrel is an irreversible P2Y<sub>12</sub> receptor antagonist with proven antithrombotic efficacy.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Nevertheless, the antiplatelet effect is delayed by the need for conversion to the active metabolite, and additionally about 14–30% of the patients are resistant to clopidogrel treatment due to genetic polymorphisms of the CYP-450 enzymes responsible for its metabolism.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Prasugrel is also an irreversible P2Y<sub>12</sub> receptor antagonist from the thienopyridine class, with a different mechanism for the formation of the active metabolite.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It achieves stronger inhibition of platelet aggregation, but the superior efficacy versus clopidogrel in moderate- to high-risk patients with ACS undergoing PCI<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> is associated with an increased bleeding risk.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Ticagrelor, the first reversible P2Y<sub>12</sub> receptor antagonist tested in clinical trials, demonstrated superiority over clopidogrel in the prevention of ischemic events with no statistically significant increase of bleeding.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Nevertheless, it is still discussed which P2Y<sub>12</sub> antagonist is the best choice and which subgroups of patients should be treated with clopidogrel, prasugrel, or ticagrelor.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Consequently, new P2Y<sub>12</sub> inhibitors combining high inhibition of platelet aggregation with low risk of bleeding are still actively searched.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Recent publication of X-ray structural information<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> as well as molecular modeling studies docking known P2Y<sub>12</sub> antagonists (including a close analog of the molecules disclosed herein)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> will likely support this dynamic research field.</div><div class="NLM_p">At Actelion, we aimed at discovering a reversible and selective P2Y<sub>12</sub> antagonist, which may provide an improved therapeutic window<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> compared to the benchmark drug clopidogrel. Indeed, reversible antagonism may cause less bleeding than irreversible blockade, since the receptor remains responsive to high local concentrations of ADP.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> In addition, some of the excess bleeding associated with thienopyridines may be due to off-target effects, as shown by comparing clopidogrel and prasugrel treatment with genetic ablation of the P2Y<sub>12</sub> receptor in mice.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide series and the SAR of the substituent on position 6 of the pyrimidine ring.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We identified two sets of highly potent P2Y<sub>12</sub> antagonists, of which compounds <b>1</b> and <b>2</b> are the most active representatives (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a). The best molecules showed IC<sub>50</sub> values in the low nanomolar range in the binding assay and in the light transmission aggregometry (LTA) assay. No inhibition of the major P450 enzymes or of the hERG channel was observed. Moderate to high clearance in the rat represented the main caveat of the two chemical classes. We set the substituent in position 6 of the pyrimidine ring to (<i>S</i>)-3-methoxypyrrolidin-1-yl as in analog <b>2</b> and the SAR of the R<sup>2</sup> group was explored (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). In the present paper we report the properties of (<i>S</i>)-6-(3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamide analogs and the path that led to the discovery of a new and potent P2Y<sub>12</sub> antagonist with a unique efficacy/safety ratio.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Previous work: 2-phenylpyrimidine-4-carboxamide analogs <b>1</b> and <b>2</b> where the central core was set as <span class="smallcaps smallerCapital">l</span>-glutamic acid. (b) This disclosure: general structure of (<i>S</i>)-6-(3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamide analogs. R<sup>1</sup> is ethyl or <i>n</i>-butyl. R<sup>2</sup> and stereochemistry at the α carbon of the amino acid core are detailed in the tables.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Retrosynthetically, the target molecules were divided into three parts, the piperazine carbamate, the central amino acid core, and the pyrimidine moiety. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows the synthesis of the pyrimidinecarboxylic acid building block <b>8</b>. Intermediate <b>5</b> was obtained in four consecutive steps starting from commercially available ethyl 4-methoxy-3-oxobutanoate <b>3</b> and benzamidine <b>4</b>. Chloropyrimidine <b>5</b> was reacted with (<i>S</i>)-3-methoxypyrrolidine <b>7</b> at 60 °C in THF in the presence of DIPEA to give the acid <b>8</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Building Block <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) see ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>, 4 steps, 51%; (b) BOC<sub>2</sub>O, Et<sub>3</sub>N, DCM, 100% (crude); (c) NaH, MeI, THF, 93% (crude); (d) HCl in EA, 95%; (e) DIPEA, THF, 60 °C, 4 days, 93%.</p></p></figure><div class="NLM_p">The synthesis of the P2Y<sub>12</sub> antagonists was designed and carried out as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The chirality at the amino acid Cα was introduced with intermediates <b>10</b> and was conserved throughout the synthesis. The piperazine carbamate <b>9</b> was coupled to the amino acid <b>10</b> using as activating agent EDC-Cl/HOBt or HATU or PyBOP. The deprotection step performed on the resulting intermediate <b>11</b> was a HCl- or TFA-mediated BOC cleavage or a palladium catalyzed hydrogenolysis of Cbz or a Fmoc removal with Et<sub>2</sub>NH. The second amide coupling step assembled the amine <b>12</b> and the acid building block <b>8</b> to give the final scaffold in good overall yield. Analogs <b>13</b>–<b>22</b> were directly obtained without any additional transformation. Compound <b>28</b> was obtained by reacting the hydroxyl group of analog <b>22</b> with trichloroacetyl isocyanate, followed by NaBH<sub>4</sub> mediated trichloroacetamide cleavage.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">When R<sup>2</sup> contained a <i>tert</i>-butyl protected acidic function such as in intermediates <b>23a</b>–<b>f</b>, TFA treatment in DCM afforded analogs <b>29a</b>–<b>f</b> in high yields. Hydrolysis of the diethyl phosphonate group of intermediates <b>24a</b>–<b>k</b> was achieved using TMSBr in anhydrous MeCN and provided analogs <b>30a</b>–<b>k</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Analogs <b>31a</b>,<b>b</b> were quantitatively obtained upon treatment of BOC-protected amino derivatives <b>25a</b>,<b>b</b> with HCl in dioxane. The cyano group of intermediates <b>26a</b>,<b>b</b> was transformed into a tetrazole ring upon treatment with NaN<sub>3</sub> in the presence of ZnBr<sub>2</sub> to provide analogs <b>32a</b>,<b>b</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Furthermore, the cyano group was reacted with NH<sub>2</sub>OH and the resulting hydroxyamidine was subsequently cyclized to the oxadiazolone analog <b>33</b> upon treatment with CDI.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Analog <b>34</b> was obtained by cleavage of the isobutyl sulfonate using Me<sub>4</sub>NCl.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Carboxylic acid analogs <b>29a</b>,<b>b</b> were further transformed into sulfonylamide analogs <b>35</b> and <b>36</b> using the corresponding primary sulfonamide reagent in combination with DCC/DMAP or SOCl<sub>2</sub>. Compound <b>37</b> was prepared starting from analog <b>31b</b> and reacted with CF<sub>3</sub>SO<sub>2</sub>Cl. Analogs <b>38a</b>,<b>b</b> were obtained by reacting 3,4-diethoxy-3-cyclobutene-1,2-dione with analogs <b>31a</b>,<b>b</b>.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of P2Y<sub>12</sub> Antagonist Analogs <b>13</b>–<b>22</b>, <b>28</b>, <b>29a</b>–<b>f</b>, <b>30a</b>–<b>k</b>, <b>31a</b>,<b>b</b>, <b>32a</b>,<b>b</b>, <b>33–37</b>, and <b>38a</b>,<b>b</b> (for R<sup>1</sup> and R<sup>2</sup>, See <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HOBt/EDC-Cl or HATU or PyBOP, DIPEA, DCM or DCM/THF, rt. (b) PG = BOC: TFA/DCM, rt, or HCl in EA or EA/dioxane. PG = Cbz: Pd/C (wet, 5%), H<sub>2</sub>, EtOH or EtOH/AcOH, rt. PG = Fmoc: Et<sub>2</sub>NH, DCM, rt. (c) <b>8</b>, similar conditions as described in (a); (d) TFA, DCM, rt, 22–100%; (e) TMSBr, MeCN, 0 °C to rt overnight, then DCM, water, rt, 1 h, 17–98%; (f) 4 M HCl in dioxane, rt, 30 min, 99–100%; (g) ZnBr<sub>2</sub>, NaN<sub>3</sub>, H<sub>2</sub>O, 100 °C, 20 h, 22% (<b>32a</b>,<b>b</b>), or NH<sub>2</sub>OH–HCl, NaHCO<sub>3</sub>, MeOH, 70 °C, 24 h, then CDI, DBU, dioxane, 105 °C, 2 h, 2% (<b>33</b>); (h) Me<sub>4</sub>NCl, DMF, 150 °C, overnight, 23%; (i) trichloroacetyl isocyanate, EtOH, 0 °C, 20 min, then NaBH<sub>4</sub>, EtOH, 0 °C to rt overnight, 5%; (j) SOCl<sub>2</sub>, rt, 1 h, then Et<sub>3</sub>N, CF<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub>, DCM, rt, overnight, 6% (<b>35</b>), or MeSO<sub>2</sub>NH<sub>2</sub>, DCC, DMAP, DCM, 0 °C, 1 h, then rt, 20 h, 36% (<b>36</b>); (k) CF<sub>3</sub>SO<sub>2</sub>Cl, Et<sub>3</sub>N, THF, 0 °C to rt, overnight, 11%; (l) 3,4-diethoxy-3-cyclobutene-1,2-dione, Et<sub>3</sub>N, EtOH, rt, overnight, 52–65%, then 4 M HCl in dioxane, THF, 50 °C, 2 days, 52–56%.</p></p></figure><div class="NLM_p">The key intermediates <b>10</b> leading to intermediates <b>23a</b>–<b>f</b>, <b>25a</b>,<b>b</b>, <b>26a</b>,<b>b</b>, and <b>27</b> and to final analogs <b>13</b>–<b>22</b> were commercially available. For the preparation of diethyl phosphonate derivatives <b>24a</b>–<b>k</b> leading to analogs <b>30a</b>–<b>k</b>, intermediates <b>10a</b>–<b>g</b> were synthesized as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. When the phosphonic acid group was directly attached to the amino acid backbone, racemic intermediate <b>10a</b> was easily prepared from commercially available racemic dimethyl phosphonate <b>39a</b> by saponification with aqueous LiOH. For the enantiomers <b>10b</b>,<b>c</b>, application of the Arbuzov protocol on the enantiomerically pure iodoserine derivatives <b>40b</b>,<b>c</b> gave the corresponding phosphonate analogs <b>39b</b>,<b>c</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Whenever the appropriate protected amino acid derivative bearing a halogenated side chain was not commercially available, it was prepared starting from the hydroxyl analog. Enantiomers <b>41d</b>,<b>e</b> were reacted with CBr<sub>4</sub> in the presence of PPh<sub>3</sub>, leading to enantiomers <b>40d</b> and <b>40e</b>, respectively. Likewise, hydroxyl precursors <b>41f</b>–<b>g</b> were reacted with iodine in the presence of PPh<sub>3</sub> and imidazole leading to enantiomers <b>40f</b> and <b>40g</b>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In case the phosphonic acid group was attached to the amino acid backbone through a <i>n</i>-propyl linker (<b>10f</b>–<b>g</b>), the side chain carboxylic groups of protected (<span class="smallcaps smallerCapital">l</span>)- and (<span class="smallcaps smallerCapital">d</span>)-glutamic acid derivatives <b>42f</b>–<b>g</b> were reduced to the corresponding alcohols by activation with isobutyl chloroformate followed by NaBH<sub>4</sub> treatment affording enantiomers <b>41f</b>–<b>g</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Intermediates <b>10a</b>–<b>g</b> for the Synthesis of Phosphonic Acid-Containing Analogs <b>30a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isobutyl chloroformate, NMM, THF, −15 °C, 14 h, then NaBH<sub>4</sub>, MeOH, −10 °C, 100% (crude) (<b>41f</b>–<b>g</b>); (b) CBr<sub>4</sub>, PS–PPh<sub>3</sub>, DCM, 0 °C, 2–3 h, 25–52% (<b>40d</b>–<b>e</b>), or imidazole, PPh<sub>3</sub>, I<sub>2</sub>, THF, 0 °C to rt, 11 h, 65–100% (<b>40f</b>–<b>g</b>); (c) P(OEt)<sub>3</sub>, 120–130 °C, overnight, 57–100% (crude); (d) LiOH, MeOH, EtOH, H<sub>2</sub>O, 0 °C, 1 h, 100% (<b>10a</b>), or rt, 3 h to overnight, 48–100% (<b>10e</b>–<b>g</b>), or LiOH, THF, H<sub>2</sub>O, rt, 3 h to overnight, 72–100% (<b>10b</b>–<b>d</b>).</p></p></figure><div class="NLM_p last">Analogs <b>43</b> and <b>44</b> were prepared following a different route (not shown) and the synthetic protocols and schemes can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationships (SARs)</h3><div class="NLM_p">The affinity of the synthesized analogs to the P2Y<sub>12</sub> receptor was measured in the binding assay. The most potent compounds (generally IC<sub>50</sub> below 100 nM) were further profiled ex vivo; i.e., inhibition of ADP-induced platelet aggregation was measured in human platelet-rich plasma (PRP) using light transmission aggregometry (LTA). An extensive screening of the amino acid side chain R<sup>2</sup> was undertaken, and a panel of representative examples are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Generally, most R<sup>2</sup> residues were well tolerated, leading to moderate to good IC<sub>50</sub> values in the binding assay. R<sup>2</sup> being hydrogen (<b>13</b>) and alkyl groups of moderate size (<b>14</b>–<b>16</b> and <b>18</b>) provided IC<sub>50</sub> values in the hundred nanomolar range. Lipophilic groups with more steric bulk at the amino acid Cβ such as <i>tert</i>-butyl (<b>17</b>) led to micromolar activities. Polar functional groups such as carboxyl (<b>2</b>, <b>29a</b>–<b>f</b>), amine (<b>31a</b>,<b>b</b>), hydroxyl (<b>22</b>, <b>43</b>), ether (<b>19</b>), sulfone (<b>20</b>), primary amide, and carbamate (<b>21</b>, <b>28</b>) were introduced, varying the length of the linker to the amino acid Cα. Among those, the most potent analogs with binding IC<sub>50</sub> values below 100 nM were hydroxymethyl (<b>22</b>), aminomethyl (<b>31a</b>), and primary carbamate (<b>28</b>) derivatives and carboxylic acids (<b>2</b>, <b>29a</b>,<b>b</b>, <b>29e</b>,<b>f</b>). Interestingly, analog <b>29c</b>, where the stereochemistry at the amino acid core is reversed to (<i>R</i>), was 11-fold less active than the corresponding (<i>S</i>) analog <b>29a</b>. The trend favoring the (<i>S</i>) orientation was even more striking when the linker was longer, as shown with analogs (<i>S</i>)-<b>29b</b> and (<i>R</i>)-<b>29d</b>. In the LTA assay in human plasma, only carboxyl-containing analogs showed IC<sub>50</sub> values below 100 nM. Finally, elongating R<sup>1</sup> from ethyl to <i>n</i>-butyl led to analogs with better affinity, increased lipophilicity, and slightly higher potency in human plasma (see <b>16</b> vs <b>15</b>, <b>2</b> vs <b>29b</b>, <b>29e</b> vs <b>29a</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Screening of the Amino Acid Side Chain R<sup>2</sup>: Binding Affinity and LTA IC<sub>50</sub> Values</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Absolute stereochemistry at the amino acid Cα.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">CHO cells expressing recombinant P2Y<sub>12</sub> receptors incubated with [<sup>33</sup>P]-2MeSADP and compound. Data are presented as the mean ± SEM of <i>n</i> = 2–4.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Incubation for 2 min in human PRP with 3 μM ADP. <i>n</i> = 1.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">See ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</p></div></div><div></div></div><div class="NLM_p">These results supported the prevalence of the carboxyl group to reach good potency in human plasma. Furthermore, the carboxyl group was most likely responsible for the medium clearance observed in the rat via excretion as unchanged drug in the bile (data not shown). Therefore, we synthesized a number of carboxylic acid bioisosteres<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> with the goal to achieve superior PK behavior while keeping the high potency. Biological data are reported in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> (PK data are discussed in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Replacement of the Carboxylic Acid by Acid Bioisosteres: Binding Affinity and LTA IC<sub>50</sub> Values, Plasma Shift, and clogP</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Absolute stereochemistry at the amino acid Cα is (<i>S</i>).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">CHO cells expressing recombinant P2Y<sub>12</sub> receptors incubated with [<sup>33</sup>P]-2MeSADP and compound. Data are presented as the mean ± SEM of <i>n</i> = 2–4.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Incubation for 2 min in human PRP with 3 μM ADP. <i>n</i> = 1.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Plasma shift = (LTA IC<sub>50</sub>)/(binding IC<sub>50</sub>).</p></div></div><div></div></div><div class="NLM_p">Indeed, apart from the sulfonic acid analog <b>34</b>, all carboxylic acid bioisosteres (<b>30f</b>, <b>32a</b>–<b>38b</b>, <b>44</b>) were potent in the binding assay ranging from 3.7 to 43 nM. In the LTA assay, analog <b>35</b> came out as an outlier with an IC<sub>50</sub> value of 2100 nM. High lipophilicity might account for this low affinity, since the two analogs <b>35</b> and <b>37</b> having the highest clogP (>3.2) also show the highest plasma shift and modest potencies in the LTA assay. All other molecules showed medium to good potencies in the LTA assay similar to carboxyl-containing derivatives. Notably, analogs <b>30f</b> and <b>44</b> showed two of the lowest plasma shifts ever encountered in the course of our medicinal chemistry program, 1.4 and 1.7, respectively. In the next step, we focused on analog <b>30f</b> and expanded the phosphonic acid-containing compound class by varying the linker length and the stereochemistry at the amino acid core. The biological data are listed in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Replacement of the Carboxylic Acid by a Phosphonic Acid: Binding Affinity and LTA IC<sub>50</sub> Values</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0014.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0015.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Absolute stereochemistry at the amino acid Cα.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">CHO cells expressing recombinant P2Y<sub>12</sub> receptors incubated with [<sup>33</sup>P]-2MeSADP and compound. Data are presented as the mean ± SEM, with <i>n</i> = 2–4.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Incubation for 2 min in human PRP with 3 μM ADP. <i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p last">Analog <b>30a</b> (epimeric mixture) with the phosphonic acid directly attached to the amino acid backbone displayed moderate activity in the binding assay. The influence of the stereocenter was analogous to what was observed with carboxyl-containing analogs <b>29a</b>–<b>d</b> favoring the forward orientation of R<sup>2</sup>, irrespective of the linker length. Indeed, analogs extending R<sup>2</sup> in the backward direction (as depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), <b>30e</b>, <b>30g</b>, <b>30i</b>, and <b>30k</b>, were at least 10 times less active in the binding assay than the corresponding analogs <b>30d</b>, <b>30f</b>, <b>30h</b>, and <b>30j</b>. Unexpectedly, <b>30c</b> was only twice less active as <b>30b</b>. In general, elongation of R<sup>1</sup> from ethyl to butyl led to increased binding affinity. However, notable exceptions are <b>30e</b> and <b>30i</b> wherein R<sup>1</sup> is butyl which are equally or less active than <b>30c</b> and <b>30g</b> wherein R<sup>1</sup> is ethyl. Overall, refinements of the SAR led to five phosphonic acid-containing analogs <b>30b</b>–<b>d</b>, <b>30h</b>, and <b>30j</b> that were extremely potent in human plasma.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Pharmacokinetic Analysis</h3><div class="NLM_p">On the basis of in vitro and ex vivo potencies, a selection of analogs from <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were progressed for evaluation of PK parameters in rat (see <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>; data for <b>1</b> and <b>2</b> are indicated for comparison). Systemic clearance was close to liver blood flow for hydroxymethyl <b>22</b>, benzoic acid-containing analog <b>29f</b>, compounds <b>32a</b>,<b>b</b>, <b>36</b>, <b>38b</b>, and <b>44</b> containing a carboxylic acid bioisostere other than a phosphonic acid and analog <b>30j</b> extending a phosphonic acid group on a <i>n</i>-propyl linker. However, compounds <b>30c</b>, <b>30d</b>, and <b>30h</b> extending a phosphonic acid group on shorter linkers showed low clearances of 3.7, 2.1, and 5.4 mL/(min·kg), respectively. With the exception of hydroxyl-containing analog <b>22</b>, volumes of distribution at steady state were in the range of total body water. Consequently half-lives were short, with a maximum of 1.8 h for <b>30d</b>. Oral bioavailability was 16% and 28% for <b>22</b> and <b>29f</b>, respectively, but below 3% for all molecules containing a carboxylic acid bioisostere including a phosphonic acid. Whether the poor oral exposure of analogs <b>32b</b>, <b>36</b>, <b>38b</b>, and <b>44</b> is the result of high clearance combined with limited oral absorption cannot be concluded from these basic pharmacokinetic experiments. However, considering the predicted p<i>K</i><sub>a</sub> of the carboxylic acid bioisosteric moiety of the four analogs (<b>32b</b>, 4.86; <b>36</b>, 4.45; <b>38b</b>, 1.23; <b>44</b>, 8.06),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> one can hypothesize that the oral exposure of <b>38b</b> below limit of quantification is likely due to the ionized state of the molecule at the pH of the upper intestine (6.8) leading to poor permeability, and to a clearance close to liver blood flow. Likewise, since the phosphonic acid group bears at least one negative charge at intestinal pH,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> analogs <b>30c</b>–<b>d</b> and <b>30h</b> may not readily undergo passive diffusion across cellular membranes and intestinal mucosa, resulting in low oral bioavailability, despite a low in vivo clearance. As a conclusion, the new P2Y<sub>12</sub> antagonists described in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> show poorer bioavailabilities and shorter half-lives compared to compound <b>1</b>. Interestingly, the phosphonic acid-containing analogs <b>30c</b>, <b>30d</b>, and <b>30h</b> exhibit markedly lower clearances than compound <b>1</b>. Among these three phosphonates, analog <b>30d</b> was deemed the best combination of potency, clearance, and exposure in the rat. Therefore, it was further progressed together with compound <b>1</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Rat Pharmacokinetic Profiles of Selected P2Y<sub>12</sub> Antagonists<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0016.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0017.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Low clearance: CL < 30% of liver blood flow (LBF). Moderate clearance: 30% < CL < 70% LBF. High clearance: >70% LBF. LBF in rat is 55–90 mL/(min·kg). For correct classification, plasma clearance needs to be converted to blood clearance considering the blood/plasma partitioning ratio, which in the absence of data is assumed to be 1.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">See ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Male Wistar rats. Dose: iv infusion at 1 mg/kg (<i>n</i> = 1 or 2); po at 10 mg/kg (<i>n</i> = 2 or 3). BLQ: below limit of quantification (∼1 ng/mL). SDs and ranges are provided as <a href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vivo Efficacy/Safety Assessment</h3><div class="NLM_p">Compounds <b>1</b> and <b>30d</b> were tested for in vivo efficacy and safety and were compared with clopidogrel. The ferric chloride model was performed in Wistar rats to determine the antithrombotic efficacy of the two P2Y<sub>12</sub> antagonists. The deposition of a 20% aqueous ferric chloride solution onto the right carotid artery of the rat induced a rapid decrease in carotid blood-flow velocity. Within 11 ± 1 min, the flow was not measurable anymore due to histologically confirmed thrombotic occlusion of the artery (data not shown). In vehicle treated rats, the vessel injury resulted in 100% thrombotic occlusion (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, vehicle). Oral treatment with clopidogrel as well as intravenous bolus injection of compound <b>1</b> dose-dependently prevented the ferric chloride-induced thrombus formation (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A,B). At the highest doses of 30 mg/kg of clopidogrel and 1 mg/kg of compound <b>1</b>, thrombus formation was fully blocked. The observed increase of 26% in blood flow at 30 mg/kg of clopidogrel was attributed to off-target effects at the vessel wall.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Intravenous bolus injection of compound <b>30d</b> dose-dependently prevented the ferric chloride-induced thrombotic occlusions (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). At the highest dose tested (0.1 mg/kg), full antithrombotic efficacy was achieved and no increase in carotid blood flow versus baseline flow was measured. Thus, the P2Y<sub>12</sub> antagonists <b>1</b> and <b>30d</b> were shown to be potent antithrombotic agents. Compound <b>30d</b> showed maximal efficacy in this rat model at about 10-fold lower dose than compound <b>1</b>.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of (A) clopidogrel, (B) compound <b>1</b>, and (C) compound <b>30d</b> on thrombotic occlusion after FeCl<sub>3</sub>-induced arterial injury in anesthetized Wistar rats (<i>n</i> = 3–4 per group (A), <i>n</i> = 5–11 per group (B), and <i>n</i> = 3–11 per group (C)). Doses are in mg/kg. Thrombotic occlusion is defined as % reduction in blood flow velocity from baseline, 30 min after arterial injury. Data are presented as the mean ± SEM. (A) Vehicle and clopidogrel were administered orally as single dose 2 h before arterial injury. Vehicle was saline 9 g/L, pH adjusted to 2.5 with 3 M HCl. (B, C) Vehicle and compounds <b>1</b> and <b>30d</b> were administered as intravenous bolus injection 5 min before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine the efficacy/safety ratio, the two compounds and clopidogrel were profiled in a rat surgical blood loss model at doses inducing the maximal antithrombotic effect (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The surgical blood loss was defined as the amount of blood oozing out of the rat spleen after placing a standardized surgical wound. In the absence of any antithrombotic treatment (vehicle group), the surgical blood loss was quantified at 0.16 and 0.18 g of blood, after oral gavage and intravenous bolus injection, respectively. At maximal antithrombotic dose of clopidogrel (30 mg/kg), the surgical blood loss was increased from 0.16 to 2.8 g of blood. At maximal antithrombotic dose of compound <b>1</b> (1 mg/kg), the surgical blood loss was increased from 0.18 to 1.5 g of blood. In striking contrast, at maximal antithrombotic dose of compound <b>30d</b> (0.1 mg/kg), the observed surgical blood loss was only 0.4 g. On the basis of these in vivo data, compound <b>30d</b>, at maximal antithrombotic efficacy, displayed a wider therapeutic window in the rat than clopidogrel and compound <b>1</b>. The clear difference in blood loss between compound <b>30d</b> and clopidogrel at maximal efficacious doses warranted further characterization of <b>30d</b> toward clinical development.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of (A) clopidogrel and (B) compounds <b>1</b> and <b>30d</b> on surgical blood loss after spleen puncture in anesthetized Wistar rats (<i>n</i> = 8–14 per group (A) or <i>n</i> = 5–20 per group (B)). Surgical blood loss was measured 30 min after spleen puncture. Data are presented as the mean ± SEM. (A) Vehicle and clopidogrel were administered orally as single dose 2 h before spleen puncture. Vehicle was saline 9 g/L, pH adjusted to 2.5 with 3 M HCl. Open bar = vehicle. Hatched bar = clopidogrel at 30 mg/kg. (B) Vehicle and compounds <b>1</b> and <b>30d</b> were administered as intravenous bolus injection 5 min before spleen puncture. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4. Open bar = vehicle. Gray bar = compound <b>1</b> at 1 mg/kg. Black bar = compound <b>30d</b> at 0.1 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preclinical Characterization of Compound <b>30d</b></h3><div class="NLM_p last">In radioligand displacement assays, [<sup>33</sup>P]-2MeSADP was able to displace prebound compound <b>30d</b> and to reach maximal binding capacity, hence confirming <b>30d</b> as a reversible P2Y<sub>12</sub> antagonist. During SAR optimization, inhibition of platelet aggregation was assessed in human PRP, with incubation time of 2 min and 3 μM ADP for platelet activation. In this setting compound <b>30d</b> displayed an IC<sub>50</sub> value of 8.0 nM. As a preparation for clinical profiling, assay conditions were adapted to the protocols used in hospital setting. Using a PAP-8 aggregometer with a 20 min incubation time and 20 μM ADP, the IC<sub>50</sub> value was confirmed to be 14 nM (<i>n</i> = 8).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> No antagonistic activity on genetically related P2Y receptors was measured. Up to 10 μM concentration of <b>30d</b> did not interfere with agonist binding to P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, P2Y<sub>11</sub>, and P2Y<sub>13</sub>. No antagonistic activity was detected on P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, and P2X<sub>7</sub> receptors. Furthermore, compound <b>30d</b> was tested for potential off-target activity against a broad panel of receptors, transporters, and enzymes. Radioligand displacement assays were performed against 68 targets, including GPCRs, ion channels, and transporters, and activity assays were performed with 30 enzymes. To expand the profiling and include potential agonism, PathHunter technology was used on a panel of 161 recombinant GPCRs. All assays were performed in duplicate using a final concentration of 10 μM. Compound <b>30d</b> did not interact with the target in any of these assays. At 50 μM concentration of <b>30d</b>, less than 10% reduction of the hERG K<sup>+</sup> current was observed.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compound <b>30d</b> did not inhibit cytochrome P450 enzymes in assays assessing competitive inhibition using human liver microsomes up to 50 μM and did not exert time-dependent inhibition of CYP2C9, CYP2D6, or CYP3A4.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Plasma protein binding in animal species used for preclinical safety testing, i.e., rat, dog, as well as in man, was above 99%. In liver microsomes of human, rat, dog, rabbit, and cynomolgus monkey, the turnover was very low and the cleavage of the −CO–N– bond of the carbamate moiety was not observed. Similar to rat (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), compound <b>30d</b> showed a low plasma clearance and volume of distribution in the dog, resulting in a half-life of 4.8 h. Oral bioavailability in the dog was around 1%. Compound <b>30d</b> successfully passed preclinical toxicology and safety studies.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vivo Efficacy of Compound <b>45</b> as Prodrug of Compound <b>30d</b></h3><div class="NLM_p">On the basis of in vitro metabolic studies and PK data in rat and dog, we expected a low oral absorption of compound <b>30d</b> in human. Therefore, we decided to mask the phosphonic acid group as a double ester prodrug.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> Briefly, we synthesized a variety of phosphonate ester prodrugs and evaluated the chemical stability, metabolic stability in plasma and liver microsomes, and PK in rat and dog. Finally, the bis((isopropoxycarbonyl)oxy)methyl ester prodrug <b>45</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) was selected for preclinical development. An overview of the synthetic procedures and optimization program toward this prodrug will be published separately.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>45</b>, bis((isopropoxycarbonyl)oxy)methyl ester prodrug of <b>30d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To confirm the oral antithrombotic efficacy of compound <b>45</b>, the ferric chloride model in Wistar rats was repeated comparing oral administration of the prodrug <b>45</b> with intravenous infusion<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> of the parent drug <b>30d</b>. The prodrug <b>45</b> was below analytical detection limits in rat blood after oral gavage. Plasma concentration of the active <b>30d</b> was measured in the two experiments at the time of vessel injury and 30 min later. In vehicle treated rats, the vessel injury resulted in complete thrombotic occlusion of the artery, i.e., 100% decrease of blood flow (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, vehicle). Intravenous infusion of 0.01 mg/kg/50 min of analog <b>30d</b> led to a blood flow velocity decrease 30 min after injury of 35 ± 16% compared to baseline flow in the absence of vessel injury; i.e., thrombotic occlusion was inhibited by 65 ± 16% (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). A similar reduction in blood flow velocity 30 min after injury of 47 ± 18% (i.e., inhibition of thrombotic occlusion by 53 ± 18%) was measured after oral administration of a 1 mg/kg dose of analog <b>45</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). During the 30 min time period of the experiments, the plasma concentration of <b>30d</b> was between 72 and 141 ng/mL for the 0.01 mg/kg intravenous dose of <b>30d</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A) and between 101 and 190 ng/mL for the 1 mg/kg oral dose of <b>45</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). Plasma concentrations of the parent drug <b>30d</b> were comparable in both experiments, which supports the observed similar antithrombotic efficacy. Therefore, one can reasonably conclude that (1) the prodrug <b>45</b> liberates the parent drug <b>30d</b> in circulation, (2) the observed antithrombotic effect after oral administration of <b>45</b> is entirely due to the parent drug <b>30d</b>, and (3) a 1 mg/kg oral dose of <b>45</b> leads to a comparable antithrombotic efficacy as a 0.01 mg/kg iv dose of <b>30d</b> in the ferric chloride rat thrombosis model. Compound <b>45</b> showed no toxicity or safety signals in preclinical studies.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of (A) compound <b>30d</b> and (B) compound <b>45</b> on thrombotic occlusion after FeCl<sub>3</sub>-induced arterial injury in anesthetized Wistar rats (<i>n</i> = 10–35 per group (A) or <i>n</i> = 6 per group (B)). Thrombotic occlusion is defined as % reduction in blood flow velocity from baseline, 30 min after arterial injury. Data are presented as the mean ± SEM. (A) Vehicle and compound <b>30d</b> were administered as continuous intravenous infusion over 50 min at the rate of 1 (mL/kg)/20 min, starting 20 min before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4. (B) Vehicle and compound <b>45</b> were administered orally as single dose 1 h before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), water, 5 mL/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma concentrations of the active drug <b>30d</b> (A) at 20 and 50 min after starting iv infusion of <b>30d</b> in the experiment described in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and (B) at 60 and 90 min after oral gavage of <b>45</b> in the experiment described in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B. Plasma was obtained from arterial blood sampling (EDTA). Experimental details are given in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The first optimization sequence of the 2-phenylpyrimidine-4-carboxamide scaffold led to analogs <b>1</b> and <b>2</b> showing high potencies in both the binding and LTA assays albeit with moderate PK profiles in rat and dog (data not shown). In a second step, keeping the newly discovered (<i>S</i>)-3-methoxypyrrolidinyl substituent in position 6 of the pyrimidine ring, we focused on the amino acid core. Introduction of various functional groups on the amino acid side chain confirmed our initial observation that an acidic group was needed to reach high potency in human plasma. We also suspected the acidic group to be responsible for the medium clearance observed in vivo in rat and dog. Therefore, we embarked on a third optimization sequence with the goal to identify a bioisosteric replacement for the carboxylic acid functionality. The phosphonic acid group was found beneficial, since it delivered the most potent molecules in the LTA assay as well as low in vivo clearance in the rat. Consequently, the phosphonic acid-containing analog <b>30d</b> was selected for preclinical development. In vitro, it was shown to be a reversible and highly selective P2Y<sub>12</sub> antagonist, potent in human plasma at a low nanomolar concentration. <b>30d</b> dose-dependently blocked thrombus formation in the rat ferric chloride model and displayed a wide therapeutic window. Overall, <b>30d</b> exhibited a very safe profile in in vitro and in vivo preclinical experiments. However, on the basis of in vitro metabolic studies and PK data in rat and dog, we expected a low oral absorption of compound <b>30d</b> in human. Therefore, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug <b>45</b> which showed antithrombotic efficacy after oral administration in the rat ferric chloride model. Both compounds <b>45</b> and the parent drug <b>30d</b> entered clinical studies in healthy volunteers.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60728" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60728" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> P2Y<sub>12</sub> Radioligand Displacement Assay (Binding Assay)</h3><div class="NLM_p last">Recombinant Chinese hamster ovary (CHO) cells with recombinant expression the human P2Y<sub>12</sub> gene were grown in Ham’s F12 medium with phenol red and <span class="smallcaps smallerCapital">l</span>-glutamine (Gibco no. 21765-029) containing 250 μg/mL Geneticin (Gibco), 100 μg/mL gygromycin B (Invitrogen), and 10% FCS Sera Plus (PAN Biotech; Aidenbach, DE). Cells were cultivated in 96-well plates at a density of 75 000 cells/well in medium supplemented with apyrase 0.1 U/mL and grown overnight at 37 °C and 5% CO<sub>2</sub>. The next day, the cells were washed three times with binding buffer (Ham’s F12 medium (Gibco) with phenol red and <span class="smallcaps smallerCapital">l</span>-glutamine (Gibco no. 21765-029), supplemented with 0.01% protease-free BSA). The assay was performed as follows: First, 100 μL of binding buffer was added to each well. Second, 50 μL of binding buffer containing 5% DMSO or compound was added. Third, 100 μL of 0.25 nM radioligand [<sup>33</sup>P]-2MeSADP (PerkinElmer CUS55563) was added to each well and incubated for 90 min at room temperature, with gentle agitation. The assay was stopped by three washes with binding buffer, followed by addition of 200 μL of scintillation liquid (Microscint 40, Packard) and quantification in a scintillation counter (Packard, Top Count NXT).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> In Vitro Light Transmission Aggregometry (LTA) Assay<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></h3><div class="NLM_p"><i>Preparation of Platelet-Rich Plasma (PRP).</i> Blood was collected from healthy, aspirin-free volunteers, after obtaining informed consent, by venipuncture of the large arm vein. The blood was immediately anticoagulated with 100 μM direct thrombin inhibitor napsagatran<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> (RO 46-6240, kindly provided by Hoffmann La Roche Ltd.). With this anticoagulant, the physiological calcium concentration is maintained. 10 mL aliquots of blood were centrifuged at 200<i>g</i> (1000 rpm) for 10 min. The top layer, representing the platelet-rich plasma (PRP), was carefully transferred into a fresh tube. The remaining blood was again centrifuged at 1800<i>g</i> (3000 rpm) for 10 min. The top layer constituting the platelet-poor plasma (PPP) was carefully transferred into a new tube. Finally, platelet numbers in PRP were determined using a CASY cell counter system (Roche Diagnostics (Schweiz) AG) and, if necessary, platelet count was adjusted to 314 × 106 platelets/mL using PPP from the same donor.</div><div class="NLM_p last"><i>In Vitro Platelet Aggregation Assay Using LTA.</i> All experiments were performed with a four-channel aggregometer (Chrono-Log Corporation, Lumi-Aggregometer 490-4D) with the AggroLink software package. First, 400 μL of PRP at 314 × 10<sup>6</sup> Plts/mL were placed into a siliconized glass cuvette (ref 70180 from Probe and Go). With napsagatran-anticoagulated PRP, 85 μL of Tyrode’s solution (NaCl 133 mM, KCl 2.7 mM, NaHCO<sub>3</sub> 11.9 mM, NaH<sub>2</sub>PO<sub>4</sub>–H<sub>2</sub>O 0.36 mM, Hepes 10 mM, glucose 5 mM, BSA 0.1%, CaCl<sub>2</sub> 2 mM, MgCl<sub>2</sub> 1 mM, pH 7.4) was added, mixed, and equilibrated at 37 °C for at least 15 min without stirring. Second, 5 μL of DMSO or test compound in DMSO was added and incubated for 2 min at 37 °C with brief stirring for 2 min only. The samples were stirred with siliconized magnetic stir bars (ref 70188 from Probe and Go) at 1100 rpm at 37 °C. In parallel, the aggregometer system was calibrated with PRP (0% aggregation control = baseline) and PPP (100% aggregation control). Third, aggregation was started by addition of 10 μL of ADP (during SAR optimization at 3 μM final concentration) to the cuvette. The addition of these various volumes resulted in final concentration of 250 × 10<sup>6</sup> Plts/mL. Aggregation was monitored for up to 8 min. The results are expressed as the maximal change in light transmission at peak response (=maximal aggregation response) or as the change in light transmission at 6 min after ADP addition (=final aggregation response).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> IC<sub>50</sub> values were calculated using XLfit software. All compounds were tested in parallel with one reference compound. The geometric mean IC<sub>50</sub> value for this reference compound was 167 nM with a 95% confidence interval of 143–196 nM over 19 independent IC<sub>50</sub> determinations.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pharmacology</h3><div class="NLM_p last">Normotensive male Wistar rats delivered from Harlan Netherlands were group-housed in climate-controlled conditions with a 12 h light/dark cycle in accordance with the guidelines of the Basel Cantonal Veterinary Office, with appropriate environmental enrichment (shelter, polycarbonate rat tunnel, chew blocks, aspen bricks). All animals were maintained under identical conditions and had free access to drinking water and normal pelleted food (no. 3336, Provimi Kliba SA, Switzerland). Plavix, 75 mg, from Sanofi/BMS (clopidogrel) was purchased in a pharmacy and stored at room temperature (max, 25 °C) protected from light. Clopidogrel was dissolved in saline (9 g/L, containing 3 μL/mL of 3 M HCl) at a concentration of 6 mg/mL pH = 2.5. Compounds <b>1</b> and <b>30d</b> were dissolved in PEG 400 (7.5% v/v), PG (7.5% v/v), Cremophor (5% v/v) (Cremophor EL, Fluka no. 27963), in phosphate buffer pH = 7.4. Compound <b>45</b> was dissolved in PEG 400 (7.5%), PG (7.5%), Cremophor (5%), water.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Rat FeCl<sub>3</sub> Thrombosis Model</h3><div class="NLM_p last">The FeCl<sub>3</sub> model was performed based on previous reports.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Specifically, after an acclimatization period of at least 7 days, the rats were anesthetized by an intraperitoneal injection of thiobutabarbital sodium salt hydrate at a dose of 150 mg/kg (Inactin, Sigma-Aldrich GmbH). The animals were then placed on a thermostatically controlled heating table to maintain body temperature at 36–38 °C. After tracheotomy, a catheter was inserted into the right femoral vein for bolus injection or continuous infusion at a rate of 1 (mL/kg)/20 min of compounds <b>1</b> and <b>30d</b> or vehicle. A second catheter was inserted in the right femoral artery to measure mean arterial pressure (MAP) and heart rate (HR). The right carotid artery was gently dissected free of connective tissue, and a silastic tubing flow transducer (D-20-0.8mm, Triton Technologies Inc.) was placed on the artery for blood flow velocity measurement. Ferric chloride (FeCl<sub>3</sub>, Fluka no. 44943) was dissolved in distilled water at a concentration of 200 mg/mL (20%). At 5 min after bolus injection or 20 min after infusion start of vehicle or compound, two filter papers (Tempo handkerchief, 4 mm × 4 mm) were soaked in this solution and placed on the carotid artery anterior to the flow transducer for 5 min to induce thrombus formation. Mean arterial pressure (MAP), heart rate (HR), and carotid blood flow velocity were continuously recorded on a PowerLab data acquisition system (IOX data acquisition, Emka Technologies, France) during 30 min after removal of the ferric chloride filter papers by using a IOX software (Emka Technologies, France). Data were exported to a Dell Dimension 733R computer for analysis (Datanalyst, version 2.10.17, Emka Technologies, France). At the end of the experiment, rats were euthanized by an intravenous infusion of pentobarbital (100 mg/kg, Esconarkon, Streuli Pharma AG, Switzerland). Clopidogrel and its vehicle were administered by oral gavage at 5 mL/kg 2 h before FeCl<sub>3</sub>-soaked filter papers were applied to the carotid artery. The time for clopidogrel gavage was determined in a pilot experiment where the FeCl<sub>3</sub> arterial induced injury was performed 2 and 4 h after oral administration of 10 mg/kg clopidogrel. The same antithrombotic efficacy was observed in both cases; therefore, the time for clopidogrel administration was set to 2 h before arterial injury.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Compound <b>45</b> and its vehicle were administered by oral gavage at 5 mL/kg 1 h before FeCl<sub>3</sub>-soaked filter papers were applied to the carotid artery. An arterial blood sample (EDTA) was withdrawn immediately before FeCl<sub>3</sub>-soaked filter papers were applied to the carotid artery and 30 min after. Blood was centrifuged, and supernatant plasma was removed and stored at −20 °C until plasma concentration measurements.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Rat Blood Loss Model</h3><div class="NLM_p last">The blood loss model was developed in house. After an acclimatization period of at least 7 days, the rats were anesthetized by an intraperitoneal injection of thiobutabarbital sodium salt hydrate at a dose of 150 mg/kg (Inactin, Sigma-Aldrich GmbH). The animals were then placed on a thermostatically controlled heating table to maintain body temperature at 36–38 °C. After tracheotomy, a catheter was inserted into the right jugular vein for injection of compound. A laparotomy was performed and vehicle or compounds <b>1</b> and <b>30d</b> were intravenously injected as a bolus of 1 mL/kg. Five minutes later, the spleen was punctured with a 4 mm biopsy punch (Stiefel) to induce a surgical wound, from which blood was collected for 30 min. The amount of blood loss was measured and reported in gram. At the end of the experiment, rats were euthanized by an intravenous infusion of pentobarbital (100 mg/kg, Esconarkon, Streuli Pharma AG, Switzerland). Clopidogrel and its vehicle were administered by oral gavage at 5 mL/kg 2 h before the spleen was punctured.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as purchased from commercial sources. Moisture sensitive reactions were carried out under an argon atmosphere. Progress of the reactions was followed either by thin-layer chromatography (TLC) analysis (Merck, 0.2 mm silica gel 60 F<sub>254</sub> on glass plates) or by liquid chromatography–mass spectrometry (LC–MS). LC–MS: Thermo Finnigan MSQ Plus, with Agilent G4220A binary pump and DAD Agilent G4212A; column, Zorbax SB-AQ, 5 μm, 120 Å, 4.6 mm × 50 mm (Agilent); gradient, 5–95% acetonitrile in water containing 0.04% of TFA, within 1 min, then 95% acetonitrile in water containing 0.04% of TFA for 0.5 min; flow, 4.5 mL/min; 40 °C; <i>t</i><sub>R</sub> is given in min. Purity of all target compounds was checked by an additional LC–MS analysis on a Waters Acquity UPLC system equipped with an ACQ-PDA detector, an ACQ-ESLD detector, and an ACQ-SQD detector; column, ACQUITY UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm or ACQUITY UPLC HSS T3 C18 1.8 μm, 2.1 mm × 50 mm; gradient, 2–98% acetonitrile containing 0.045% formic acid in water containing 0.05% formic acid over 2 min; flow, 1.0 mL/min; 60 °C. Chiral HPLC (chiral stationary phase): hardware from UltiMate instrument series (Dionex), HPG-3200SD binary pump, WPS-3000 autosampler, TCC-3200 thermostated column compartment, DAD-3000 detector, SRD-3400 degasser. Column, solvent, and retention time (<i>t</i><sub>R</sub>) are as indicated, at 25 °C, flow 1 mL/min. High resolution LC–MS (LC–HRMS): analytical pump, Waters Acquity Binary; MS, SYNAPT G2 MS; source temperature, 150 °C; desolvation temperature, 400 °C; desolvatation gas flow, 700 L/h; cone gas flow, 10 L/h; extraction cone, 4; RF lens, 0.1 V; sampling cone, 30; capillary, 3 kV; high-resolution mode; gain, 1.0; MS function, 0.2 s per scan, 120–1000 amu in full scan, centroid mode; lock spray, leucine enkephalin 2 ng/mL (556.2771 Da) scan time 0.2 s with interval of 10 s and average of five scans; DAD, Acquity UPLC PDA detector; column, Acquity UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm from Waters; gradient, 2–98% acetonitrile containing 0.05% formic acid in water containing 0.05% formic acid over 2 min; flow, 0.6 mL/min; 60 °C; detection, UV 214 nm and MS, <i>t</i><sub>R</sub> is given in min. NMR spectroscopy: Bruker Avance II 400 MHz Ultrashield or Bruker Ascend 500. Chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS), and multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet), quint (quint), or m (multiplet), br = broad, and coupling constants are given in Hz. Compound purification: compounds were purified by either flash column chromatography (CC) on silica gel 60 (Fluka Sigma–Aldrich, Switzerland) or preparative LC–MS (column, solvent and retention time (<i>t</i><sub>R</sub>) as indicated). Purity of all target compounds was assessed using the two independent LC–MS methods described above: (1) a Zorbax SB-AQ, 5 μm, 120 Å, 4.6 mm × 50 mm (Agilent) column, eluting with a gradient of 5–95% acetonitrile in water containing 0.04% of TFA, within 1 min, flow of 4.5 mL/min at 40 °C; (2) an ACQUITY UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm column or an ACQUITY UPLC HSS T3 C18 1.8 μm, 2.1 mm × 50 mm column, eluting with a gradient of 2–98% acetonitrile containing 0.045% formic acid in water containing 0.05% formic acid over 2 min, flow of 1.0 mL/min at 60 °C. In addition, target compounds were analyzed by LC–HRMS as described above. Purity and identity of the target compounds were further corroborated by NMR spectroscopy, and chiral integrity was proven by HPLC using chiral stationary phases. According to these LC–MS analyses, target compounds showed a purity of greater than or equal to 95% (UV at 230 and at 214 nm).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Clopidogrel<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></h3><div class="NLM_p last">Plavix 75 mg (6.3 g, 84 tablets) was grounded in a mortar, and the powder was suspended in Et<sub>2</sub>O (160 mL) and sat. aq Na<sub>2</sub>CO<sub>3</sub> (160 mL). The resulting mixture was vigorously stirred for 30 min, filtered off, and the phases were separated. The organic layer was washed with sat. aq Na<sub>2</sub>CO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated in vacuo. The obtained colorless paste was dissolved in Et<sub>2</sub>O (137 mL), and HCl (2 M, 16 mL) was added. The resulting suspension was stirred at rt for 5 min and filtered off. The white powder was washed with Et<sub>2</sub>O and dried in high vacuum to afford 5.1 g of clopidogrel as HCl salt. LC–MS: <i>t</i><sub>R</sub> = 0.72 min, [M + H]<sup>+</sup> = 321.94. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 7.8 Hz, 1 H), 7.55–7.44 (m, 3 H), 7.30 (m, 1 H), 6.78 (br, 1 H), 5.56 (s, 1 H), 4.44 (br, 1 H), 3.54 (s, 3 H), 3.85 (s, 3 H), 3.80 (m, 1 H), 3.19 (m, 1 H).** [α]<sub>D</sub><sup>24.5</sup> +57 (<i>c</i> 1, MeOH).</div></div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-3-Methoxypyrrolidine Hydrochloride (<b>7</b>)</h3><div class="NLM_p">(a) Di-<i>tert</i>-butyl-dicarbonate (27.5 g) was added portionwise to a solution of (<i>S</i>)-3-hydroxypyrrolidine (<b>6</b>) (10.0 g) and Et<sub>3</sub>N (32.0 mL) in DCM (240 mL). The reaction mixture was stirred overnight at rt. Water was added, and the phases were separated. The organic layer was washed with water and saturated aq NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated off to give (<i>S</i>)-3-hydroxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (23.0 g, 100%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.45 (s, 1 H), 3.49–3.32 (m, 4 H), 2.17 (s, 1 H), 2.07–1.81 (m, 2 H), 1.47 (s, 9 H).</div><div class="NLM_p">(b) To an ice-cold solution of (<i>S</i>)-3-hydroxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (23.0 g) in THF (230 mL), NaH (7.37 g, 60% dispersion in mineral oil) was added portionwise. The reaction mixture was stirred for 30 min at rt, and MeI (11.5 mL) was added dropwise. Stirring was continued for additional 20 h at rt. Water was added to the reaction mixture. The layers were separated, and the aq phase was extracted with DCM three times. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated off to give (<i>S</i>)-3-methoxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (23.0 g, 93%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.93 (s, 1 H), 3.50–3.35 (m, 4 H), 3.34 (s, 3 H), 2.04–1.88 (m, 2 H), 1.47 (s, 9 H).</div><div class="NLM_p last">(c) (<i>S</i>)-3-Methoxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (23.0 g) was dissolved in EA (100 mL), and 3 M HCl in EA (115 mL) was added. The reaction mixture was stirred at rt for 20 h, and the solvent was evaporated off. The residue was taken up in Et<sub>2</sub>O and the compound precipitated out. The suspension was filtered off and the powder washed with Et<sub>2</sub>O. High vacuum drying afforded title compound <b>7</b> (15.2 g, 95%) as hydrochloride salt, brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.71 (br, 1 H), 9.37 (br, 1 H), 4.07 (s, 1 H), 3.23 (s, 3 H), 3.18–3.04 (m, 4 H), 3.34 (s, 3 H), 2.05–1.99 (m, 1 H), 1.93–1.84 (m, 1 H).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxylic Acid (<b>8</b>)</h3><div class="NLM_p">(a) Benzamidine hydrochloride (<b>4</b>) (6.00 g), ethyl 4-methoxy-3-oxobutanoate (<b>3</b>) (7.30 g), and NaOMe (30% in MeOH, 18.0 g) were suspended in EtOH (30.0 mL). The reaction mixture was refluxed overnight, cooled down, and water (50.0 mL) was added. The resulting suspension was filtered off and the solid was washed with Et<sub>2</sub>O and dried to give 6-methoxymethyl-2-phenylpyrimidin-4-ol (3.81 g). The remaining aq liquors were extracted three times, and the combined organic layers were dried over MgSO<sub>4</sub>, filtered, and evaporated off. The resulting crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) to give additional 2.20 g. An amount of 6.01 g (65%) of 6-methoxymethyl-2-phenylpyrimidin-4-ol was obtained as a brown solid. LC–MS: <i>t</i><sub>R</sub> = 0.68 min, [M + H]<sup>+</sup> = 217.11. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 13.1 (br, 1 H), 8.24 (m, 2 H), 7.58–7.54 (m, 3 H), 6.60 (s, 1 H), 4.46 (s, 2 H), 3.54 (s, 3 H).</div><div class="NLM_p">(b) POCl<sub>3</sub> (40.0 mL) was slowly added to a stirred powder of 6-methoxymethyl-2-phenylpyrimidin-4-ol (8.64 g). The resulting mixture was refluxed for 2 h, cooled down, and carefully added onto crushed ice. After 30 min of stirring, the obtained suspension was extracted twice with EA. The organic layers were washed twice with aq NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated off to afford 4-chloro-6-methoxymethyl-2-phenylpyrimidine (8.81 g, 94%) as a brown oil. LC–MS: <i>t</i><sub>R</sub> = 1.00 min, [M + H]<sup>+</sup> = 235.08. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.30 (m, 2 H), 7.56–7.49 (m, 3 H), 7.45 (s, 1 H), 4.57 (s, 2 H), 3.42 (s, 3 H).</div><div class="NLM_p">(c) A solution of BBr<sub>3</sub> (2.51 mL) in DCM (20.0 mL) was syringed into a solution of the above material (4.85 g) in DCM (100 mL) under argon at 0 °C. After 30 min of stirring at 0 °C, the reaction was complete. It was quenched by the addition of Et<sub>2</sub>O (100 mL), water (100 mL), and 1 M NaOH (100 mL). After 1 h of stirring at rt, the mixture was extracted three times with DCM and the organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated off. The resulting oil crushed out and the solid was washed with heptane to give (6-chloro-2-phenylpyrimidin-4-yl)methanol (4.58 g, 100%) as a brown oil. LC–MS: <i>t</i><sub>R</sub> = 0.88 min, [M + H]<sup>+</sup> = 221.29. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (m, 2 H), 7.43 (m, 3 H), 7.20 (s, 1 H), 4.74 (d, <i>J</i> = 5.1 Hz, 2 H), 3.08 (t, <i>J</i> = 5.3 Hz, 1 H).</div><div class="NLM_p">(d) The above alcohol (4.58 g) was dissolved in dioxane (170 mL), and a solution of NaOH (0.829 g) in water (400 mL) was added, followed by KMnO<sub>4</sub> (9.82 g). The mixture was stirred at rt for 3 h. Then 2 M HCl (100 mL) was added and the resulting mixture was stirred for 1 h and filtered off. The solution was extracted twice with EA. The organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated off to afford <b>5</b> (4.04 g, 83%) as a white solid. LC–MS: <i>t</i><sub>R</sub> = 0.87 min, [M + H]<sup>+</sup> = 235.28. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.37 (m, 2 H), 7.95 (s, 1 H), 7.55 (m, 3 H).</div><div class="NLM_p last">(e) A solution of intermediates <b>5</b> (3.20 g) and <b>7</b> (2.25 g) and DIPEA (5.14 mL) in THF (40.0 mL) was stirred at 60 °C for 20 h. Intermediate <b>7</b> (0.375 g) and DIPEA (0.467 mL) were added, and the reaction mixture was further stirred at 60 °C for 72 h. Water and DCM were added, and the phases were separated. The aq phase was extracted three times with DCM and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated off to give title compound <b>8</b> (3.78 g, 93%) as a beige solid. LC–MS: <i>t</i><sub>R</sub> = 0.74 min, [M + H]<sup>+</sup> = 300.42. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.39 (m, 2 H), 7.56–7.48 (m, 3 H), 7.09 (d, 1 H), 4.22–4.01 (m, 2 H), 3.86–3.66 (m, 1 H), 3.62 (br, 2 H), 3.41 (s, 3 H), 2.37–2.06 (m, 2 H).</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Piperazine-1-carboxylic Acid Butyl Ester (<b>9b</b>)</h3><div class="NLM_p">(a) To a solution of 1-benzylpiperazine (1.97 mL) and Et<sub>3</sub>N (1.90 mL) in DCM (100 mL), butyl chloroformate (1.47 mL) was added. The mixture was stirred at rt for 2 h. Water was added, and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated off to give 4-benzylpiperazine-1-carboxylic acid butyl ester (3.13 g, 100%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35–7.25 (m, 5 H), 4.10 (t, <i>J</i> = 6.5 Hz, 2 H), 3.53 (s, 2 H), 3.49 (br, 4 H), 2.41 (br, 4 H), 1.63 (m, 2 H), 1.40 (m, 2 H), 0.95 (t, <i>J</i> = 7.2 Hz, 3 H).</div><div class="NLM_p last">(b) The above material (3.13 g) was hydrogenated in EtOH (100 mL) with Pd/C (wet, 5%, 0.480 g) for 24 h. The mixture was filtered through Celite and evaporated off to give title compound <b>9b</b> (2.04 g, 96%) as a pale yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.54 (s, 1 H), 4.06 (t, <i>J</i> = 6.6 Hz, 2 H), 3.45 (m, 4 H), 2.83 (m, 4 H), 1.78 (s, 1 H), 1.66–1.59 (quint, <i>J</i> = 6.7 Hz, 2 H), 1.45–1.35 (m, 2 H), 0.95 (t, <i>J</i> = 7.4 Hz, 3 H).</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-((<i>S</i>)-3-Methoxy-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>19</b>)</h3><div class="NLM_p">(a) A solution of <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-serine (2.00 g), HOBt (1.97 g), and EDC-Cl (2.24 g) in DCM (20.0 mL) was stirred for 15 min at rt. <b>9b</b> (1.81 g) was added, and the reaction mixture was stirred overnight at rt. Precipitation occurred upon addition of 1 M NaHSO<sub>4</sub>. After 10 min of stirring, the suspension was filtered off. The layers were separated, and the aq phase was extracted three times with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The resulting crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:1 to heptane/EA 0:1) to give 4-((<i>S</i>)-2-<i>tert</i>-butoxycarbonylamino-3-hydroxypropionyl)piperazine-1-carboxylic acid butyl ester (0.500 mg, 14%) as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 0.82 min, [M + H]<sup>+</sup> = 374.34. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.64 (d, <i>J</i> = 8.0 Hz, 1 H), 4.64 (m, 1 H), 4.13 (t, <i>J</i> = 6.7 Hz, 2 H), 3.87 (m, 1 H), 3.77–3.65 (m, 3 H), 3.63–3.40 (m, 6 H), 3.26 (br, 1 H), 1.63 (m, 2 H), 1.46 (s, 9 H), 1.39 (quint, <i>J</i> = 7.5 Hz, 2 H), 0.96 (t, <i>J</i> = 7.4 Hz, 3 H).</div><div class="NLM_p">(b) To a solution of the above compound (0.900 g) in THF (10.0 mL), NaH (0.174 g, 60% dispersion in mineral oil) was added at rt. After stirring at rt for 15 min, MeI (0.150 mL) was added and the stirring was continued for 4 h. Water was added, the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated off to give 4-((<i>S</i>)-2-<i>tert</i>-butoxycarbonylamino-3-methoxypropionyl)piperazine-1-carboxylic acid butyl ester (0.500 g, 54%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.91 min, [M + H]<sup>+</sup> = 388.35.</div><div class="NLM_p">(c) A mixture of the above material (0.500 g) in DCM/TFA (6.00 mL, 5:1) was stirred at rt for 4 h and concentrated to dryness. The residue was taken up in DCM and washed with aq Na<sub>2</sub>CO<sub>3</sub>. The layers were separated, and the aq phase was extracted three times with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness to give 4-((<i>S</i>)-2-amino-3-methoxypropionyl)piperazine-1-carboxylic acid butyl ester (0.120 g, 32%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.62 min, [M + H]<sup>+</sup> = 288.23. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.13 (t, <i>J</i> = 6.7 Hz, 2 H), 3.95 (m, 1 H), 3.76 (br, 1 H), 3.64–3.40 (m, 8 H), 3.36 (s, 3 H), 2.86 (br, 1 H), 1.90 (br, NH<sub>2</sub>), 1.64 (m, 2 H), 1.46 (s, 9 H), 1.41 (m, 2 H), 0.97 (t, <i>J</i> = 7.4 Hz, 3 H).</div><div class="NLM_p last">(d) A solution of <b>8</b> (0.120 g), HOBt (0.081 g), and EDC-Cl (0.092 g) was stirred for 15 min at rt. The above material (0.115 g) was added, and the reaction mixture was stirred overnight at rt. Addition of 1 M NaHSO<sub>4</sub> was followed by 20 min of stirring and filtration of the resulting suspension. The layers were separated, and the aq phase was extracted three times with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The resulting crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:1 to heptane/EA 0:1) to give title compound <b>19</b> (0.074 g, 32%) as a pale yellow foam. LC–MS: <i>t</i><sub>R</sub> = 1.3 min, [M + H]<sup>+</sup> = 569.5. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.97 (d, <i>J</i> = 8.3 Hz, 1 H), 8.48 (s, 2 H), 7.47 (s, 3 H), 7.05 (br, 1 H), 5.33 (m, 1 H), 4.15 (m, 1 H), 4.12 (t, <i>J</i> = 6.7 Hz, 2 H), 4.01 (br, 1 H), 3.88–3.54 (m, 11 H), 3.47 (m, 2 H), 3.39 (s, 6 H), 2.32–2.05 (m, 2 H), 1.64 (quint, <i>J</i> = 6.8 Hz, 2 H), 1.40 (m, 2 H), 0.96 (t, <i>J</i> = 7.4 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 163.1, 162.5, 161.4, 155.1, 137.6, 131.2, 128.9, 128.4, 99.8, 79.6, 78.8, 72.4, 65.2, 59.1, 56.4, 52.0, 51.7, 49.4, 45.3, 45.1, 44.8, 44.0, 43.6, 42.1, 31.1, 30.6, 30.1, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.42 min, [M + H]/<i>z</i> = 569.3087, found 569.3087.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-((<i>S</i>)-3-Carbamoyloxy-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>28</b>)</h3><div class="NLM_p last">To a solution of <b>22</b> (0.160 g) in THF (2.00 mL) at 0 °C, trichloroacetyl isocyanate (0.089 g) was added. After 20 min of stirring at rt, EtOH (0.200 mL) was added and the reaction mixture was concentrated to dryness. The residue was dissolved in EtOH (10.0 mL), cooled to 0 °C, and treated with NaBH<sub>4</sub> (0.123 g). The reaction mixture was stirred at rt overnight. Aqueous Na<sub>2</sub>CO<sub>3</sub> was added, and the mixture was stirred for 3 h and extracted with DCM three times. The combined organic phases were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) and by preparative TLC (DCM/MeOH, 97:3) to give title compound <b>28</b> (0.006 g, 5%) as a white solid. LC–MS: <i>t</i><sub>R</sub> = 1.18 min, [M + H]<sup>+</sup> = 598.5. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.07 (m, 1 H), 8.49 (m, 2 H), 7.48 (m, 3 H), 7.05 (s, 1 H), 5.43 (m, 1 H), 4.80 (br, 2 H), 4.48 (m, 1 H), 4.28 (m, 1 H), 4.15 (m, 1 H), 4.12 (t, <i>J</i> = 6.3 Hz, 2 H), 4.02 (m, 1 H), 3.84–3.46 (m, 11 H), 3.40 (s, 3 H), 2.31–2.04 (m, 2 H), 1.64 (m, 2 H), 1.40 (m, 2 H), 0.96 (t, <i>J</i> = 7.3 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 163.4, 162.5, 161.3, 156.9, 155.1, 137.7, 131.2, 128.9, 128.5, 99.9, 99.8, 79.6, 78.8, 65.2, 63.2, 56.4, 52.0, 51.7, 49.7, 45.2, 44.8, 43.8, 43.5, 42.2, 31.1, 30.6, 30.1, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.29 min, [M + H]/<i>z</i> = 598.2989, found 598.2991.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-((<i>R</i>)-3-Carboxy-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Ethyl Ester (<b>29c</b>)</h3><div class="NLM_p">(a) A suspension of Cbz-<span class="smallcaps smallerCapital">d</span>-Asp(O<sup><i>t</i></sup>Bu)-OH (3.00 g), HOBt (0.500 g), EDC-Cl (0.356 g), and DIPEA (0.291 mL) in THF/DCM (6.00 mL, 5:1) was stirred for 15 min at rt. 1-(Ethoxycarbonyl)piperazine (0.244 g) was added, and the reaction mixture was stirred for 24 h at rt. The reaction mixture was partitioned between water and EA. The organic layer was washed with 2 M Na<sub>2</sub>CO<sub>3</sub>, with 1 M NaHSO<sub>4</sub>, dried over MgSO<sub>4</sub>, and concentrated to dryness to give 4-((<i>R</i>)-2-benzyloxycarbonylamino-3-<i>tert</i>-butoxycarbonylpropionyl)piperazine-1-carboxylic acid ethyl ester (0.800 g, 100%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35 (m, 5 H), 5.70 (m, 1 H), 5.11 (s, 2 H), 5.00 (m, 1 H), 4.18 (q, <i>J</i> = 7.1 Hz, 2 H), 3.70–3.38 (m, 8 H), 2.76 (dd, <i>J</i> = 7.2 and 15.8 Hz, 1 H), 2.55 (dd, <i>J</i> = 5.6 and 15.8 Hz, 1 H), 1.43 (s, 9 H), 1.29 (t, <i>J</i> = 7.1 Hz, 3 H).</div><div class="NLM_p">(b) The above material (0.800 g) was hydrogenated in EtOH (20.0 mL) with Pd/C (wet, 5%, 0.080 g) for 24 h. The mixture was filtered through Celite and evaporated off to give 4-((<i>R</i>)-2-amino-3-<i>tert</i>-butoxycarbonylpropionyl)piperazine-1-carboxylic acid ethyl ester (0.600 g, 100%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.18 (q, <i>J</i> = 7.0 Hz, 2 H), 3.68–3.46 (m, 8 H), 2.63 (dd, <i>J</i> = 4.9 and 16.2 Hz, 1 H), 2.49 (dd, <i>J</i> = 8.0 and 16.3 Hz, 1 H), 1.46 (s, 9 H), 1.29 (t, <i>J</i> = 7.1 Hz, 3 H).</div><div class="NLM_p">(c) A solution of <b>8</b> (0.363 g) and PyBOP (0.695 g) in DCM (10.0 mL) was stirred at rt for 10 min. DIPEA (0.173 mL) and the above material (0.400 g) were added. After 24 h of stirring at rt, the reaction mixture was diluted with DCM and 2 M Na<sub>2</sub>CO<sub>3</sub>. The organic layer was washed with 1 M NaHSO<sub>4</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness. The resulting crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) to give 4-((<i>R</i>)-3-<i>tert</i>-butoxycarbonyl-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid ethyl ester (<b>23c</b>) (0.250 g, 34%) as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 1.09 min, [M + H]<sup>+</sup> = 611.12. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.91 (d, <i>J</i> = 9.4 Hz, 1 H), 8.47 (m, 2 H), 7.48 (m, 3 H), 7.05 (br, 1 H), 5.47 (m, 1 H), 4.16 (m, 2 H), 4.08–3.97 (m, 1 H), 3.84–3.44 (m, 12 H), 3.41 (s, 3 H), 2.99 (dd, <i>J</i> = 7.8 and 16.0 Hz, 1 H), 2.71 (dd, <i>J</i> = 5.0 and 16.0 Hz, 1 H), 2.32–2.08 (m, 2 H), 1.46 (s, 9 H), 1.28 (t, <i>J</i> = 7.1 Hz, 3 H).</div><div class="NLM_p last">(d) A solution of the above compound (0.250 g) in DCM/TFA (2.00 mL/1.20 mL) was stirred at rt for 4 h and concentrated to dryness. The crude product was purified by preparative LC–MS (Gemini C18 110A Ax, 10 μm, 21.2 mm × 50 mm, 38.8–95% MeCN in water containing 0.2% formic acid, 45 mL/min) to afford the title compound <b>29c</b> (0.090 g, 40%) as a white powder. LC–MS: <i>t</i><sub>R</sub> = 1.07 min, [M + H]<sup>+</sup> = 555.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.11 (m, 1 H), 8.44 (m, 2 H), 7.46 (m, 3 H), 7.02 (br, 1 H), 5.52 (m, 1 H), 4.15 (q, <i>J</i> = 7.0 Hz, 3 H), 4.01 (m, 1 H), 3.84–3.44 (m, 11 H), 3.40 (s, 3 H), 3.09 (dd, <i>J</i> = 7.2 and 16.5 Hz, 1 H), 2.86 (dd, <i>J</i> = 4.6 and 16.5 Hz, 1 H), 2.30–2.07 (m, 2 H), 1.26 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.6, 169.8, 163.3, 162.5, 161.3, 155.2, 155.0, 137.7, 131.2, 128.8, 128.7, 100.0, 79.6, 78.8, 61.4, 56.4, 51.9, 51.7, 46.6, 45.2, 45.1, 44.8, 43.6, 42.2, 36.8, 30.6, 30.1, 15.0. LC–HRMS: <i>t</i><sub>R</sub> = 1.19 min, [M + H]/<i>z</i> = 555.2567, found 555.2569.</div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-((<i>S</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-oxo-4-trifluoromethanesulfonylaminobutyryl)piperazine-1-carboxylic Acid Ethyl Ester (<b>35</b>)</h3><div class="NLM_p last">A solution of <b>29a</b> (0.153 g) in SOCl<sub>2</sub> (1.00 mL) was stirred at rt for 1 h and concentrated to dryness. The residue was taken up in DCM (4.00 mL), and Et<sub>3</sub>N (0.115 mL) was added, followed by CF<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub> (0.041 g). The reaction mixture was stirred overnight at rt and poured onto aq NaHCO<sub>3</sub>. The layers were separated, and the aq phase was acidified to pH 1 with 2 M HCl and extracted with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by preparative LC–MS (Zorbax PrepHT SB.Aq, 5 μm, 21.2 mm × 50 mm, 31.5–100% MeCN in water containing 0.2% formic acid, 100 mL) and by preparative TLC (DCM/MeOH, 97:3) to afford title compound <b>35</b> (0.012 g, 6%) as a white foam. LC–MS: <i>t</i><sub>R</sub> = 1.61 min, [M + H]<sup>+</sup> = 686.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.17 (br, 1 H), 8.44 (m, 2 H), 7.46 (m, 3 H), 7.01 (br, 1 H), 5.52 (s, 1 H), 4.13 (m, 2 H), 3.95 (m, 1 H), 3.82–3.42 (m, 11 H), 3.39 (s, 3 H), 3.04 (m, 1 H), 2.83 (m, 1 H), 2.30–2.00 (m, 2 H), 1.25 (m, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.9, 169.8, 163.1, 162.5, 161.4, 155.3, 155.1, 137.7, 131.1, 128.8, 128.6, 122.1, 119.5, 99.8, 79.6, 78.8, 61.4, 56.4, 46.8, 45.4, 45.1, 44.8, 43.6, 42.1, 30.6, 30.1, 29.5, 29.2, 22.6, 15.0, 14.5. LC–HRMS: <i>t</i><sub>R</sub> = 1.20 min, [M + H]/<i>z</i> = 686.2220, found 686.2231.</div></div><div id="sec4_7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-((S)-5-Methanesulfonylamino-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-5-oxopentanoyl)piperazine-1-carboxylic Acid Ethyl Ester (<b>36</b>)</h3><div class="NLM_p last">To a solution of <b>29b</b> (0.325 g) in DCM (10.0 mL), DMAP (0.076 g) and MeSO<sub>2</sub>NH<sub>2</sub> (0.059 g) were added, followed by DCC (0.128 g) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and at rt for 20 h and was filtered off. The filtrate was concentrated to dryness and the crude product was purified by CC on silica gel (eluting with DCM/MeOH 10:1) and preparative TLC (DCM/acetone, 1:5) to give title compound <b>36</b> (0.111 g, 36%) as a white solid. LC–MS: <i>t</i><sub>R</sub> = 1.1 min, [M + H]<sup>+</sup> = 646.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.6 (s, 1 H), 9.8 (d, <i>J</i> = 7.8 Hz, 1 H), 8.49 (m, 2 H), 7.54 (m, 3 H), 6.97 (s, 1 H), 5.01 (m, 1 H), 4.14 (m, 1 H), 4.07 (q, <i>J</i> = 7.0 Hz, 2 H), 3.88 (m, 1 H), 3.74–3.34 (m, 11 H), 3.30 (s, 3 H), 3.21 (s, 3 H), 2.18–2.06 (m, 3 H), 1.93 (m, 1 H), 1.20 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.6, 169.6, 163.5, 162.5, 161.4, 155.2, 155.1, 137.7, 131.2, 128.9, 128.4, 99.8, 99.7, 79.6, 78.8, 61.5, 56.4, 52.0, 51.7, 48.7, 45.1, 44.8, 43.9, 43.5, 42.0, 41.4, 40.9, 31.6, 30.6, 30.1, 26.3, 15.0. LC–HRMS: <i>t</i><sub>R</sub> = 1.33 min, [M + H]/<i>z</i> = 646.2659, found 646.2659.</div></div><div id="sec4_7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-((<i>S</i>)-3-Amino-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>31a</b>)</h3><div class="NLM_p last">A mixture of 4-((<i>S</i>)-3-<i>tert</i>-butoxycarbonylamino-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid butyl ester (<b>25a</b>) (0.305 g) in 4 M HCl in dioxane (1.50 mL) was stirred at rt for 30 min and concentrated to dryness to give title compound <b>31a</b> (0.250 g, 99%) as hydrochloride salt, as a beige solid. LC–MS: <i>t</i><sub>R</sub> = 0.86 min, [M + H]<sup>+</sup> = 554.5. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + drop of D<sub>2</sub>O): δ 8.48 (m, 2 H), 7.51 (m, 3 H), 6.96 (s, 1 H), 5.20 (m, 1 H), 4.13 (m, 1 H), 3.94 (t, <i>J</i> = 5.8 Hz, 2 H), 3.86 (m, 1 H), 3.69–3.35 (m, 10 H), 3.30–3.15 (m, 3 H), 3.26 (s, 3 H), 2.12 (m, 2 H), 1.47 (m, 2 H), 1.25 (m, 2 H), 0.81 (m, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 164.4, 162.5, 161.3, 155.1, 155.0, 137.6, 131.2, 128.7, 100.1, 79.6, 78.8, 65.2, 56.4, 52.0, 51.7, 48.0, 45.2, 44.8, 43.6, 42.3, 31.0, 30.6, 30.1, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 0.93 min, [M + H]/<i>z</i> = 554.3091, found 554.3094.</div></div><div id="sec4_7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-((<i>S</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-trifluoromethanesulfonylaminobutyryl)piperazine-1-carboxylic Acid Butyl Ester (<b>37</b>)</h3><div class="NLM_p last">To a suspension of <b>31b</b> (0.053 g) in DCM (1.00 mL) at 0 °C, Et<sub>3</sub>N (0.368 mL) was added, followed by trifluorosulfonyl chloride (0.112 mL). The reaction mixture was stirred at rt and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from DCM/MeOH 1:0 to DCM/MeOH 9:1) to give title compound <b>37</b> (0.007 g, 11%) as a white solid. LC–MS: <i>t</i><sub>R</sub> = 1.38 min, [M + H]<sup>+</sup> = 700.5. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.50 (m, 2 H), 7.48 (m, 3 H), 7.01 (s, 1 H), 5.22 (m, 1 H), 4.58 (br, 1 H), 4.19 (m, 1 H), 4.11 (t, <i>J</i> = 6.5 Hz, 2 H), 3.99 (br, 1 H), 3.80–3.45 (m, 11 H), 3.40 (s, 3 H), 3.38 (m, 2 H), 2.23 (m, 2 H), 2.16–2.00 (m, 2 H), 1.64 (m, 2 H), 1.41 (m, 2 H), 0.96 (t, <i>J</i> = 7.4 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.1, 163.7, 162.5, 161.4, 155.1, 137.7, 131.2, 128.8, 128.5, 123.9, 121.4, 118.8, 99.8, 79.6, 78.8, 65.2, 56.4, 52.0, 51.7, 47.3, 45.1, 44.8, 43.9, 43.6, 42.1, 40.9, 33.0, 31.0, 30.7, 30.1, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.49 min, [M + H]/<i>z</i> = 700.2740, found 700.2742.</div></div><div id="sec4_7_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-((<i>S</i>)-3-(2-Hydroxy-3,4-dioxocyclobut-1-enylamino)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>38a</b>)</h3><div class="NLM_p">(a) To a solution of 3,4-diethoxy-3-cyclobutene-1,2-dione (0.022 g) in EtOH (0.500 mL), a solution of <b>31a</b> (0.075 g) and Et<sub>3</sub>N (0.188 mL) in EtOH (0.500 mL) was added dropwise. The reaction mixture was stirred overnight at rt and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) to give 4-((<i>S</i>)-3-(2-ethoxy-3,4-dioxocyclobut-1-enylamino)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid butyl ester (0.045 g, 52%) as a white foam. LC–MS: <i>t</i><sub>R</sub> = 1.01 min, [M + H]<sup>+</sup> = 678.25.</div><div class="NLM_p last">(b) 4 M HCl in dioxane (0.500 mL) was added to a solution of the above compound (0.045 g) in THF (1.00 mL). The reaction mixture was stirred at 50 °C for 48 h and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) to give title compound <b>38a</b> (0.024 g, 56%) as a gray solid. LC–MS: <i>t</i><sub>R</sub> = 1.38 min, [M + H]<sup>+</sup> = 650.5. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.44 (m, 2 H), 7.46 (m, 3 H), 6.91 (s, 1 H), 5.36 (m, 1 H), 4.17–3.99 (m, 2 H), 4.10 (t, <i>J</i> = 6.4 Hz, 2 H), 3.89 (m, 2 H), 3.78 (m, 2 H), 3.68–3.45 (m, 9 H), 3.37 (s, 3 H), 2.25–2.02 (m, 2 H), 1.64 (m, 2 H), 1.41 (m, 2 H), 0.96 (t, <i>J</i> = 7.4 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 200.1, 189.1, 168.4, 163.7, 162.5, 161.3, 155.4, 155.1, 137.7, 131.1, 128.9, 128.6, 99.7, 79.6, 78.8, 65.2, 56.4, 51.8, 45.2, 44.1, 42.0, 31.1, 19.2, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.15 min, [M + H]/<i>z</i> = 650.2938, found 650.2939.</div></div><div id="sec4_7_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-[(<i>S</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-(1<i>H</i>-tetrazol-5-yl)butyryl]piperazine-1-carboxylic Acid Ethyl Ester (<b>32b</b>)</h3><div class="NLM_p">(a) A solution of Cbz-Gln-OH (25.0 g), HOBt (14.5 g), and EDC-Cl (20.5 g) in THF/DCM (750 mL, 4:1) was stirred for 5 min at rt. 1-(Ethoxycarbonyl)piperazine (14.1 g) was added, and the reaction mixture was stirred at rt for 24 h. Water and EA were added, and the layers were separated. The organic phase was washed with 2 M Na<sub>2</sub>CO<sub>3</sub> and 1 M NaHSO<sub>4</sub>, was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated off to give 4-((<i>S</i>)-2-benzyloxycarbonylamino-4-carbamoylbutyryl)piperazine-1-carboxylic acid ethyl ester (37.5 g, 100%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.74 min, [M + H]<sup>+</sup> = 421.49.</div><div class="NLM_p">(b) Benzenesulfonyl chloride (13.8 mL) was added to a solution of the above compound (37.4 g) in pyridine (29.6 mL), and the resulting reaction mixture was stirred at 50 °C for 1 h. After cooling down, 2 N HCl was added to pH 7 and the mixture was extracted three times with EA. The combined organic layers were washed with 1 N HCl, aq NaHCO<sub>3</sub>, and water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to dryness to give 4-((<i>S</i>)-2-benzyloxycarbonylamino-4-cyanobutyryl)piperazine-1-carboxylic acid ethyl ester (30.0 g, 84%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.85 min, [M + H]<sup>+</sup> = 403.48.</div><div class="NLM_p">(c) The above material (10.0 g) was hydrogenated in EtOH (40.0 mL) with Pd/C (wet, 5%, 1.22 g) for 24 h. The mixture was filtered through Celite and evaporated off to give 4-((<i>S</i>)-2-amino-4-cyanobutyryl)piperazine-1-carboxylic acid ethyl ester (6.99 g, 100%) as a brown oil. LC–MS: <i>t</i><sub>R</sub> = 0.51 min, [M + H]<sup>+</sup> = 269.39.</div><div class="NLM_p">(d) A solution of <b>8</b> (0.200 g), HOBt (0.108 g), and EDC-Cl (0.154 g) in THF/DCM (5.00 mL, 4:1) was stirred for 5 min at rt. The above product (0.179 g) was added, and the reaction mixture was stirred at rt for 24 h. Water and EA were added, and the layers were separated. The organic phase was washed with 2 M Na<sub>2</sub>CO<sub>3</sub> and 1 M NaHSO<sub>4</sub>, was dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated off to give 4-((<i>S</i>)-4-cyano-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}butyryl)piperazine-1-carboxylic acid ethyl ester (<b>26b</b>) (0.290 g, 79%) as a brown foam. LC–MS: <i>t</i><sub>R</sub> = 0.97 min, [M + H]<sup>+</sup> = 550.56.</div><div class="NLM_p last">(e) A mixture of <b>26b</b> (0.250 g), ZnBr<sub>2</sub> (0.102 g), and NaN<sub>3</sub> (0.032 g) in water (2.00 mL) was stirred at 100 °C in a sealed tube overnight. After cooling down, 2 N HCl was added to pH 1, followed by DCM (100 mL), EA (50.0 mL), and water (30.0 mL). The layers were separated, and the aq phase was extracted with DCM. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from DCM/MeOH 1:0 to DCM/MeOH 7:3) to give title compound <b>32b</b> (0.060 g, 22%) as a beige solid. LC–MS: <i>t</i><sub>R</sub> = 1.04 min, [M + H]<sup>+</sup> = 593.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.15 (d, <i>J</i> = 7.9 Hz, 1 H), 8.49 (m, 2 H), 7.53 (m, 3 H), 6.96 (s, 1 H), 5.11 (m, 1 H), 4.13 (m, 1 H), 4.06 (q, <i>J</i> = 7.0 Hz, 2 H), 3.89 (m, 1 H), 3.73–3.33 (m, 11 H), 3.30 (s, 3 H), 3.02–2.89 (m, 2 H), 2.36 (m, 1 H), 2.20–2.04 (m, 3 H), 1.20 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.4, 163.6, 162.5, 161.4, 156.1, 155.2, 155.1, 137.7, 131.2, 128.9, 128.4, 99.8, 79.6, 78.8, 61.5, 56.4, 52.0, 51.7, 48.9, 45.1, 44.8, 44.0, 43.5, 42.0, 30.6, 30.1, 30.0, 19.8, 15.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.19 min, [M + H]/<i>z</i> = 593.2948, found 593.2959.</div></div><div id="sec4_7_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-[(<i>S</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-(5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl)propionyl]piperazine-1-carboxylic Acid Ethyl Ester (<b>33</b>)</h3><div class="NLM_p">(a) Hydroxylamine hydrochloride (0.233 g) and NaHCO<sub>3</sub> (0.279 g) were added to a solution of 4-((<i>S</i>)-3-cyano-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid ethyl ester (<b>26a</b>) (1.60 g) in MeOH (5.50 mL), and the reaction mixture was stirred at reflux for 20 h. Hydroxylamine hydrochloride (0.062 g) and NaHCO<sub>3</sub> (0.076 g) were added, the reflux was continued for 3 h, and the reaction mixture was concentrated to dryness. The residue was taken up in EA/water, and the resulting suspension was filtered off. The filtrate was decanted, and the organic layer was washed with water, dried (MgSO<sub>4</sub>), and evaporated off. The crude product was purified by preparative LC–MS (Zorbax PrepHT SB.Aq, 5 μm, 21.2 mm × 50 mm, 21–100% MeCN in water containing 0.2% formic acid, 100 mL/min) to afford 4-((<i>S</i>,<i>Z</i>)-4-amino-4-(hydroxyimino)-2-(6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamido)butanoyl)piperazine-1-carboxylic acid ethyl ester (0.046 g, 3%) as a white solid. LC–MS: <i>t</i><sub>R</sub> = 0.47 min, [M + H]<sup>+</sup> = 569.32. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.07 (m, 1 H), 8.47 (m, 2 H), 7.48 (m, 3 H), 7.03 (s, 1 H), 5.32 (m, 1 H), 5.17 (br, 1 H), 4.17 (q, <i>J</i> = 7.0 Hz, 2 H), 4.08–3.95 (m, 1 H), 3.84–3.70 (m, 2 H), 3.67–3.47 (m, 8 H), 3.41 (s, 3 H), 3.02–2.85 (m, 2 H), 2.82–2.75 (m, 1 H), 2.70–2.63 (m, 1 H), 2.30–2.05 (m, 2 H), 1.28 (t, <i>J</i> = 7.1 Hz, 3 H).</div><div class="NLM_p last">(b) 1,1′-Carbonyldiimidazole (0.016 g) and DBU (0.013 mL) were added to a solution of the above material (0.045 g) in dioxane (0.100 mL). The reaction mixture was refluxed for 2 h and poured onto DCM/water. pH was adjusted to 2 with 1 N HCl, and the layers were separated. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified by preparative TLC (DCM/acetone/acetic acid, 10:4:0.1) to give title compound <b>33</b> (0.026 g, 55%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 1.1 min, [M + H]<sup>+</sup> = 595.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.3 (br, 1 H), 9.34 (m, 1 H), 8.52 (m, 2 H), 7.52 (m, 3 H), 6.94 (s, 1 H), 5.29 (m, 1 H), 4.13 (m, 1 H), 4.05 (m, 2 H), 3.88 (m, 1 H), 3.72 (m, 1 H), 3.65–3.40 (m, 10 H), 3.30 (s, 3 H), 3.10 (m, 1 H), 2.90 (m, 1 H), 2.19–2.05 (m, 2 H), 1.17 (t, <i>J</i> = 7.2 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.9, 163.6, 162.5, 161.4, 155.0, 137.7, 131.2, 128.8, 128.6, 99.9, 79.6, 78.8, 62.5, 61.5, 56.4, 52.0, 51.7, 47.1, 45.2, 44.8, 43.5, 42.3, 30.6, 30.1, 29.5, 28.5, 28.2, 26.0, 15.0. LC–HRMS: <i>t</i><sub>R</sub> = 1.21 min, [M + H]/<i>z</i> = 595.2628, found 595.2635.</div></div><div id="sec4_7_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-((<i>S</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-sulfobutyryl)piperazine-1-carboxylic Acid Ethyl Ester (<b>34</b>)</h3><div class="NLM_p last">A mixture of <b>27</b> (0.404 g) and Me<sub>4</sub>NCl (0.402 g) in DMF (6.00 mL) was heated at 150 °C overnight and partitioned in DCM/water. The aq phase was extracted with DCM, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified by preparative LC–MS (XBridge Prep C18, 10 μm, OBD 30 mm × 75 mm, 5–95% MeCN in water containing 0.5% concentrated ammonia, 75 mL/min) to afford title compound <b>34</b> (0.082 g, 23%) as a beige powder. LC–MS: <i>t</i><sub>R</sub> = 1.43 min, [M + H]<sup>+</sup> = 605.30. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.01 (m, 1 H), 8.49 (m, 2 H), 7.54 (m, 3 H), 7.20 (s, 1 H), 7.09 (s, 1 H), 6.99 (s, 1 H), 6.98 (s, 1 H), 5.14 (m, 1 H), 4.17–4.10 (m, 1 H), 4.07 (q, <i>J</i> = 7.0 Hz, 2 H), 3.91–3.86 (m, 1 H), 3.74–3.35 (m, 11 H), 3.30 (s, 3 H), 2.53 (m, 1 H), 2.40 (m, 1 H), 2.18–1.95 (m, 4 H), 1.20 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.9, 163.2, 162.4, 161.4, 155.3, 155.1, 137.7, 131.2, 128.9, 128.4, 99.8, 99.7, 79.6, 78.8, 61.4, 56.4, 51.9, 51.7, 48.9, 47.7, 45.1, 44.8, 44.0, 43.6, 42.0, 30.6, 30.1, 29.0, 15.0. LC–HRMS: <i>t</i><sub>R</sub> = 1.19 min, [M + H]/<i>z</i> = 605.2393, found 605.2394.</div></div><div id="sec4_7_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>R</i>)-2-<i>tert</i>-Butoxycarbonylamino-3-(diethoxyphosphoryl)propionic Acid Methyl Ester (<b>39b</b>)</h3><div class="NLM_p last">A mixture of Boc-3-iodo-<span class="smallcaps smallerCapital">l</span>-Ala-OMe (<b>40b</b>) (4.00 g) in P(OEt)<sub>3</sub> (40.4 g) was stirred at 150 °C overnight and was concentrated to dryness to give title compound <b>39b</b> (3.95 g, 96%) as crude, as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.85 min, [M + H]<sup>+</sup> = 340.09. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5 H), 5.41 (m, 1 H), 5.14 (s, 2 H), 4.53 (m, 1 H), 3.78 (s, 3 H), 3.45 (t, <i>J</i> = 6.9 Hz, 2 H), 2.46 (m, 1 H), 2.27 (m, 1 H).</div></div><div id="sec4_7_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>R</i>)-2-<i>tert</i>-Butoxycarbonylamino-3-(diethoxyphosphoryl)propionic Acid (<b>10b</b>)</h3><div class="NLM_p last">A solution of LiOH (monohydrate, 0.418 g) in water (11.8 mL) was added to a solution of <b>39b</b> (3.95 g) in THF (35.0 mL). After stirring at rt for 2 h, LiOH (monohydrate, 0.139 g) was added and the stirring was continued for 2 h. Water and Et<sub>2</sub>O were added, and the layers were separated. The aq phase was acidified with 2 M HCl to pH 1 and extracted with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness to give title compound <b>10b</b> (2.03 g, 53%) as a yellow solid. LC–MS: <i>t</i><sub>R</sub> = 0.77 min, [M + H]<sup>+</sup> = 326.13. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.75 (br, 1 H), 5.75 (d, <i>J</i> = 7.2 Hz, 1 H), 4.51 (dd, <i>J</i> = 6.4 and 27.8 Hz, 1 H), 4.12 (m, 4 H), 2.47 (m, 2 H), 1.32 (t, <i>J</i> = 7.1 Hz, 6 H).</div></div><div id="sec4_7_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-((<i>R</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>30d</b>)</h3><div class="NLM_p last">A solution of 4-((<i>R</i>)-3-(diethoxyphosphoryl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid butyl ester (<b>24d</b>) (2.66 g) in MeCN (11.8 mL) was cooled down to 0 °C, and TMSBr (10.2 mL) was added dropwise. The reaction mixture was stirred at rt overnight. Water (20.0 mL) was added, and the reaction mixture was stirred at rt for 2 h and extracted with DCM five times. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on reverse phase (using a gradient from water/MeCN/TFA 95:5:1 to water/MeCN/TFA 10:90:1) to give title compound <b>30d</b> (1.54 g, 63%) as a white powder. LC–MS: <i>t</i><sub>R</sub> = 1.37 min, [M + H]<sup>+</sup> = 619.4. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.38 (d, <i>J</i> = 7.1 Hz, 2 H), 7.55 (m, 3 H), 7.16 (s, 1 H), 5.39 (m, 1 H), 4.27–4.19 (m, 1 H), 4.13 (t, <i>J</i> = 6.5 Hz, 2 H), 3.89–3.67 (m, 7 H), 3.63–3.55 (m, 3 H), 3.53–3.47 (m, 2 H), 3.41 (s, 3 H), 2.45–2.17 (m, 4 H), 1.66 (m, 2 H), 1.43 (m, 2 H), 0.98 (t, <i>J</i> = 7.3 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 163.3, 162.4, 161.4, 155.1, 137.7, 130.9, 128.7, 128.4, 99.5, 79.6, 78.8, 65.1, 56.4, 51.8, 51.6, 47.1, 45.4, 44.9, 44.7, 43.7, 42.1, 31.0, 30.6, 30.1, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.14 min, [M + H]/<i>z</i> = 619.2645, found 647.2651. HPLC with chiral stationary phase (ChiralCel OZ-H 4.6 mm × 250 mm, 5 μm; 60% heptane/TFA 100:0.5, 40% EtOH/MeOH/TFA 50:50:0.5): <i>t</i><sub>R</sub> = 14.1 min, 94% de.</div></div><div id="sec4_7_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-2-Benzyloxycarbonylamino-4-hydroxybutyric Acid Methyl Ester (<b>41d</b>)</h3><div class="NLM_p">(a) To an ice-cold solution of H-Hse-OH (5.00 g) in dioxane (168 mL) and 2 M NaOH (42.0 mL), Cbz-Cl (8.12 g) was added portionwise. The reaction mixture was stirred at rt overnight, and dioxane was removed in vacuo. The resulting aq solution was extracted with Et<sub>2</sub>O, acidified with 2 M HCl to pH 1, and extracted with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness to give (<i>S</i>)-2-benzyloxycarbonylamino-4-hydroxybutyric acid (8.90 g, 84%) as a beige solid. LC–MS: <i>t</i><sub>R</sub> = 0.71 min, [M + H]<sup>+</sup> = 254.41. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.34 (m, 5 H), 5.09 (s, 2 H), 4.34 (m, 1 H), 3.66 (m, 2 H), 2.09 (m, 1 H), 1.88 (m, 1 H).</div><div class="NLM_p">(b) Dicyclohexylamine (6.37 g) was added portionwise to a solution of the above material (8.90 g) in EtOH (77.0 mL). The mixture was concentrated leading to a white suspension which was filtered off. The white solid was suspended in Et<sub>2</sub>O, filtered off, and dried under vacuum to give (<i>S</i>)-2-benzyloxycarbonylamino-4-hydroxybutyric acid as dicyclohexylamine salt (12.2 g, 80%), as a white powder. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.35 (m, 5 H), 5.10 (s, 2 H), 4.12 (m, 1 H), 3.65 (m, 2 H), 2.07 (m, 5 H), 1.88 (m, 5 H), 1.74 (m, 2 H), 1.45–1.18 (m, 12 H).</div><div class="NLM_p last">(c) MeI (2.10 mL) was added dropwise at rt to a suspension of the above material (12.2 g) in DMF (196 mL). The reaction mixture was stirred overnight at rt. MeI (1.75 mL) was added, and the stirring was continued at rt for 6 h. MeI (3.50 mL) was added, and the stirring was continued at rt overnight. The solvent was removed in vacuo, and the residue was taken up in water and EA. The layers were separated, the organic phase was washed with saturated NaCl, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with Et<sub>2</sub>O) to give title compound <b>41d</b> (4.82 g, 64%) as a colorless resin. LC–MS: <i>t</i><sub>R</sub> = 0.79 min, [M + H]<sup>+</sup> = 268.30. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.38 (m, 5 H), 5.66 (m, 1 H), 5.15 (m, 2 H), 4.58 (m, 1 H), 4.45 (br, 0.5 H), 4.29 (br, 0.5 H), 3.79 (s, 3 H), 3.73 (m, 1 H), 2.19 (m, 1 H), 1.74 (m, 1 H).</div></div><div id="sec4_7_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-2-Benzyloxycarbonylamino-4-bromobutyric Acid Methyl Ester (<b>40d</b>)</h3><div class="NLM_p last">To an ice-cold solution of <b>41d</b> (2.41 g) and CBr<sub>4</sub> (6.75 g) in DCM (120 mL), PPh<sub>3</sub> on resin (12.4 g, 1.60 mmol/g) was added. The ice bath was removed, the reaction mixture was stirred at rt for 2.5 h, filtered off, and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 3:1) to give title compound <b>40d</b> (1.54 g, 52%) as a colorless resin. LC–MS: <i>t</i><sub>R</sub> = 0.98 min, [M + H]<sup>+</sup> = 330.33. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5 H), 5.41 (m, 1 H), 5.14 (s, 2 H), 4.53 (m, 1 H), 3.78 (s, 3 H), 3.45 (t, <i>J</i> = 6.9 Hz, 2 H), 2.46 (m, 1 H), 2.27 (m, 1 H).</div></div><div id="sec4_7_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>R</i>)-2-Benzyloxycarbonylamino-5-hydroxypentanoic Acid Methyl Ester (<b>41g</b>)</h3><div class="NLM_p last">To a −15 °C solution of Cbz-<span class="smallcaps smallerCapital">d</span>-Glu-OMe (<b>42g</b>, 0.700 g) in THF (35.0 mL), NMM (0.264 g) was added followed by dropwise addition of isobutyl chloroformate (0.341 mL). The reaction mixture was stirred at −15 °C for 14 h. NaBH<sub>4</sub> (0.269 g) was added followed by dropwise addition of MeOH (23.0 mL). The reaction mixture was stirred at 0 °C for 50 min and quenched by adding 1 M KHSO<sub>4</sub>. The mixture was extracted with EA three times, the combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness to give title compound <b>41g</b> (0.647 g, 100%) as a colorless gel. LC–MS: <i>t</i><sub>R</sub> = 0.82 min, [M + H]<sup>+</sup> = 282.11. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5 H), 5.46 (m, 1 H), 5.13 (m, 2 H), 4.44 (m, 1 H), 3.80 (m, 2 H), 3.76 (s, 3 H), 1.96 (m, 1 H), 1.78 (m, 1 H), 1.63 (m, 2 H).</div></div><div id="sec4_7_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>R</i>)-2-Benzyloxycarbonylamino-5-iodopentanoic Acid Methyl Ester (<b>40g</b>)</h3><div class="NLM_p last">PPh<sub>3</sub> (0.905 g) and imidazole (0.251 g) were added to a solution of <b>41g</b> (0.647 g) in THF (25.0 mL). At 0 °C iodine (0.876 g) was added portionwise. The reaction mixture was stirred at rt for 3 h. Aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> was added to quench the excess iodine, followed by Et<sub>2</sub>O and water. The layers were separated, and the organic phase was dried over MgSO<sub>4</sub> and concentrated in vacuo. Et<sub>2</sub>O (20.0 mL) was added to the residue. Precipitation occurred upon standing. The suspension was decanted, the solution was separated and concentrated to dryness to give title compound <b>40g</b> (0.586 g, 65%) as a brown oil. LC–MS: <i>t</i><sub>R</sub> = 1.04 min, [M + H]<sup>+</sup> = 391.84.</div></div><div id="sec4_7_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>R</i>)-2-Benzyloxycarbonylamino-5-(diethoxyphosphoryl)pentanoic Acid (<b>10g</b>)</h3><div class="NLM_p last">A mixture of <b>39g</b> (0.602 g) and LiOH (0.126 g) in water/EtOH/MeOH (5.00 mL, 1:2:2) was stirred at 0 °C for 1 h and at rt for 2 h. Water and Et<sub>2</sub>O were added. The layers were separated. The aq phase was acidified with 2 M HCl to pH 3 and extracted with Et<sub>2</sub>O. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness to give title compound <b>10g</b> (0.277 g, 48%) as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 0.80 min, [M + H]<sup>+</sup> = 388.09. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (m, 5 H), 5.64–5.51 (m, 1 H), 5.12 (br, 2 H), 4.43 (m, 2 H), 4.12 (m, 4 H), 2.03 (m, 1 H), 1.90–1.66 (m, 3 H), 1.35 (t, <i>J</i> = 7.1 Hz, 6 H).</div></div><div id="sec4_7_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-((2<i>S</i>,3<i>R</i>)-3,4-Dihydroxy-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}butyryl)piperazine-1-carboxylic Acid Ethyl Ester (<b>43</b>)</h3><div class="NLM_p">(a) Imidazole (1.83 g) was added to a solution of (<i>R</i>)-3,4-dihydroxybutyric acid methyl ester<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> (2.40 g) in DMF (40.0 mL) at rt. After 15 min of stirring, chlorotriisopropylsilane (3.79 mL) was added and the stirring was pursued overnight at rt. Additional chlorotriisopropylsilane (0.758 mL) was added, and the mixture was stirred at 35 °C for 2 days and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 95:5) to give (<i>R</i>)-3-hydroxy-4-triisopropylsilanyloxybutyric acid methyl ester (2.61 g, 50%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.13 (m, 1 H), 3.80–3.67 (m, 2 H), 3.73 (s, 3 H), 2.89 (m, 1 H), 2.63–2.51 (m, 2 H), 1.14 (m, 3 H), 1.08 (d, 18 H).</div><div class="NLM_p">(b) Reference <a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">56</a>. ZnBr<sub>2</sub> (0.733 g) was charged into a heat gun dried flask. The solid was heated to 120 °C under vacuum for 2 h and filled with argon. The flask was cooled down to −50 °C, and THF (3.00 mL) was added, followed by dropwise addition of MeLi (1.6 M in Et<sub>2</sub>O, 2.00 mL). The reaction mixture was allowed to warm up to 0 °C. A flask was charged with THF (6.00 mL) and diisopropylamine (0.963 mL) under argon. The solution was cooled to −78 °C, and BuLi (2.5 M in hexane, 2.80 mL) was added dropwise. The resulting solution was allowed to warm up to 0 °C over 15 min and was cooled down to −78 °C. To a third flask containing (<i>R</i>)-3-hydroxy-4-triisopropylsilanyloxybutyric acid methyl ester (0.900 g) in THF (3.00 mL) under argon at 0 °C was added the MeZnBr solution. After stirring at 0 °C for 1 h, the mixture was cooled down to −78 °C and the −78 °C LDA solution was added. The dark blue reaction mixture was stirred at −78 °C for 1 h, and a solution of dibenzylazocarboxylate (1.85 g) in THF (3.00 mL) was added dropwise. The reaction mixture was stirred for 40 min at −78 °C, was quenched with saturated aq NH<sub>4</sub>Cl and allowed to warm up to rt and extracted with Et<sub>2</sub>O three times. The combined organic layers were dried over MgSO<sub>4</sub>, filtered off, and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 1:1) to give dibenzyl 1-((2<i>S</i>,3<i>R</i>)-3-hydroxy-1-methoxy-1-oxo-4-((triisopropylsilyl)oxy)butan-2-yl)hydrazine-1,2-dicarboxylate (0.480 g, 26%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 1.19 min, [M + H]<sup>+</sup> = 589.37.</div><div class="NLM_p">(c) 2,6-Lutidine (0.178 mL) was added to a solution of the above material (0.450 g) in DCM (1.00 mL) at 0 °C. After 15 min of stirring at 0 °C, <i>tert</i>-butyldimethylsilyltrifluoromethanesulfonate (1.15 mL) was added dropwise and the reaction mixture was stirred at 0 °C for 2 h. Aqueous saturated NH<sub>4</sub>Cl was added, the aqueous phase was extracted with EA three times, the combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 9:1) to give dibenzyl 1-((2<i>S</i>,3<i>R</i>)-3-((<i>tert</i>-butyldimethylsilyl)oxy)-1-methoxy-1-oxo-4-((triisopropylsilyl)oxy)butan-2-yl)hydrazine-1,2-dicarboxylate (0.490 g, 91%) as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 1.33 min, [M + H]<sup>+</sup> = 703.64.</div><div class="NLM_p">(d) To a solution of the above material (0.220 g) in EtOH (5.00 mL), Pd/C (wet, 5%, 0.033 g) was added. The flask was evacuated and backfilled with argon, evacuated, and backfilled with hydrogen. The reaction mixture was stirred for 1 h, and Raney nickel (suspension in water, 5.00 mL) was added. The reaction mixture was stirred at rt under hydrogen overnight and filtered off over Celite. The Celite was washed with DCM/MeOH/Et<sub>3</sub>N 9:1:0.1 and the filtrate was concentrated to dryness to give (2<i>S</i>,3<i>R</i>)-2-amino-3-(<i>tert</i>-butyldimethylsilanyloxy)-4-triisopropylsilanyloxybutyric acid methyl ester (0.280 g, 100%) as crude, as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 1.05 min, [M + H]<sup>+</sup> = 420.56.</div><div class="NLM_p">(e) PyBOP (0.287 g) was added to a solution of <b>8</b> (0.150 g) in DCM (2.00 mL). The reaction mixture was stirred at rt for 15 min, and the above material (0.210 g) and DIPEA (0.094 mL) were added. The resulting mixture was stirred at rt overnight and partitioned in saturated aq NH<sub>4</sub>Cl and EA. The aq phase was extracted with EA, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 4:6) to give (2<i>S</i>,3<i>R</i>)-3-(<i>tert</i>-butyldimethylsilanyloxy)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-triisopropylsilanyloxybutyric acid methyl ester (0.170 g, 48%) as a colorless oil. LC–MS: <i>t</i><sub>R</sub> = 1.37 min, [M + H]<sup>+</sup> = 701.30. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (d, <i>J</i> = 8.7 Hz, 1 H), 8.51 (m, 2 H), 7.46 (m, 3 H), 7.11 (br, 1 H), 5.18 (dd, <i>J</i> = 2.0 and 8.7 Hz, 1 H), 4.22 (m, 1 H), 4.16–3.98 (m, 2 H), 3.93 (m, 1 H), 3.80 (s, 3 H), 3.79 (m, 2 H), 3.58 (m, 2 H), 3.38 (s, 3 H), 2.29–2.03 (m, 2 H), 1.15 (m, 3 H), 1.13 (s, 12 H), 1.12 (s, 6 H), 0.90 (s, 9 H), 0.09 (s, 3 H), 0.07 (s, 3 H).</div><div class="NLM_p">(f) 2 M LiOH (0.350 mL) was added to a solution of the above material (0.170 g) in THF (5.00 mL) and water (0.700 mL). The reaction mixture was stirred overnight at rt and then quenched with aq NH<sub>4</sub>Cl followed by addition of 2 M HCl until pH 3. The mixture was extracted with EA three times, and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness to give (2<i>S</i>,3<i>R</i>)-3-(<i>tert</i>-butyldimethylsilanyloxy)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-triisopropylsilanyloxybutyric acid (0.160 g, 96%) as a white foam. LC–MS: <i>t</i><sub>R</sub> = 1.30 min, [M + H]<sup>+</sup> = 687.63. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.24 (m, 1 H), 8.51 (m, 2 H), 7.47 (m, 3 H), 7.07 (br, 1 H), 5.04 (m, 1 H), 4.32 (m, 1 H), 4.19–4.00 (m, 2 H), 3.97 (dd, <i>J</i> = 4.5 and 10.3 Hz, 1 H), 3.87–3.55 (m, 4 H), 3.40 (s, 3 H), 2.30–2.08 (m, 2 H), 1.23 (m, 3 H), 1.15 (s, 12 H), 1.14 (s, 6 H), 0.89 (s, 9 H), 0.05 (s, 3 H), 0.04 (s, 3 H).</div><div class="NLM_p">(g) A solution of the above material (0.160 g), EDC-Cl (0.536 g), and HOBt (0.472 g) in DCM (2.00 mL) was stirred at rt for 15 min, and <b>9a</b> (0.368 g) was added. The reaction mixture was stirred at rt overnight, and aq NH<sub>4</sub>Cl was added. The resulting mixture was extracted three times with EA. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 1:1) to give 4-((2<i>S</i>,3<i>R</i>)-3-(<i>tert</i>-butyldimethylsilanyloxy)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-4-triisopropylsilanyloxybutyryl)piperazine-1-carboxylic acid ethyl ester (0.130 g, 67%) as a white foam. LC–MS: <i>t</i><sub>R</sub> = 1.35 min, [M + H]<sup>+</sup> = 827.80. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (d, <i>J</i> = 9.5 Hz, 1 H), 8.47 (m, 2 H), 7.48 (m, 3 H), 7.04 (br, 1 H), 5.40 (t, <i>J</i> = 8.8 Hz, 1 H), 4.19–4.00 (m, 4 H), 4.17 (q, <i>J</i> = 7.0 Hz, 2 H), 3.85–3.71 (m, 2 H), 3.83 (d, <i>J</i> = 3.8 Hz, 2 H), 3.63–3.52 (m, 3 H), 3.41 (s, 3 H), 3.37–3.23 (m, 3 H), 2.30–2.09 (m, 2 H), 1.29 (m, 6 H), 1.02 (br, 18 H), 0.90 (s, 9 H), 0.13 (s, 3 H), 0.08 (s, 3 H).</div><div class="NLM_p last">(h) TBAF (1 M in THF, 0.363 mL) was added to a solution of the above material (0.120 g) in THF (3.00 mL). The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude product was purified by CC on silica gel (using a gradient from DCM/MeOH 1:0 to DCM/MeOH 9:1) to give title compound <b>43</b> (0.061 g, 76%) as a beige foam. LC–MS: <i>t</i><sub>R</sub> = 1.39 min, [M + H]<sup>+</sup> = 557.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.27 (d, <i>J</i> = 7.7 Hz, 1 H), 8.47 (m, 2 H), 7.53 (dd, <i>J</i> = 1.8 and 5.2 Hz, 3 H), 6.96 (s, 1 H), 5.29 (d, <i>J</i> = 5.6 Hz, 1 H), 5.01 (t, <i>J</i> = 7.6 Hz, 1 H), 4.96 (t, <i>J</i> = 4.9 Hz, 1 H), 4.13 (d, <i>J</i> = 23.6 Hz, 1 H), 4.07 (q, <i>J</i> = 7.1 Hz, 2 H), 3.88 (m, 1 H), 3.80 (m, 1 H), 3.72–3.41 (m, 11 H), 3.34 (m, 2 H), 3.30 (s, 3 H), 2.16–2.01 (m, 2 H), 1.21 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.4, 163.3, 162.4, 161.4, 155.1, 137.6, 131.2, 128.9, 128.4, 99.7, 79.6, 78.8, 72.3, 63.9, 61.4, 56.4, 52.1, 52.0, 51.7, 45.7, 45.1, 44.8, 43.9, 43.6, 42.1, 30.6, 30.1, 15.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.14 min, [M + H]/<i>z</i> = 557.2723, found 557.2728.</div></div><div id="sec4_7_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-((<i>S</i>)-3-(3-Hydroxyisoxazol-5-yl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Ethyl Ester (<b>44</b>)</h3><div class="NLM_p">(a) Reference <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">57</a>. A suspension of methyl 3-hydroxyisoxazole-5-carboxylate (1.00 g) and K<sub>2</sub>CO<sub>3</sub> (1.97 g) in acetone (20.0 mL) was heated at 70 °C for 1 h. Benzyl bromide (1.27 mL) was added, and the reaction mixture was stirred at 70 °C for 3 h and at rt for 2 h. The mixture was filtered off and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 5:1) to give 3-benzyloxyisoxazole-5-carboxylic acid methyl ester (1.60 g, 100%) as a beige oil. LC–MS: <i>t</i><sub>R</sub> = 0.97 min, [M + H]<sup>+</sup> = 234.24.</div><div class="NLM_p">(b) NaBH<sub>4</sub> (0.353 g) was added to a solution of the above material (1.60 g) in MeOH (49.0 mL) at 0 °C, and the reaction mixture was stirred at 0 °C for 4 h. MeOH (100 mL) and 1 M HCl (200 mL) were added, and the resulting mixture was extracted three times with DCM. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 3:1) to give (3-benzyloxyisoxazol-5-yl)methanol (1.23 g, 87%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.81 min, [M + H]<sup>+</sup> = 206.22.</div><div class="NLM_p">(c) Reference <a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">58</a>. A solution of the above material (1.23 g) and pyridine (0.989 mL) in DCM (22.5 mL) was added dropwise to a 0 °C suspension of triphenylphosphine dibromide (4.10 g) in DCM (30.0 mL). The reaction mixture was stirred at 0 °C for 1 h and washed twice with 10% aq sodium bisulfite. The aq layers were extracted with Et<sub>2</sub>O. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The resulting solid was triturated with Et<sub>2</sub>O, the suspension was filtered off, and the solution was concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 2:1) to give 3-benzyloxy-5-bromomethylisoxazole (1.54 g, 96%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 0.99 min, [M + H]<sup>+</sup> = 268.03.</div><div class="NLM_p">(d) Reference <a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">59</a>. BuLi (1.6 M in hexane, 2.53 mL) was added to a solution of (<i>R</i>)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (1.06 mL) in THF (53.0 mL) cooled at −78 °C, and the reaction mixture was stirred at −78 °C for 30 min. A solution of 3-benzyloxy-5-bromomethylisoxazole (1.54 g) in THF (42.0 mL) was added, and the reaction mixture was stirred at −78 °C for 4 h. A solution of (<i>R</i>)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (1.06 mL) and BuLi (1.6 M in hexane, 2.53 mL) in THF (53.0 mL) prepared as before was added three more times at 1 h intervals to the reaction mixture stirred at −78 °C. The reaction mixture was allowed to warm to 0 °C, aq NH<sub>4</sub>Cl was added, and the mixture was concentrated in vacuo. The residue was extracted with Et<sub>2</sub>O three times. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated to dryness. The crude product was purified by CC on silica gel (eluting with heptane/EA 9:1) to give (2<i>S</i>,5<i>R</i>)-2-(3-benzyloxyisoxazol-5-ylmethyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (2.14 g, 100%) as a yellow oil. LC–MS: <i>t</i><sub>R</sub> = 1.06 min, [M + H]<sup>+</sup> = 372.24. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45–7.32 (m, 6 H), 5.66 (s, 1 H), 5.23 (s, 2 H), 4.30 (m, 1 H), 4.03–3.98 (m, 2 H), 3.88 (t, <i>J</i> = 3.5 Hz, 1 H), 3.72 (s, 5 H), 3.69 (s, 2 H), 3.66 (s, 3 H), 3.22 (dd, <i>J</i> = 4.3 and 15 Hz, 1 H), 3.10 (dd, <i>J</i> = 6.3 and 15 Hz, 1 H), 2.24 (m, 2 H), 3.88 (t, <i>J</i> = 6.4 Hz, 6 H).</div><div class="NLM_p">(e) A mixture of the above compound (2.14 g) and 1 M HCl (11.5 mL) in MeCN (57.5 mL) was stirred at rt for 2 h and evaporated in vacuo. Concentrated ammonia was added to the residue until pH 9, and the mixture was extracted with DCM. The organic phase was dried (MgSO<sub>4</sub>) and concentrated to dryness to give (<i>S</i>)-2-amino-3-(3-benzyloxyisoxazol-5-yl)propionic acid methyl ester (1.85 g, 100%) as a beige solid. LC–MS: <i>t</i><sub>R</sub> = 0.69 min, [M + H]<sup>+</sup> = 277.28.</div><div class="NLM_p">(f) A solution of <b>8</b> (0.861 g), HOBt (0.497 g), and EDC-Cl (0.619 g) in DCM (16.0 mL) was stirred for 5 min at rt. The above product (0.794 g) was added, and the reaction mixture was stirred at rt overnight. Aqueous NaHSO<sub>4</sub> was added, and the layers were separated. The organic phase was washed with aq NH<sub>4</sub>Cl, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated off. The crude product was purified by CC on silica gel (eluting with heptane/EA 1:1) to give (<i>S</i>)-3-(3-benzyloxyisoxazol-5-yl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionic acid methyl ester (0.447 g, 28%) as a beige powder. LC–MS: <i>t</i><sub>R</sub> = 1.10 min, [M + H]<sup>+</sup> = 558.20. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.89 (s, 1 H), 8.46 (s, 2 H), 7.49–7.34 (m, 8 H), 7.05 (s, 1 H), 5.84 (s, 1 H), 5.25 (s, 2 H), 5.09 (m, 1 H), 4.20–3.94 (m, 2 H), 3.84 (br, 3 H), 3.78–3.53 (m, 3 H), 3.49–3.36 (m, 2 H), 3.41 (br, 3H), 2.33–2.07 (m, 2 H).</div><div class="NLM_p">(g) A solution of the above compound (0.447 g) and LiOH·H<sub>2</sub>O (0.168 g) in THF/H<sub>2</sub>O (10.0 mL, 3:1) was stirred at rt for 1 h. The solvent was removed in vacuo, and 1 M HCl and EA were added to the residue. The layers were separated, and the aq phase was further extracted with EA. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated off to give (<i>S</i>)-3-(3-benzyloxyisoxazol-5-yl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionic acid (0.430 g, 98%) as a beige foam which was used without further purification. LC–MS: <i>t</i><sub>R</sub> = 1.03 min, [M + H]<sup>+</sup> = 544.21.</div><div class="NLM_p">(h) A solution of the above material (0.430 g), HOBt (0.139 g), EDC-Cl (0.164 g), and DIPEA (0.282 mL) in DCM (9.00 mL) was stirred for 15 min at rt. <b>9a</b> (0.129 g) was added, and the reaction mixture was stirred at rt overnight. Aqueous NaHSO<sub>4</sub> was added, and the layers were separated. The aq phase was extracted with EA, and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated off. The crude product was purified by CC on silica gel (eluting with DCM/MeOH 9:1) to give 4-((<i>S</i>)-3-(3-benzyloxyisoxazol-5-yl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic acid ethyl ester (0.542 g, 99%) as a beige powder. LC–MS: <i>t</i><sub>R</sub> = 1.09 min, [M + H]<sup>+</sup> = 684.28. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.90 (m, 1 H), 8.45 (br, 2 H), 7.50–7.34 (m, 8 H), 7.04 (s, 1 H), 5.84 (s, 1 H), 5.48 (m, 1 H), 5.25 (s, 2 H), 4.15 (m, 2 H), 4.03 (m, 1 H), 3.86–3.43 (m, 12 H), 3.41 (s, 3 H), 3.34 (m, 1 H), 3.20 (m, 1 H), 2.32–2.08 (m, 2 H), 1.28 (m, 3 H).</div><div class="NLM_p last">(i) Pd on barium sulfate (5%, 0.098 g) was added to a solution of the above material (0.393 g) in MeOH (13.0 mL). The flask was evacuated and backfilled with argon, evacuated, and backfilled with hydrogen. The reaction mixture was stirred for 3.5 h, and additional Pd on barium sulfate (5%, 0.098 g) was added. The reaction mixture was stirred at rt under hydrogen overnight and filtered off over Celite. The Celite was washed with MeOH, and the filtrate was concentrated to dryness. The crude was purified by preparative LC–MS (Gemini C18 110A Ax, 10 μm, 21.2 mm × 50 mm, 27.7–95% MeCN in water containing 0.2% formic acid, 45 mL/min) to give title compound <b>44</b> (0.070 g, 21%) as a white powder. LC–MS: <i>t</i><sub>R</sub> = 1.10 min, [M + H]<sup>+</sup> = 594.4. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.91 (d, <i>J</i> = 8.6 Hz, 1 H), 8.45 (m, 2 H), 7.48 (m, 3 H), 7.25 (m, 0.5 H), 7.19 (m, 0.5 H), 7.05 (s, 1 H), 5.83 (s, 1 H), 5.49 (m, 1 H), 4.19–4.10 (m, 3 H), 4.02 (m, 1 H), 3.85–3.70 (m, 2 H), 3.68–3.43 (m, 9 H), 3.40 (s, 3 H), 3.35–3.27 (m, 1 H), 3.22–3.14 (m, 1 H), 2.31–2.10 (m, 2 H), 1.27 (m, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.7, 169.8, 168.4, 163.4, 162.5, 161.3, 155.0, 137.7, 131.2, 128.8, 128.5, 99.8, 95.0, 79.6, 78.8, 61.5, 56.4, 52.0, 51.7, 48.0, 45.2, 44.8, 43.6, 42.2, 30.6, 29.9, 15.0. LC–HRMS: <i>t</i><sub>R</sub> = 1.21 min, [M + H]/<i>z</i> = 594.2676, found 594.2671.</div></div><div id="sec4_7_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 4-((<i>R</i>)-3-(Bis-isopropoxycarbonyloxymethoxyphosphoryl)-2-{[6-((<i>S</i>)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}propionyl)piperazine-1-carboxylic Acid Butyl Ester (<b>45</b>)</h3><div class="NLM_p">(a) Reference <a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">60</a>. Chloromethyl chloroformate (2.07 mL) and isopropyl alcohol (1.75 mL) were dissolved in Et<sub>2</sub>O (34.0 mL). The solution was cooled down to 0 °C, and pyridine was added dropwise. The ice bath was removed, and the reaction mixture was stirred at rt overnight. The suspension was filtered off, and the filtrate was washed with 10% aq citric acid, water, sat. aq NaHCO<sub>3</sub>, and brine. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo to give carbonic acid chloromethyl ester isopropyl ester (3.03 g, 87%) as a colorless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.74 (s, 2 H), 4.98 (m, 1 H), 1.35 (d, <i>J</i> = 6.3 Hz, 6 H).</div><div class="NLM_p last">(b) Reference <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">61</a>. Et<sub>3</sub>N (0.101 mL) was added to a solution of <b>30d</b> (0.150 g) in anhydrous DMPU (0.44 mL). The mixture was stirred at rt for 10 min, and carbonic acid chloromethyl ester isopropyl ester (0.416 mL) followed by NaI (0.0441 g) was added. The reaction mixture was stirred at 45 °C overnight. TEA (0.101 mL) and carbonic acid chloromethyl ester isopropyl ester (0.416 mL) were added, and the mixture was stirred for 3.5 h at 45 °C and partitioned between toluene and water/brine. The layers were separated, the aq phase was extracted with toluene, and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered off, and concentrated to dryness. The resulting crude product was purified by CC on silica gel (using a gradient from heptane/EA 1:0 to heptane/EA 0:1) to give a yellow oil contaminated with residual DMPU. The oil was lyophilized twice to give title compound <b>45</b> (0.094 g, 45%) as a white powder. LC–MS: <i>t</i><sub>R</sub> = 1.38 min, [M + H]<sup>+</sup> = 851.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.27 (m, 1 H), 8.54 (m, 2 H), 7.52 (m, 3 H), 6.96 (s, 1 H), 5.63–5.52 (m, 4 H), 5.24 (m, 1 H), 4.79 (m, 2 H), 4.19–4.09 (m, 1 H), 4.00 (t, <i>J</i> = 6.5 Hz, 2 H), 3.89 (m, 1 H), 3.80–3.37 (m, 11 H), 3.30 (s, 3 H), 2.66–2.54 (m, 1 H), 2.21–2.04 (m, 2 H), 1.54 (m, 2 H), 2.33 (m, 2 H), 1.23 (m, 12 H), 1.04 (d, <i>J</i> = 6.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.4, 163.4, 162.6, 161.4, 155.1, 153.1, 137.7, 131.2, 128.8, 128.6, 99.9, 84.6, 79.6, 78.8, 73.3, 65.2, 62.5, 56.4, 51.9, 51.7, 47.9, 45.3, 45.1, 44.8, 44.6, 43.7, 43.3, 42.3, 35.6, 31.0, 30.6, 30.1, 29.5, 28.3, 26.0, 22.3, 21.8, 19.1, 14.1. LC–HRMS: <i>t</i><sub>R</sub> = 1.29 min, [M + H]/<i>z</i> = 851.3514, found 851.3585.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00933">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00933" class="ext-link">10.1021/acs.jmedchem.5b00933</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Characterization of all target compounds not described in the main text, synthetic schemes for analogs <b>43</b> and <b>44</b>, and SDs and ranges for the data in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_001.csv">jm5b00933_si_001.csv (4.69 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_002.pdf">jm5b00933_si_002.pdf (231.63 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00933" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Caroff</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dfbaa9bef1bcbeadb0b9b99fbebcabbab3b6b0b1f1bcb0b2"><span class="__cf_email__" data-cfemail="90f5e6f1bef3f1e2fff6f6d0f1f3e4f5fcf9fffebef3fffd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francis Hubler</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuel Meyer</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorte Renneberg</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmela Gnerre</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Treiber</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus Rey</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Hess</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beat Steiner</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurt Hilpert</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus A. Riederer</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery and Preclinical
Research and Development, Actelion Pharmaceuticals
Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d6914e5078-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Raimund Brauner, Simon Buetikofer, Rémy Castro, Dominik Fosshag, Yannick Gallin, Marie Idoux, Petar Maric, Valérie Siefken, and Gina Wintenberger for the synthetic chemistry work, Martine Baumann, Brigitte Butscha, Isabelle Guillaumat, and Benoit Lack for biological testing, Markus Kramberg for technical assistance for in vivo experiments, Fabienne Drouet, Rolf Wuest, Isabelle Weber, Aude Weigel, and Nathalie Jaouen for generating DMPK data, Eric Ertel for providing hERG data, Bruno Capeleto for early formulation, and Henri Ramuz for stimulating discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i52" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i52"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> Abbreviations Used</h2><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMPU</td><td class="NLM_def"><p class="first last">1,3-dimethyl-3,4,5,6-tetrahydro-2(1<i>H</i>)-pyrimidinone</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EDC-Cl</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">PS</td><td class="NLM_def"><p class="first last">polymer-supported</p></td></tr><tr><td class="NLM_term">PyBOP</td><td class="NLM_def"><p class="first last">(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">[<sup>33</sup>P]-2MeSADP</td><td class="NLM_def"><p class="first last"><sup>33</sup>P-labeled 2-methylthioadenosine 5′-diphosphate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Davies, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangartner, J. R.</span><span> </span><span class="NLM_article-title">Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1161/01.CIR.73.3.418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1161%2F01.CIR.73.3.418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1986&pages=418-427&author=M.+J.+Daviesauthor=A.+C.+Thomasauthor=P.+A.+Knapmanauthor=J.+R.+Hangartner&title=Intramyocardial+platelet+aggregation+in+patients+with+unstable+angina+suffering+sudden+ischemic+cardiac+death&doi=10.1161%2F01.CIR.73.3.418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.73.3.418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.73.3.418%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BJ.%26aulast%3DThomas%26aufirst%3DA.%2BC.%26aulast%3DKnapman%26aufirst%3DP.%2BA.%26aulast%3DHangartner%26aufirst%3DJ.%2BR.%26atitle%3DIntramyocardial%2520platelet%2520aggregation%2520in%2520patients%2520with%2520unstable%2520angina%2520suffering%2520sudden%2520ischemic%2520cardiac%2520death%26jtitle%3DCirculation%26date%3D1986%26volume%3D73%26spage%3D418%26epage%3D427%26doi%3D10.1161%2F01.CIR.73.3.418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Davì, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrono, C.</span><span> </span><span class="NLM_article-title">Platelet activation and atherothrombosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2482</span><span class="NLM_x">–</span> <span class="NLM_lpage">2494</span><span class="refDoi"> DOI: 10.1056/NEJMra071014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMra071014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=18077812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVemurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2482-2494&author=G.+Dav%C3%ACauthor=C.+Patrono&title=Platelet+activation+and+atherothrombosis&doi=10.1056%2FNEJMra071014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">.Mechanisms of disease: platelet activation and atherothrombosis</span></div><div class="casAuthors">Davi, Giovanni; Patrono, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2482-2494</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The role of thrombin and protease-activated receptors in platelet-activated mechanism in atherothrombosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ9gf2beAZ_LVg90H21EOLACvtfcHk0lifDN46gMHucA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVemurrL&md5=b24fcd4b4aff95fb8fa9487881d76d33</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra071014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra071014%26sid%3Dliteratum%253Aachs%26aulast%3DDav%25C3%25AC%26aufirst%3DG.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DPlatelet%2520activation%2520and%2520atherothrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2482%26epage%3D2494%26doi%3D10.1056%2FNEJMra071014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Michelson, A. D.</span><span> </span><span class="NLM_article-title">Antiplatelet therapies for the treatment of cardiovascular disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1038/nrd2957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnrd2957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=20118963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=154-169&author=A.+D.+Michelson&title=Antiplatelet+therapies+for+the+treatment+of+cardiovascular+disease&doi=10.1038%2Fnrd2957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet therapies for the treatment of cardiovascular disease</span></div><div class="casAuthors">Michelson, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-169</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antiplatelet therapy was successful in reducing mortality and morbidity in acute myocardial infarction.  Recent advances in understanding the mol. basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity.  This article reviews the role of platelets in hemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Jl1XbcNzGrVg90H21EOLACvtfcHk0liwEkP0YZjO4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yns7c%253D&md5=aef13552bb92d3311c04a2e9505442ad</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2957%26sid%3Dliteratum%253Aachs%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26atitle%3DAntiplatelet%2520therapies%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D154%26epage%3D169%26doi%3D10.1038%2Fnrd2957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Andre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRocca, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span><span class="refDoi"> DOI: 10.1172/JCI17864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1172%2FJCI17864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=398-406&author=P.+Andreauthor=S.+M.+Delaneyauthor=T.+LaRoccaauthor=D.+Vincentauthor=F.+DeGuzmanauthor=M.+Jurekauthor=B.+Kollerauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=P2Y12+regulates+platelet+adhesion%2Factivation%2C+thrombus+growth%2C+and+thrombus+stability+in+injured+arteries&doi=10.1172%2FJCI17864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI17864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI17864%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DLaRocca%26aufirst%3DT.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DJurek%26aufirst%3DM.%26aulast%3DKoller%26aufirst%3DB.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DP2Y12%2520regulates%2520platelet%2520adhesion%252Factivation%252C%2520thrombus%2520growth%252C%2520and%2520thrombus%2520stability%2520in%2520injured%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D112%26spage%3D398%26epage%3D406%26doi%3D10.1172%2FJCI17864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Dorsam, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Central role of the P2Y12 receptor in platelet activation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span><span class="refDoi"> DOI: 10.1172/JCI20986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1172%2FJCI20986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=14755328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation&doi=10.1172%2FJCI20986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Central role of the P2Y12 receptor in platelet activation</span></div><div class="casAuthors">Dorsam, Robert T.; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Platelet activation occurs in response to vessel injury and is important for the arrest of bleeding.  Platelet activation during disease states leads to vascular occlusion and ischemic damage.  The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y12 receptor antagonists that have proven therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjFviIpPpTLVg90H21EOLACvtfcHk0liwEkP0YZjO4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D&md5=a0a6e94419e76fe78d2cef969ece6274</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI20986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI20986%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345%26doi%3D10.1172%2FJCI20986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gachet, C.</span><span> </span><span class="NLM_article-title">Antiplatelet drugs: which targets for which treatments?</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S313</span><span class="NLM_x">–</span> <span class="NLM_lpage">S322</span><span class="refDoi"> DOI: 10.1111/jth.12947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1111%2Fjth.12947" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=S313-S322&issue=Suppl.+1&author=C.+Gachet&title=Antiplatelet+drugs%3A+which+targets+for+which+treatments%3F&doi=10.1111%2Fjth.12947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fjth.12947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12947%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DAntiplatelet%2520drugs%253A%2520which%2520targets%2520for%2520which%2520treatments%253F%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2015%26volume%3D13%26issue%3DSuppl.%25201%26spage%3DS313%26epage%3DS322%26doi%3D10.1111%2Fjth.12947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Steg, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badano, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomstrom Lundqvist, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Mario, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducrocq, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Aviles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershlick, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannuzzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halvorsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuuti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenzen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahaffey, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valgimigli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van’t Hof, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widimsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bax, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceconi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Brentano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasdai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchhof, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuuti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonagh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popescu, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiner, Ž.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechtem, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirnes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tendera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vahanian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasdai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åström-Olsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustiene, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancellotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkely, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piepoli, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Werf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheugt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span> </span><span class="NLM_article-title">ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2569</span><span class="NLM_x">–</span> <span class="NLM_lpage">2619</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehs215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehs215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=22922416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFektbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2569-2619&author=P.+G.+Stegauthor=S.+K.+Jamesauthor=D.+Atarauthor=L.+P.+Badanoauthor=C.+Blomstrom+Lundqvistauthor=M.+A.+Borgerauthor=C.+Di+Marioauthor=K.+Dicksteinauthor=G.+Ducrocqauthor=F.+Fernandez-Avilesauthor=A.+H.+Gershlickauthor=P.+Giannuzziauthor=S.+Halvorsenauthor=K.+Huberauthor=P.+Juniauthor=A.+Kastratiauthor=J.+Knuutiauthor=M.+J.+Lenzenauthor=K.+W.+Mahaffeyauthor=M.+Valgimigliauthor=A.+van%E2%80%99t+Hofauthor=P.+Widimskyauthor=D.+Zahgerauthor=J.+J.+Baxauthor=H.+Baumgartnerauthor=C.+Ceconiauthor=V.+Deanauthor=C.+Deatonauthor=R.+Fagardauthor=C.+Funck-Brentanoauthor=D.+Hasdaiauthor=A.+Hoesauthor=P.+Kirchhofauthor=J.+Knuutiauthor=P.+Kolhauthor=T.+McDonaghauthor=C.+Moulinauthor=B.+A.+Popescuauthor=%C5%BD.+Reinerauthor=U.+Sechtemauthor=P.+A.+Sirnesauthor=M.+Tenderaauthor=A.+Torbickiauthor=A.+Vahanianauthor=S.+Windeckerauthor=D.+Hasdaiauthor=F.+Astinauthor=K.+%C3%85str%C3%B6m-Olssonauthor=A.+Budajauthor=P.+Clemmensenauthor=J.-P.+Colletauthor=K.+A.+Foxauthor=A.+Fuatauthor=O.+Gustieneauthor=C.+W.+Hammauthor=P.+Kalaauthor=P.+Lancellottiauthor=A.+P.+Maggioniauthor=B.+Merkelyauthor=F.-J.+Neumannauthor=M.+F.+Piepoliauthor=F.+Van+de+Werfauthor=F.+Verheugtauthor=L.+Wallentin&title=ESC+Guidelines+for+the+management+of+acute+myocardial+infarction+in+patients+presenting+with+ST-segment+elevation%3A+The+Task+Force+on+the+management+of+ST-segment+elevation+acute+myocardial+infarction+of+the+European+Society+of+Cardiology+%28ESC%29&doi=10.1093%2Feurheartj%2Fehs215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</span></div><div class="casAuthors">Steg, Ph. Gabriel; James, Stefan K.; Atar, Dan; Badano, Luigi P.; Lundqvist, Carina Blomstrom; Borger, Michael A.; Di Mario, Carlo; Dickstein, Kenneth; Ducrocq, Gregory; Fernandez-Aviles, Francisco; Gershlick, Anthony H.; Giannuzzi, Pantaleo; Halvorsen, Sigrun; Huber, Kurt; Juni, Peter; Kastrati, Adnan; Knuuti, Juhani; Lenzen, Mattie J.; Mahaffey, Kenneth W.; Valgimigli, Marco; van't Hof, Arnoud; Widimsky, Petr; Zahger, Doron; Bax, Jeroen J.; Baumgartner, Helmut; Ceconi, Claudio; Dean, Veronica; Deaton, Christi; Fagard, Robert; Funck-Brentano, Christian; Hasdai, David; Hoes, Arno; Kirchhof, Paulus; Knuuti, Juhani; Kolh, Philippe; McDonagh, Theresa; Moulin, Cyril; Popescu, Bogdan A.; Reiner, Zeljko; Sechtem, Udo; Sirnes, Per Anton; Tendera, Michal; Torbicki, Adam; Vahanian, Alec; Windecker, Stephan; Hasdai, David; Astin, Felicity; Aastroem-Olsson, Karin; Budaj, Andrzej; Clemmensen, Peter; Collet, Jean-Philippe; Fox, Keith A.; Fuat, Ahmet; Gustiene, Olivija; Hamm, Christian W.; Kala, Petr; Lancellotti, Patrizio; Maggioni, Aldo Pietro; Merkely, Bela; Neumann, Franz-Josef; Piepoli, Massimo F.; Van de Werf, Frans; Verheugt, Freek; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2569-2619</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The present guidelines pertain to the management of acute myocardial infarction in patients presenting with ischemic symptoms and persistent ST-segment elevation on the ECG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroXU4uG_IjH7Vg90H21EOLACvtfcHk0lj8SgaHyqu0MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFektbrE&md5=96241715be7c10947e6b691dd76b4b9a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehs215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehs215%26sid%3Dliteratum%253Aachs%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DJames%26aufirst%3DS.%2BK.%26aulast%3DAtar%26aufirst%3DD.%26aulast%3DBadano%26aufirst%3DL.%2BP.%26aulast%3DBlomstrom%2BLundqvist%26aufirst%3DC.%26aulast%3DBorger%26aufirst%3DM.%2BA.%26aulast%3DDi%2BMario%26aufirst%3DC.%26aulast%3DDickstein%26aufirst%3DK.%26aulast%3DDucrocq%26aufirst%3DG.%26aulast%3DFernandez-Aviles%26aufirst%3DF.%26aulast%3DGershlick%26aufirst%3DA.%2BH.%26aulast%3DGiannuzzi%26aufirst%3DP.%26aulast%3DHalvorsen%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DJuni%26aufirst%3DP.%26aulast%3DKastrati%26aufirst%3DA.%26aulast%3DKnuuti%26aufirst%3DJ.%26aulast%3DLenzen%26aufirst%3DM.%2BJ.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DValgimigli%26aufirst%3DM.%26aulast%3Dvan%25E2%2580%2599t%2BHof%26aufirst%3DA.%26aulast%3DWidimsky%26aufirst%3DP.%26aulast%3DZahger%26aufirst%3DD.%26aulast%3DBax%26aufirst%3DJ.%2BJ.%26aulast%3DBaumgartner%26aufirst%3DH.%26aulast%3DCeconi%26aufirst%3DC.%26aulast%3DDean%26aufirst%3DV.%26aulast%3DDeaton%26aufirst%3DC.%26aulast%3DFagard%26aufirst%3DR.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DHasdai%26aufirst%3DD.%26aulast%3DHoes%26aufirst%3DA.%26aulast%3DKirchhof%26aufirst%3DP.%26aulast%3DKnuuti%26aufirst%3DJ.%26aulast%3DKolh%26aufirst%3DP.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DMoulin%26aufirst%3DC.%26aulast%3DPopescu%26aufirst%3DB.%2BA.%26aulast%3DReiner%26aufirst%3D%25C5%25BD.%26aulast%3DSechtem%26aufirst%3DU.%26aulast%3DSirnes%26aufirst%3DP.%2BA.%26aulast%3DTendera%26aufirst%3DM.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DVahanian%26aufirst%3DA.%26aulast%3DWindecker%26aufirst%3DS.%26aulast%3DHasdai%26aufirst%3DD.%26aulast%3DAstin%26aufirst%3DF.%26aulast%3D%25C3%2585str%25C3%25B6m-Olsson%26aufirst%3DK.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DCollet%26aufirst%3DJ.-P.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DFuat%26aufirst%3DA.%26aulast%3DGustiene%26aufirst%3DO.%26aulast%3DHamm%26aufirst%3DC.%2BW.%26aulast%3DKala%26aufirst%3DP.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMerkely%26aufirst%3DB.%26aulast%3DNeumann%26aufirst%3DF.-J.%26aulast%3DPiepoli%26aufirst%3DM.%2BF.%26aulast%3DVan%2Bde%2BWerf%26aufirst%3DF.%26aulast%3DVerheugt%26aufirst%3DF.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DESC%2520Guidelines%2520for%2520the%2520management%2520of%2520acute%2520myocardial%2520infarction%2520in%2520patients%2520presenting%2520with%2520ST-segment%2520elevation%253A%2520The%2520Task%2520Force%2520on%2520the%2520management%2520of%2520ST-segment%2520elevation%2520acute%2520myocardial%2520infarction%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2012%26volume%3D33%26spage%3D2569%26epage%3D2619%26doi%3D10.1093%2Feurheartj%2Fehs215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">O’Gara, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascheim, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, D. E.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lemos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesmire, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krumholz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderbaum, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newby, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornato, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamis-Holland, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommaso, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, D. X.</span><span> </span><span class="NLM_article-title">2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">e78</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1016/j.jacc.2012.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.jacc.2012.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=23256914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=e78-140&author=P.+T.+O%E2%80%99Garaauthor=F.+G.+Kushnerauthor=D.+D.+Ascheimauthor=D.+E.+Caseyauthor=M.+K.+Chungauthor=J.+A.+de+Lemosauthor=S.+M.+Ettingerauthor=J.+C.+Fangauthor=F.+M.+Fesmireauthor=B.+A.+Franklinauthor=C.+B.+Grangerauthor=H.+M.+Krumholzauthor=J.+A.+Linderbaumauthor=D.+A.+Morrowauthor=L.+K.+Newbyauthor=J.+P.+Ornatoauthor=N.+Ouauthor=M.+J.+Radfordauthor=J.+E.+Tamis-Hollandauthor=C.+L.+Tommasoauthor=C.+M.+Tracyauthor=Y.+J.+Wooauthor=D.+X.+Zhao&title=2013+ACCF%2FAHA+Guideline+for+the+Management+of+ST-Elevation+Myocardial+Infarction%3A+A+Report+of+the+American+College+of+Cardiology+Foundation%2FAmerican+Heart+Association+Task+Force+on+Practice+Guidelines&doi=10.1016%2Fj.jacc.2012.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Gara%26aufirst%3DP.%2BT.%26aulast%3DKushner%26aufirst%3DF.%2BG.%26aulast%3DAscheim%26aufirst%3DD.%2BD.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DChung%26aufirst%3DM.%2BK.%26aulast%3Dde%2BLemos%26aufirst%3DJ.%2BA.%26aulast%3DEttinger%26aufirst%3DS.%2BM.%26aulast%3DFang%26aufirst%3DJ.%2BC.%26aulast%3DFesmire%26aufirst%3DF.%2BM.%26aulast%3DFranklin%26aufirst%3DB.%2BA.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DKrumholz%26aufirst%3DH.%2BM.%26aulast%3DLinderbaum%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DNewby%26aufirst%3DL.%2BK.%26aulast%3DOrnato%26aufirst%3DJ.%2BP.%26aulast%3DOu%26aufirst%3DN.%26aulast%3DRadford%26aufirst%3DM.%2BJ.%26aulast%3DTamis-Holland%26aufirst%3DJ.%2BE.%26aulast%3DTommaso%26aufirst%3DC.%2BL.%26aulast%3DTracy%26aufirst%3DC.%2BM.%26aulast%3DWoo%26aufirst%3DY.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%2BX.%26atitle%3D2013%2520ACCF%252FAHA%2520Guideline%2520for%2520the%2520Management%2520of%2520ST-Elevation%2520Myocardial%2520Infarction%253A%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%2520Foundation%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Practice%2520Guidelines%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D61%26spage%3De78%26epage%3D140%26doi%3D10.1016%2Fj.jacc.2012.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">King, S. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshfeld, J. W.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. O.</span><span> </span><span class="NLM_article-title">2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=261-295&author=S.+B.+Kingauthor=S.+C.+Smithauthor=J.+W.+Hirshfeldauthor=A.+K.+Jacobsauthor=D.+A.+Morrisonauthor=D.+O.+Williams&title=2007+Focused+Update+of+the+ACC%2FAHA%2FSCAI+2005+Guideline+Update+for+Percutaneous+Coronary+Intervention.+A+Report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Practice+Guidelines%3A+2007+Writing+Group+to+Review+New+Evidence+and+Update+the+ACC%2FAHA%2FSCAI+2005+Guideline+Update+for+Percutaneous+Coronary+Intervention%2C+Writing+on+Behalf+of+the+2005+Writing+Committee"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DS.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DHirshfeld%26aufirst%3DJ.%2BW.%26aulast%3DJacobs%26aufirst%3DA.%2BK.%26aulast%3DMorrison%26aufirst%3DD.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BO.%26atitle%3D2007%2520Focused%2520Update%2520of%2520the%2520ACC%252FAHA%252FSCAI%25202005%2520Guideline%2520Update%2520for%2520Percutaneous%2520Coronary%2520Intervention.%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Practice%2520Guidelines%253A%25202007%2520Writing%2520Group%2520to%2520Review%2520New%2520Evidence%2520and%2520Update%2520the%2520ACC%252FAHA%252FSCAI%25202005%2520Guideline%2520Update%2520for%2520Percutaneous%2520Coronary%2520Intervention%252C%2520Writing%2520on%2520Behalf%2520of%2520the%25202005%2520Writing%2520Committee%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D261%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrolavicius, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. K.</span><span> </span><span class="NLM_article-title">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1056/NEJMoa010746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=11519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=494-502&author=S.+Yusufauthor=F.+Zhaoauthor=S.+R.+Mehtaauthor=S.+Chrolaviciusauthor=G.+Tognoniauthor=K.+K.+Fox&title=Effects+of+clopidogrel+in+addition+to+aspirin+in+patients+with+acute+coronary+syndromes+without+ST-segment+elevation&doi=10.1056%2FNEJMoa010746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span></div><div class="casAuthors">Yusuf, Salim; Zhao, Feng; Mehta, Shamir R.; Chrolavicius, Susan; Tognoni, Gianni; Fox, Keith K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">494-502</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events.  We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.  We randomly assigned 12,562 patients who had presented within 24 h after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addn. to aspirin for 3 to 12 mo.  The first primary outcome - a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001).  The second primary outcome - the first primary outcome or refractory ischemia - occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001).  The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel.  There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.  The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.  However, the risk of major bleeding is increased among patients treated with clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihXPVAbDPg7Vg90H21EOLACvtfcHk0liBiFWXc74k6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D&md5=3ddc47281ccad90f046038a4c3f98a21</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa010746%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DMehta%26aufirst%3DS.%2BR.%26aulast%3DChrolavicius%26aufirst%3DS.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DFox%26aufirst%3DK.%2BK.%26atitle%3DEffects%2520of%2520clopidogrel%2520in%2520addition%2520to%2520aspirin%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%2520without%2520ST-segment%2520elevation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D494%26epage%3D502%26doi%3D10.1056%2FNEJMoa010746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakkis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gersh, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span> </span><span class="NLM_article-title">Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">–</span> <span class="NLM_lpage">1208</span><span class="refDoi"> DOI: 10.1161/01.CIR.0000140675.85342.1B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1161%2F01.CIR.0000140675.85342.1B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=15313956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=1202-1208&author=K.+A.+Foxauthor=S.+R.+Mehtaauthor=R.+Petersauthor=F.+Zhaoauthor=N.+Lakkisauthor=B.+J.+Gershauthor=S.+Yusuf&title=Benefits+and+risks+of+the+combination+of+clopidogrel+and+aspirin+in+patients+undergoing+surgical+revascularization+for+non-ST-elevation+acute+coronary+syndrome%3A+the+Clopidogrel+in+Unstable+angina+to+prevent+Recurrent+ischemic+Events+%28CURE%29+Trial&doi=10.1161%2F01.CIR.0000140675.85342.1B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits and risks of the combination of Clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome</span></div><div class="casAuthors">Fox, Keith A. A.; Mehta, Shamir R.; Peters, Ron; Zhao, Feng; Lakkis, Nasser; Gersh, Bernard J.; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1202-1208</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding.  In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12,562 patients were randomized to clopidogrel or placebo in addn. to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke.  The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% for placebo; relative risk (RR), 0.72; 95% CI, 0.57-0.90], coronary artery bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 0.89; 95% CI, 0.71-1.11), and medical therapy only (8.1% for clopidogrel, 10.0% for placebo; RR, 0.80; 95% CI, 0.69-0.92; test for interaction among strata, 0.53).  For CABG during the initial hospitalization (530 for placebo, 485 for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29-1.08).  For the entire study, there was a 1% excess of major bleeding but no significant excess of life-threatening bleeding.  Among patients undergoing CABG, the rates of life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 1.30; 95% CI, 0.91-1.95; both nonsignificant).  The benefits vs. risks of early and long-term clopidogrel therapy (freedom from CV death, MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization (CABG or PCI) and in the study population as a whole.  Overall, the benefits of starting clopidogrel on admission appear to outweigh the risks, even among those who proceed to CABG during the initial hospitalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot-5k67TQzCrVg90H21EOLACvtfcHk0liBiFWXc74k6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSksL8%253D&md5=404fadafe6de6dcd91c5a49e8722c95f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000140675.85342.1B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000140675.85342.1B%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DMehta%26aufirst%3DS.%2BR.%26aulast%3DPeters%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DLakkis%26aufirst%3DN.%26aulast%3DGersh%26aufirst%3DB.%2BJ.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DBenefits%2520and%2520risks%2520of%2520the%2520combination%2520of%2520clopidogrel%2520and%2520aspirin%2520in%2520patients%2520undergoing%2520surgical%2520revascularization%2520for%2520non-ST-elevation%2520acute%2520coronary%2520syndrome%253A%2520the%2520Clopidogrel%2520in%2520Unstable%2520angina%2520to%2520prevent%2520Recurrent%2520ischemic%2520Events%2520%2528CURE%2529%2520Trial%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26spage%3D1202%26epage%3D1208%26doi%3D10.1161%2F01.CIR.0000140675.85342.1B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Snoep, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hovens, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eikenboom, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Bom, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jukema, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, M. V.</span><span> </span><span class="NLM_article-title">Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.ahj.2007.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.ahj.2007.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2007&pages=221-231&author=J.+D.+Snoepauthor=M.+M.+Hovensauthor=J.+C.+Eikenboomauthor=J.+G.+van+der+Bomauthor=J.+W.+Jukemaauthor=M.+V.+Huisman&title=Clopidogrel+nonresponsiveness+in+patients+undergoing+percutaneous+coronary+intervention+with+stenting%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2Fj.ahj.2007.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2007.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2007.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSnoep%26aufirst%3DJ.%2BD.%26aulast%3DHovens%26aufirst%3DM.%2BM.%26aulast%3DEikenboom%26aufirst%3DJ.%2BC.%26aulast%3Dvan%2Bder%2BBom%26aufirst%3DJ.%2BG.%26aulast%3DJukema%26aufirst%3DJ.%2BW.%26aulast%3DHuisman%26aufirst%3DM.%2BV.%26atitle%3DClopidogrel%2520nonresponsiveness%2520in%2520patients%2520undergoing%2520percutaneous%2520coronary%2520intervention%2520with%2520stenting%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2007%26volume%3D154%26spage%3D221%26epage%3D231%26doi%3D10.1016%2Fj.ahj.2007.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">O’Connor, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collet, J. P.</span><span> </span><span class="NLM_article-title">Pharmacogenetics of Clopidogrel</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5309</span><span class="NLM_x">–</span> <span class="NLM_lpage">5327</span><span class="refDoi"> DOI: 10.2174/138161212803251880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.2174%2F138161212803251880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=22724417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ont7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5309-5327&author=S.+A.+O%E2%80%99Connorauthor=J.+S.+Hulotauthor=J.+Silvainauthor=G.+Caylaauthor=G.+Montalescotauthor=J.+P.+Collet&title=Pharmacogenetics+of+Clopidogrel&doi=10.2174%2F138161212803251880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics of clopidogrel</span></div><div class="casAuthors">O'Connor, Stephen A.; Hulot, Jean-Sebastien; Silvain, Johanne; Cayla, Guillaume; Montalescot, Gilles; Collet, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5309-5327</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clopidogrel used in conjunction with aspirin has a central role in the treatment of patients with an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI).  The pharmacokinetic and pharmacodynamic responses to this drug are highly variable leaving up to one third of patients with inadequate platelet inhibition or high on-treatment platelet reactivity (HPR), and subsequent increased ischemic cardiovascular events.  Genetic variability in drug absorption and metab. is a key factor responsible for the inefficient generation of the active drug metabolite.  The two-step hepatic cytochrome P 450 (CYP)-dependant oxidative metab. of the prodrug appears to be of particular importance.  Pharmacogenomic analyses have identified loss-of-function variant alleles of CYP 2C19 and specifically the 2C19*2 allele, to be the predominant genetic mediators of the antiplatelet effect of clopidogrel.  Carriers were have been shown to have lower active metabolite levels of clopidogrel, higher platelet reactivity and assocd. poorer outcomes.  Rapid and accurate point-of-care genetic tests to identify these alleles are currently in development but several questions about the role of such testing remain such as patient selection and whether personalized treatment based on genotype has a pos. impact on clin. outcome.  At present, genetic testing cannot be recommended in routine clin. practice due to insufficient prospective data.  However, the significant body of research published to date suggests a likely role when used in combination with platelet function anal. in ACS patients undergoing stenting who have other known risk factors for recurrent ischemic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaOK_TFTLbebVg90H21EOLACvtfcHk0liBiFWXc74k6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ont7nF&md5=91cbc50c058a5646530d8ff072c6fea4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138161212803251880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212803251880%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BA.%26aulast%3DHulot%26aufirst%3DJ.%2BS.%26aulast%3DSilvain%26aufirst%3DJ.%26aulast%3DCayla%26aufirst%3DG.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DCollet%26aufirst%3DJ.%2BP.%26atitle%3DPharmacogenetics%2520of%2520Clopidogrel%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D5309%26epage%3D5327%26doi%3D10.2174%2F138161212803251880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Schrör, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siller-Matula, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetic basis of the antiplatelet action of prasugrel</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1111/j.1472-8206.2011.00986.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1111%2Fj.1472-8206.2011.00986.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21895761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC387isFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=39-46&author=K.+Schr%C3%B6rauthor=J.+M.+Siller-Matulaauthor=K.+Huber&title=Pharmacokinetic+basis+of+the+antiplatelet+action+of+prasugrel&doi=10.1111%2Fj.1472-8206.2011.00986.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic basis of the antiplatelet action of prasugrel</span></div><div class="casAuthors">Schror Karsten; Siller-Matula Jolanta M; Huber Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & clinical pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prasugrel is the most recent development of thienopyridine-type antiplatelet drugs.  Like the earlier-generation thienopyridines, i.e. ticlopidine and clopidogrel, prasugrel is also an inactive prodrug that requires metabolic processing in vivo to generate the active antiplatelet metabolite.  The efficacy of this bioactivation is the key determinant for the pharmacodynamic potency of the compound, i.e. the irreversible blockade of the platelet P2Y12-ADP receptor.  Prasugrel is rapidly absorbed from the gut.  After oral administration of standard-loading doses of 60 mg, maximum plasma levels of the active metabolite are achieved within 1 h, effective, maximum inhibition of platelet aggregation at 1-2 h.  Bioconversion of prasugrel into the active metabolite requires two metabolic steps that occur in sequence.  The first is the generation of a thiolactone-intermediate, mainly by carboxyesterases-2 in the intestine, the second the cytochrome (CYP)-dependent conversion of the thiolactone into the active metabolite.  This second step involves several cytochromes, most notably CYP3A4, CYP2C19, CYP2B6, and CYP2C9.  The enzymatic generation of the active metabolite of prasugrel is much more effective than that of clopidogrel where only about 5% of oral clopidogrel is transformed into the active compound by two-step CYP-dependent procedures.  About 70% of prasugrel metabolites are excreted in the urine and 30% in the feces.  The molar potency of the respective active metabolites of prasugrel and clopidogrel is identical.  Thus, the more rapid onset, higher potency and lower interindividual variability of antiplatelet effects of prasugrel as compared to clopidogrel in vivo are entirely because of its more efficient pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0mErGQHcRnQxyojvcjibhfW6udTcc2ebeOsOYTqiN4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387isFCktQ%253D%253D&md5=6973f63544f4e80cc9c624f4217548f8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2011.00986.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2011.00986.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6r%26aufirst%3DK.%26aulast%3DSiller-Matula%26aufirst%3DJ.%2BM.%26aulast%3DHuber%26aufirst%3DK.%26atitle%3DPharmacokinetic%2520basis%2520of%2520the%2520antiplatelet%2520action%2520of%2520prasugrel%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D26%26spage%3D39%26epage%3D46%26doi%3D10.1111%2Fj.1472-8206.2011.00986.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Jernberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naganuma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span> </span><span class="NLM_article-title">Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1173</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehi877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehi877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=16621870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Crt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1166-1173&author=T.+Jernbergauthor=C.+D.+Payneauthor=K.+J.+Wintersauthor=C.+Darsteinauthor=J.+T.+Brandtauthor=J.+A.+Jakubowskiauthor=H.+Naganumaauthor=A.+Siegbahnauthor=L.+Wallentin&title=Prasugrel+achieves+greater+inhibition+of+platelet+aggregation+and+a+lower+rate+of+non-responders+compared+with+clopidogrel+in+aspirin-treated+patients+with+stable+coronary+artery+disease&doi=10.1093%2Feurheartj%2Fehi877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease</span></div><div class="casAuthors">Jernberg, Tomas; Payne, Christopher D.; Winters, Kenneth J.; Darstein, Christelle; Brandt, John T.; Jakubowski, Joseph A.; Naganuma, Hideo; Siegbahn, Agneta; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1166-1173</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD).  Methods and results: Subjects (n = 101) were randomly assigned to the following loading dose (LD) (day 1)/maintenance dose (MD) (days 2-28) combinations: prasugrel, 40 mg/5 mg; 40 mg/7.5 mg; 60 mg/10 mg; 60 mg/15 mg; or clopidogrel, 300 mg/75 mg.  Turbidometric platelet aggregation was measured at multiple timepoints during the study.  At 4 h after dosing, with 20 μM ADP, both prasugrel LDs achieved significantly higher mean IPA levels (60.6% and 68.4 vs. 30.0%, resp.; all P < 0.0001) and lower percentage (3 vs. 52%, P < 0.0001) of pharmacodynamic non-responders (defined as IPA <20%) than clopidogrel.  Prasugrel 10 and 15 mg MDs achieved consistently higher mean IPA than clopidogrel 75 mg at day 28 (all P < 0.0001).  At pre-MD on day 28, there were no non-responders in the 10 and 15 mg prasugrel group, compared with 45% in the clopidogrel group (P = 0.0007).  Conclusion: In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekrzLKAa5jbVg90H21EOLACvtfcHk0lgsWIafmDgIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Crt7g%253D&md5=62bd6495d6bbf8b2cf1a2953a8507ad9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehi877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehi877%26sid%3Dliteratum%253Aachs%26aulast%3DJernberg%26aufirst%3DT.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DDarstein%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DJ.%2BT.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DNaganuma%26aufirst%3DH.%26aulast%3DSiegbahn%26aufirst%3DA.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DPrasugrel%2520achieves%2520greater%2520inhibition%2520of%2520platelet%2520aggregation%2520and%2520a%2520lower%2520rate%2520of%2520non-responders%2520compared%2520with%2520clopidogrel%2520in%2520aspirin-treated%2520patients%2520with%2520stable%2520coronary%2520artery%2520disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2006%26volume%3D27%26spage%3D1166%26epage%3D1173%26doi%3D10.1093%2Feurheartj%2Fehi877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varenhorst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span> </span><span class="NLM_article-title">Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehm545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehm545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=18055486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Sqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=21-30&author=L.+Wallentinauthor=C.+Varenhorstauthor=S.+Jamesauthor=D.+Erlingeauthor=O.+O.+Braunauthor=J.+A.+Jakubowskiauthor=A.+Sugidachiauthor=K.+J.+Wintersauthor=A.+Siegbahn&title=Prasugrel+achieves+greater+and+faster+P2Y12+receptor-mediated+platelet+inhibition+than+clopidogrel+due+to+more+efficient+generation+of+its+active+metabolite+in+aspirin-treated+patients+with+coronary+artery+disease&doi=10.1093%2Feurheartj%2Fehm545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease</span></div><div class="casAuthors">Wallentin, Lars; Varenhorst, Christoph; James, Stefan; Erlinge, David; Braun, Oscar Oe; Jakubowski, Joseph A.; Sugidachi, Atsuhiro; Winters, Kenneth J.; Siegbahn, Agneta</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: P2Y12 receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease.  Methods and results: One hundred and ten aspirin treated subjects were randomized to double-blind treatment with clopidogrel (n = 55) 600 mg loading dose (LD) and 75 mg maintenance dose (MD) or prasugrel (n = 55) 60 mg LD and 10 mg MD for 28 days.  Concns. of prasugrel and clopidogrel active metabolites were detd.  Platelet aggregation to 20 μM ADP, measured by light transmission aggregometry, was reported as maximal platelet aggregation (MPA).  P2Y12 function was assessed by the vasodilator-stimulated phosphoprotein assay and reported as platelet reactivity index (PRI).  The same pharmacodynamic measurements were performed after ex vivo addn. of clopidogrel's active metabolite.  At 2 h post-LD, mean MPA was 31 vs. 55%, and mean PRI 8.3 vs. 55.9% for prasugrel and clopidogrel, resp. (P < 0.001).  During MD on day 14 and 28, mean MPA was 42 vs. 54% and mean PRI was 25 vs. 51%, resp. (P < 0.001).  Peak level of the active metabolite and P2Y12 inhibition occurred earlier and was greater with prasugrel (P < 0.001).  Mean area under the time-concn. curve (AUC; μM/h) of the resp. active metabolite was higher with prasugrel vs. clopidogrel post-LD (1.11 vs. 0.24) and post-MD (0.16 vs. 0.062).  Ex vivo addn. of clopidogrel's active metabolite further reduced PRI in all patients whose platelets were not already maximally inhibited.  Conclusion: In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y12 receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrDYed-6tQALVg90H21EOLACvtfcHk0lgsWIafmDgIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Sqtr8%253D&md5=1c02df46b20b6345d6df9cffea4b4a89</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehm545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehm545%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DVarenhorst%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DBraun%26aufirst%3DO.%2BO.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DSiegbahn%26aufirst%3DA.%26atitle%3DPrasugrel%2520achieves%2520greater%2520and%2520faster%2520P2Y12%2520receptor-mediated%2520platelet%2520inhibition%2520than%2520clopidogrel%2520due%2520to%2520more%2520efficient%2520generation%2520of%2520its%2520active%2520metabolite%2520in%2520aspirin-treated%2520patients%2520with%2520coronary%2520artery%2520disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2008%26volume%3D29%26spage%3D21%26epage%3D30%26doi%3D10.1093%2Feurheartj%2Fehm545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wiviott, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braunwald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzyllo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardissino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Servi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riesmeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerakkody, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antman, E. M.</span><span> </span><span class="NLM_article-title">Prasugrel versus clopidogrel in patients with acute coronary syndromes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2001</span><span class="NLM_x">–</span> <span class="NLM_lpage">2015</span><span class="refDoi"> DOI: 10.1056/NEJMoa0706482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa0706482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=17982182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWis7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2001-2015&author=S.+D.+Wiviottauthor=E.+Braunwaldauthor=C.+H.+McCabeauthor=G.+Montalescotauthor=W.+Ruzylloauthor=S.+Gottliebauthor=F.+J.+Neumannauthor=D.+Ardissinoauthor=S.+De+Serviauthor=S.+A.+Murphyauthor=J.+Riesmeyerauthor=G.+Weerakkodyauthor=C.+M.+Gibsonauthor=E.+M.+Antman&title=Prasugrel+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0706482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wiviott, Stephen D.; Bruanwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzylio, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antmann, Elliott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2001-2015</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.  METHODS To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 mo.  The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.  The key safety end point was major bleeding.  RESULTS The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P < 0.001).  We also found significant redns. in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P < 0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P < 0.001), and stent thrombosis (2.4% vs. 1.1%; P < 0.001).  Major bleeding was obsd. in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P = 0.03).  Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P = 0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P = 0.23) and fatal bleeding (0.4% vs. 0.1%; P = 0.002).  CONCLUSIONS In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was assocd. with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.  Overall mortality did not differ significantly between treatment groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetj1787mjK7Vg90H21EOLACvtfcHk0ljDHyrVX_Qa8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWis7rN&md5=dd3d3362a7c48f897a94a517cfdc06cd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706482%26sid%3Dliteratum%253Aachs%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DMcCabe%26aufirst%3DC.%2BH.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DGottlieb%26aufirst%3DS.%26aulast%3DNeumann%26aufirst%3DF.%2BJ.%26aulast%3DArdissino%26aufirst%3DD.%26aulast%3DDe%2BServi%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26aulast%3DRiesmeyer%26aufirst%3DJ.%26aulast%3DWeerakkody%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DAntman%26aufirst%3DE.%2BM.%26atitle%3DPrasugrel%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2001%26epage%3D2015%26doi%3D10.1056%2FNEJMoa0706482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuelsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Held, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahaffey, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scirica, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steg, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freij, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PLATO Investigators.</span><span> </span><span class="NLM_article-title">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa0904327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=19717846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1045-1057&author=L.+Wallentinauthor=R.+C.+Beckerauthor=A.+Budajauthor=C.+P.+Cannonauthor=H.+Emanuelssonauthor=C.+Heldauthor=J.+Horrowauthor=S.+Hustedauthor=S.+Jamesauthor=H.+Katusauthor=K.+W.+Mahaffeyauthor=B.+M.+Sciricaauthor=A.+Skeneauthor=P.+G.+Stegauthor=R.+F.+Storeyauthor=R.+A.+Harringtonauthor=A.+Freijauthor=M.+Thors%C3%A9nauthor=PLATO+Investigators.&title=Ticagrelor+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0904327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wallentin, Lars; Becker, Richard C.; Budaj, Andrej; Cannon, Christopher P.; Emanuelsson, Hakan; Held, Claes; Horrow, Jay; Husted, Steen; James, Stefan; Katus, Hugo; Mahaffey, Kenneth W.; Scirica, Benjamin M.; Skene, Allan; Steg, Philppe Gabriel; Storey, Robert F.; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1045-1057</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ticagrelor is an oral, reversible, direct-acting inhibitor of the ADP receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.  In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg. loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.  At 12 mo, the primary end point - a composite of death from vascular causes, myocardial infarction, or stroke - had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P < 0.001).  Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P = 0.005) and death from vascular causes (4.0% vs. 5.1%0/, P = 0.001) but not stroke alone (1.5% vs. 1.3%, P = 0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P < 0.001).  No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, resp.; P = 0.43), but ticagrelor was assocd. with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P = 0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.  In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTdvlM1dfTz7Vg90H21EOLACvtfcHk0ljDHyrVX_Qa8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ&md5=9c215c4ceeb6dd14d406ab26e2db25d5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904327%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DEmanuelsson%26aufirst%3DH.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DHorrow%26aufirst%3DJ.%26aulast%3DHusted%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DKatus%26aufirst%3DH.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSkene%26aufirst%3DA.%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DFreij%26aufirst%3DA.%26aulast%3DThors%25C3%25A9n%26aufirst%3DM.%26aulast%3D%26atitle%3DTicagrelor%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1045%26epage%3D1057%26doi%3D10.1056%2FNEJMoa0904327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Reny, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, P.</span><span> </span><span class="NLM_article-title">Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1517/14656566.2015.993608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1517%2F14656566.2015.993608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25495963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisl2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=449-452&author=J.+L.+Renyauthor=P.+Fontana&title=Antiplatelet+drugs+and+platelet+reactivity%3A+is+it+time+to+halt+clinical+research+on+tailored+strategies%3F&doi=10.1517%2F14656566.2015.993608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?</span></div><div class="casAuthors">Reny, Jean-Luc; Fontana, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-452</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Personalized medicine of antiplatelet drugs in cardiovascular patients has led to a significant enthusiasm.  Indeed, numerous longitudinal studies showed an assocn. between high platelet reactivity and the recurrence of ischemic events.  The first small randomized trials of P2Y12 blockers tailored to each patient's platelet reactivity yielded encouraging redns. of coronary stent thrombosis in high-risk populations.  The discovery of genetic variants contributing to the pharmacodynamic effect of clopidogrel has then paved the way toward a personalized antiplatelet therapy based on reliable and stable genetic tests.  This enthusiasm was soon tempered by large interventional trials demonstrating that a platelet function testing-based strategy did not improve clin. outcome and that genetic variants discovered up to now only explained a small part of the pharmacodynamic effect of clopidogrel, thus limiting its clin. use.  Looking back to the most recent trials, their target populations and the type of clin. setting, it seems that the one-size-fits all policy regarding antiplatelet drugs may be well acceptable for low-risk patients.  On the contrary, integration of the clin. setting as well as other risk factors may help to identify subgroups of patients who could derive a benefit from a truly personalized management of antiplatelet therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeSPA04O2Y0rVg90H21EOLACvtfcHk0ljDHyrVX_Qa8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisl2msbY%253D&md5=cde4d30f2be3202bc91c20a2c1b211fa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.993608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.993608%26sid%3Dliteratum%253Aachs%26aulast%3DReny%26aufirst%3DJ.%2BL.%26aulast%3DFontana%26aufirst%3DP.%26atitle%3DAntiplatelet%2520drugs%2520and%2520platelet%2520reactivity%253A%2520is%2520it%2520time%2520to%2520halt%2520clinical%2520research%2520on%2520tailored%2520strategies%253F%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D449%26epage%3D452%26doi%3D10.1517%2F14656566.2015.993608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, m. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y12 Antagonists for Inhibition of Platelet Aggregation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2010</span><span class="NLM_x">–</span> <span class="NLM_lpage">2037</span><span class="refDoi"> DOI: 10.1021/jm901518t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901518t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2010-2037&author=J.+J.+Parlowauthor=m.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl+Glutamate+Pyridines+as+Potent+Orally+Bioavailable+P2Y12+Antagonists+for+Inhibition+of+Platelet+Aggregation&doi=10.1021%2Fjm901518t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Fjm901518t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901518t%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3Dm.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl%2520Glutamate%2520Pyridines%2520as%2520Potent%2520Orally%2520Bioavailable%2520P2Y12%2520Antagonists%2520for%2520Inhibition%2520of%2520Platelet%2520Aggregation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2010%26epage%3D2037%26doi%3D10.1021%2Fjm901518t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zech, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Just, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czechtizky, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Görlitzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazaré, M.</span><span> </span><span class="NLM_article-title">Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8615</span><span class="NLM_x">–</span> <span class="NLM_lpage">8629</span><span class="refDoi"> DOI: 10.1021/jm300771j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300771j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8615-8629&author=G.+Zechauthor=G.+Hesslerauthor=A.+Eversauthor=T.+Weissauthor=P.+Florianauthor=M.+Justauthor=J.+Czechauthor=W.+Czechtizkyauthor=J.+G%C3%B6rlitzerauthor=S.+Rufauthor=M.+Kohlmannauthor=M.+Nazar%C3%A9&title=Identification+of+High-Affinity+P2Y12+Antagonists+Based+on+a+Phenylpyrazole+Glutamic+Acid+Piperazine+Backbone&doi=10.1021%2Fjm300771j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm300771j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300771j%26sid%3Dliteratum%253Aachs%26aulast%3DZech%26aufirst%3DG.%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DWeiss%26aufirst%3DT.%26aulast%3DFlorian%26aufirst%3DP.%26aulast%3DJust%26aufirst%3DM.%26aulast%3DCzech%26aufirst%3DJ.%26aulast%3DCzechtizky%26aufirst%3DW.%26aulast%3DG%25C3%25B6rlitzer%26aufirst%3DJ.%26aulast%3DRuf%26aufirst%3DS.%26aulast%3DKohlmann%26aufirst%3DM.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520High-Affinity%2520P2Y12%2520Antagonists%2520Based%2520on%2520a%2520Phenylpyrazole%2520Glutamic%2520Acid%2520Piperazine%2520Backbone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8615%26epage%3D8629%26doi%3D10.1021%2Fjm300771j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bylund, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Björkman, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Österlund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordanetto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giezen, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachrisson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, F.</span><span> </span><span class="NLM_article-title">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7015</span><span class="NLM_x">–</span> <span class="NLM_lpage">7024</span><span class="refDoi"> DOI: 10.1021/jm400820m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400820m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7015-7024&author=P.+Bachauthor=T.+Antonssonauthor=R.+Bylundauthor=J.-A.+Bj%C3%B6rkmanauthor=K.+%C3%96sterlundauthor=F.+Giordanettoauthor=J.+J.+J.+van+Giezenauthor=S.+M.+Andersenauthor=H.+Zachrissonauthor=F.+Zetterberg&title=Lead+Optimization+of+Ethyl+6-Aminonicotinate+Acyl+Sulfonamides+as+Antagonists+of+the+P2Y12+Receptor.+Separation+of+the+Antithrombotic+Effect+and+Bleeding+for+Candidate+Drug+AZD1283&doi=10.1021%2Fjm400820m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span></div><div class="casAuthors">Bach, Peter; Antonsson, Thomas; Bylund, Ruth; Bjoerkman, Jan-Arne; Oesterlund, Krister; Giordanetto, Fabrizio; van Giezen, J. J. J.; Andersen, Soeren M.; Zachrisson, Helen; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7015-7024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationships of Et 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented.  Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay.  Evaluation of PK parameters in vivo in dog for six compds. showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines.  In a modified Folts model in dog, both piperidine (I) and azetidine (II) dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, resp.  The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for I and II, resp.  Thus, the therapeutic index (TI) was ≥10 for both compds.  On the basis of these data, compd. I was progressed into human clin. trials as candidate drug AZD1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmCuB-1CBurVg90H21EOLACvtfcHk0lgZyvHpNiRa4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP&md5=3810ed67647a776b9ad8bdb165f715e7</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fjm400820m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400820m%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DAntonsson%26aufirst%3DT.%26aulast%3DBylund%26aufirst%3DR.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DJ.-A.%26aulast%3D%25C3%2596sterlund%26aufirst%3DK.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DLead%2520Optimization%2520of%2520Ethyl%25206-Aminonicotinate%2520Acyl%2520Sulfonamides%2520as%2520Antagonists%2520of%2520the%2520P2Y12%2520Receptor.%2520Separation%2520of%2520the%2520Antithrombotic%2520Effect%2520and%2520Bleeding%2520for%2520Candidate%2520Drug%2520AZD1283%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7015%26epage%3D7024%26doi%3D10.1021%2Fjm400820m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Boldron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordes, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tissandié, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yvon, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badorc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseaux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barré, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meneyrol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflieger, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet-Lignon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hérault, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassalle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span> </span><span class="NLM_article-title">N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7293</span><span class="NLM_x">–</span> <span class="NLM_lpage">7316</span><span class="refDoi"> DOI: 10.1021/jm500588w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500588w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7293-7316&author=C.+Boldronauthor=A.+Besseauthor=M.-F.+Bordesauthor=S.+Tissandi%C3%A9author=X.+Yvonauthor=B.+Gauauthor=A.+Badorcauthor=T.+Rousseauxauthor=G.+Barr%C3%A9author=J.+Meneyrolauthor=G.+Zechauthor=M.+Nazareauthor=V.+Fosseyauthor=A.-M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=C.+Briotauthor=F.+Dolauthor=J.-P.+H%C3%A9raultauthor=P.+Saviauthor=G.+Lassalleauthor=N.+Delesqueauthor=J.-M.+Herbertauthor=F.+Bono&title=N-%5B6-%284-Butanoyl-5-methyl-1H-pyrazol-1-yl%29pyridazin-3-yl%5D-5-chloro-1-%5B2-%284-methylpiperazin-1-yl%29-2-oxoethyl%5D-1H-indole-3-carboxamide+%28SAR216471%29%2C+a+Novel+Intravenous+and+Oral%2C+Reversible%2C+and+Directly+Acting+P2Y12+Antagonist&doi=10.1021%2Fjm500588w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Fjm500588w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500588w%26sid%3Dliteratum%253Aachs%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBordes%26aufirst%3DM.-F.%26aulast%3DTissandi%25C3%25A9%26aufirst%3DS.%26aulast%3DYvon%26aufirst%3DX.%26aulast%3DGau%26aufirst%3DB.%26aulast%3DBadorc%26aufirst%3DA.%26aulast%3DRousseaux%26aufirst%3DT.%26aulast%3DBarr%25C3%25A9%26aufirst%3DG.%26aulast%3DMeneyrol%26aufirst%3DJ.%26aulast%3DZech%26aufirst%3DG.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DFossey%26aufirst%3DV.%26aulast%3DPflieger%26aufirst%3DA.-M.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DBriot%26aufirst%3DC.%26aulast%3DDol%26aufirst%3DF.%26aulast%3DH%25C3%25A9rault%26aufirst%3DJ.-P.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DN-%255B6-%25284-Butanoyl-5-methyl-1H-pyrazol-1-yl%2529pyridazin-3-yl%255D-5-chloro-1-%255B2-%25284-methylpiperazin-1-yl%2529-2-oxoethyl%255D-1H-indole-3-carboxamide%2520%2528SAR216471%2529%252C%2520a%2520Novel%2520Intravenous%2520and%2520Oral%252C%2520Reversible%252C%2520and%2520Directly%2520Acting%2520P2Y12%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7293%26epage%3D7316%26doi%3D10.1021%2Fjm500588w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenalti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span> </span><span class="NLM_article-title">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">509</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/nature13083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnature13083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=24670650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=115-118&author=K.+Zhangauthor=J.+Zhangauthor=Z.+G.+Gaoauthor=D.+Zhangauthor=L.+Zhuauthor=G.+W.+Hanauthor=S.+M.+Mossauthor=S.+Paolettaauthor=E.+Kiselevauthor=W.+Luauthor=G.+Fenaltiauthor=W.+Zhangauthor=C.+E.+M%C3%BCllerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Structure+of+the+human+P2Y12+receptor+in+complex+with+an+antithrombotic+drug&doi=10.1038%2Fnature13083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span></div><div class="casAuthors">Zhang, Kaihua; Zhang, Jin; Gao, Zhan-Guo; Zhang, Dandan; Zhu, Lan; Han, Gye Won; Moss, Steven M.; Paoletta, Silvia; Kiselev, Evgeny; Lu, Weizhen; Fenalti, Gustavo; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides.  There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.  Their ligands are generally charged mols. with relatively low bioavailability and stability in vivo, which limits the authors' understanding of this receptor family.  P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R-including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analog ticagrelor (Brilinta) that acts directly on the receptor-have been approved for the prevention of stroke and myocardial infarction.  However, limitations of these drugs (for example, a very long half-life of clopidogrel action and a characteristic adverse effect profile of ticagrelor) suggest that there is an unfulfilled medical need for developing a new generation of P2Y12R inhibitors.  Here the authors report the 2.6 Å resoln. crystal structure of human P2Y12R in complex with a non-nucleotide reversible antagonist, AZD1283.  The structure reveals a distinct straight conformation of helix V, which sets P2Y12R apart from all other known class A GPCR structures.  With AZD1283 bound, the highly conserved disulfide bridge in GPCRs between helix III and extracellular loop 2 is not obsd. and appears to be dynamic.  Along with the details of the AZD1283-binding site, anal. of the extracellular interface reveals an adjacent ligand-binding region and suggests that both pockets could be required for dinucleotide binding.  The structure provides essential insights for the development of improved P2Y12R ligands and allosteric modulators as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY06VN4D76bVg90H21EOLACvtfcHk0lglWvmWEIEJTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D&md5=539bb91325c547737bc98baf59f3ff26</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature13083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13083%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DMoss%26aufirst%3DS.%2BM.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520P2Y12%2520receptor%2520in%2520complex%2520with%2520an%2520antithrombotic%2520drug%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature13083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span> </span><span class="NLM_article-title">Agonist-bound structure of the human P2Y12 receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">509</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1038/nature13288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnature13288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=24784220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=119-122&author=J.+Zhangauthor=K.+Zhangauthor=Z.+G.+Gaoauthor=S.+Paolettaauthor=D.+Zhangauthor=G.+W.+Hanauthor=T.+Liauthor=L.+Maauthor=W.+Zhangauthor=C.+E.+M%C3%BCllerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Agonist-bound+structure+of+the+human+P2Y12+receptor&doi=10.1038%2Fnature13288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound structure of the human P2Y12 receptor</span></div><div class="casAuthors">Zhang, Jin; Zhang, Kaihua; Gao, Zhan-Guo; Paoletta, Silvia; Zhang, Dandan; Han, Gye Won; Li, Tingting; Ma, Limin; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The P2Y12 receptor (P2Y12R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clin. drug targets for inhibition of platelet aggregation.  Although mutagenesis and modeling studies of the P2Y12R provided useful insights into ligand binding, the agonist and antagonist recognition and function at the P2Y12R remain poorly understood at the mol. level.  Here we report the structures of the human P2Y12R in complex with the full agonist 2-methylthio-adenosine-5'-diphosphate (2MeSADP, a close analog of endogenous agonist ADP) at 2.5 Å resoln., and the corresponding ATP deriv. 2-methylthio-adenosine-5'-triphosphate (2MeSATP) at 3.1 Å resoln.  These structures, together with the structure of the P2Y12R with antagonist Et 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283), reveal striking conformational changes between nucleotide and non-nucleotide ligand complexes in the extracellular regions.  Further anal. of these changes provides insight into a distinct ligand binding landscape in the δ-group of class A G-protein-coupled receptors (GPCRs).  Agonist and non-nucleotide antagonist adopt different orientations in the P2Y12R, with only partially overlapped binding pockets.  The agonist-bound P2Y12R structure answers long-standing questions surrounding P2Y12R-agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding.  As a first example, to our knowledge, of a GPCR in which agonist access to the binding pocket requires large-scale rearrangements in the highly malleable extracellular region, the structural and docking studies will therefore provide invaluable insight into the pharmacol. and mechanisms of action of agonists and different classes of antagonists for the P2Y12R and potentially for other closely related P2YRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJkF4VbScbarVg90H21EOLACvtfcHk0lglWvmWEIEJTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyis7k%253D&md5=7fdb421ab2f3757a7e7134d586de84bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature13288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13288%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DAgonist-bound%2520structure%2520of%2520the%2520human%2520P2Y12%2520receptor%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D119%26epage%3D122%26doi%3D10.1038%2Fnature13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbadin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kügelgen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelrahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straßburger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baqi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">756</span><span class="refDoi"> DOI: 10.1007/s10822-015-9858-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs10822-015-9858-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=26194851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=737-756&author=S.+Paolettaauthor=S.+Sabbadinauthor=I.+von+K%C3%BCgelgenauthor=S.+Hinzauthor=V.+Katritchauthor=K.+Hoffmannauthor=A.+Abdelrahmanauthor=J.+Stra%C3%9Fburgerauthor=Y.+Baqiauthor=Q.+Zhaoauthor=R.+C.+Stevensauthor=S.+Moroauthor=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Modeling+ligand+recognition+at+the+P2Y12+receptor+in+light+of+X-ray+structural+information&doi=10.1007%2Fs10822-015-9858-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span></div><div class="casAuthors">Paoletta, Silvia; Sabbadin, Davide; von Kugelgen, Ivar; Hinz, Sonja; Katritch, Vsevolod; Hoffmann, Kristina; Abdelrahman, Aliaa; Strassburger, Jens; Baqi, Younis; Zhao, Qiang; Stevens, Raymond C.; Moro, Stefano; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery.  Its recently solved, highly divergent crystallog. structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition.  Therefore, we performed extensive mol. modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported.  Various nucleotide derivs. docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6.  Supervised mol. dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites.  Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R.  Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets.  Thus, our structure-based approach consistently rationalized the main structure-activity relationships within each ligand class, giving useful information for designing improved ligands.  Graphical Abstr.: [Figure not available: see full text.].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QHrDrSpB57Vg90H21EOLACvtfcHk0lgVQ-jHiWQi9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J&md5=f6d2128d8067de9a9e0aed5dd1a375d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9858-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9858-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DSabbadin%26aufirst%3DS.%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DStra%25C3%259Fburger%26aufirst%3DJ.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DModeling%2520ligand%2520recognition%2520at%2520the%2520P2Y12%2520receptor%2520in%2520light%2520of%2520X-ray%2520structural%2520information%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D737%26epage%3D756%26doi%3D10.1007%2Fs10822-015-9858-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tantry, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bliden, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span> </span><span class="NLM_article-title">Resistance to antiplatelet drugs: what progress has been made?</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2553</span><span class="NLM_x">–</span> <span class="NLM_lpage">2564</span><span class="refDoi"> DOI: 10.1517/14656566.2014.968126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1517%2F14656566.2014.968126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25297833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=2553-2564&author=U.+S.+Tantryauthor=M.+Gesheffauthor=F.+Liuauthor=K.+P.+Blidenauthor=P.+A.+Gurbel&title=Resistance+to+antiplatelet+drugs%3A+what+progress+has+been+made%3F&doi=10.1517%2F14656566.2014.968126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to antiplatelet drugs: what progress has been made?</span></div><div class="casAuthors">Tantry, Udaya S.; Gesheff, Martin; Liu, Fang; Bliden, Kevin P.; Gurbel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2553-2564</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel.  The latter observation stimulated the close scrutiny of the pharmacodynamic effects of clopidogrel and revealed the 'wide variability' and the phenomenon of 'antiplatelet resistance'.  High on-treatment platelet reactivity to ADP (HPR) during clopidogrel therapy is an independent risk factor for ischemic event occurrences in post-percutaneous coronary intervention (post-PCI) patients.  Recent observational studies demonstrated a link between low on-treatment platelet reactivity to bleeding.  The concept of a 'therapeutic window' of P2Y12 receptor reactivity assocd. with both ischemic event occurrence (upper threshold) and bleeding risk (lower threshold) has been proposed.  Areas covered: An update on and a brief review of the current knowledge on antiplatelet resistance were presented.  Evidence available from studies evaluating aspirin resistance and high and low on-treatment platelet reactivity to ADP during P2Y12 receptor blocker therapy was collected from a selective literature search.  Expert opinion: The available evidence indicates that HPR is an independent risk factor for post-PCI ischemic event occurrences.  The therapeutic window concept for the P2Y12 receptor blocker therapy may facilitate the balance between reducing ischemic events and avoiding bleeding events, thereby improving net clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnOqEOVeDYN7Vg90H21EOLACvtfcHk0lgVQ-jHiWQi9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsrzK&md5=5705156905244abf22cb4608b300bde1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.968126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.968126%26sid%3Dliteratum%253Aachs%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DGesheff%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DBliden%26aufirst%3DK.%2BP.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DResistance%2520to%2520antiplatelet%2520drugs%253A%2520what%2520progress%2520has%2520been%2520made%253F%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D2553%26epage%3D2564%26doi%3D10.1517%2F14656566.2014.968126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">van Giezen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berntsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachrisson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkman, J. A.</span><span> </span><span class="NLM_article-title">Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1016/j.thromres.2009.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.thromres.2009.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=19692114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=565-571&author=J.+J.+van+Giezenauthor=P.+Berntssonauthor=H.+Zachrissonauthor=J.+A.+Bjorkman&title=Comparison+of+ticagrelor+and+thienopyridine+P2Y%2812%29+binding+characteristics+and+antithrombotic+and+bleeding+effects+in+rat+and+dog+models+of+thrombosis%2Fhemostasis&doi=10.1016%2Fj.thromres.2009.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis</span></div><div class="casAuthors">van Giezen, J. J. J.; Berntsson, Pia; Zachrisson, Helen; Bjoerkman, Jan-Arne</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ticagrelor (AZD6140), the first reversibly binding oral P2Y12 receptor antagonist, blocks ADP-induced platelet aggregation via a mode of action distinct from that of thienopyridine antiplatelet agents.  The latter must be metabolically activated and binds irreversibly to P2Y12 for the life of the platelet, precluding restoration of hemostatic function without the generation of new platelets.  In in vitro studies comparing binding characteristics of ticagrelor and compd. 105, a chem. compd. indistinguishable from the active metabolite of prasugrel, ticagrelor exhibited (1) an approx. 100-fold higher affinity for P2Y12 and rapid achievement of equil. (vs no equil. reached with compd. 105) as assessed by radioligand displacement in a receptor filtration binding assay, (2) 48-fold greater potency in a functional receptor assay using recombinant human P2Y12, and (3) 63-fold greater potency in inhibiting ADP-induced aggregation in washed human platelets.  In rat and dog models of thrombosis/hemostasis, there was greater sepn. between doses that provided antithrombotic effect and those that increased bleeding for ticagrelor compared with clopidogrel and compd. 072, a chem. compd. indistinguishable from the prasugrel parent compd.  The ratio of dose resulting in 3-fold increase in bleeding time to dose resulting in 50% restoration of blood flow in rats was 9.7 for ticagrelor compared with 2.0 for clopidogrel and 1.4 for compd. 072.  Similar results were obsd. in dogs.  Our findings suggest that reversibility of P2Y12 binding with ticagrelor may account for the greater sepn. between antithrombotic effects and increased bleeding compared with the irreversible binding of clopidogrel and prasugrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi34tt_gTEe7Vg90H21EOLACvtfcHk0lgVQ-jHiWQi9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yls7jK&md5=65a2a28bed4e31c6109f37fc9d34ab50</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2009.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2009.06.029%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DBerntsson%26aufirst%3DP.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520ticagrelor%2520and%2520thienopyridine%2520P2Y%252812%2529%2520binding%2520characteristics%2520and%2520antithrombotic%2520and%2520bleeding%2520effects%2520in%2520rat%2520and%2520dog%2520models%2520of%2520thrombosis%252Fhemostasis%26jtitle%3DThromb.%2520Res.%26date%3D2009%26volume%3D124%26spage%3D565%26epage%3D571%26doi%3D10.1016%2Fj.thromres.2009.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Becker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span> </span><span class="NLM_article-title">Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1160/TH09-07-0491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1160%2FTH09-07-0491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=20135066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=535-544&author=R.+C.+Beckerauthor=P.+A.+Gurbel&title=Platelet+P2Y12+receptor+antagonist+pharmacokinetics+and+pharmacodynamics%3A+A+foundation+for+distinguishing+mechanisms+of+bleeding+and+anticipated+risk+for+platelet-directed+therapies&doi=10.1160%2FTH09-07-0491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies</span></div><div class="casAuthors">Becker, Richard C.; Gurbel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">535-544</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">A review.  The platelet P2Y12 receptor is involved in all aspects of arterial thrombosis, including adhesion, activation, aggregation, secretion and development of a stable aggregate on which coagulation proteins can assemble and fibrin strands can mesh.  Inhibition of the P2Y12 receptor has been shown convincingly to reduce cardiovascular events among patients with acute coronary syndromes (ACS) and in patients undergoing percutaneous intervention (PCI).  Current studies are exploring whether there is a threshold of platelet aggregation below which only more bleeding occurs, without a concomitant redn. in clin. events.  The following review considers the potential relevance of reversible and irreversible mechanisms of P2Y12 inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y12 receptor is inhibited that dets. the attributable safety profile".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr199vMChfdcbVg90H21EOLACvtfcHk0lgVQ-jHiWQi9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKrsLw%253D&md5=9d1c9b9adfda85293d450bd1c537cc19</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1160%2FTH09-07-0491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH09-07-0491%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DPlatelet%2520P2Y12%2520receptor%2520antagonist%2520pharmacokinetics%2520and%2520pharmacodynamics%253A%2520A%2520foundation%2520for%2520distinguishing%2520mechanisms%2520of%2520bleeding%2520and%2520anticipated%2520risk%2520for%2520platelet-directed%2520therapies%26jtitle%3DThromb.%2520Haemostasis%26date%3D2010%26volume%3D103%26spage%3D535%26epage%3D544%26doi%3D10.1160%2FTH09-07-0491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">André, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberstock-Debic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1124/jpet.110.178574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1124%2Fjpet.110.178574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21447613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=22-30&author=P.+Andr%C3%A9author=F.+DeGuzmanauthor=H.+Haberstock-Debicauthor=S.+Millsauthor=Y.+Pakauthor=M.+Inagakiauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=Thienopyridines%2C+but+not+elinogrel%2C+result+in+off-target+effects+at+the+vessel+wall+that+contribute+to+bleeding&doi=10.1124%2Fjpet.110.178574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span></div><div class="casAuthors">Andre, Patrick; DeGuzman, Francis; Haberstock-Debic, Helena; Mills, Scott; Pak, Yvonne; Inagaki, Mayuko; Pandey, Anjali; Hollenbach, Stanley; Phillips, David R.; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. studies with clopidogrel or prasugrel show that although increased inhibition of P2Y12 and platelet function improves efficacy, bleeding is also increased.  Other preclin. and clin. studies have suggested a greater therapeutic index (TI) with reversible inhibitors and disproportionate effects of thienopyridines on bleeding at high doses.  We used multiple in vivo (FeCl3-induced arterial thrombosis in mesenteric arteries, blood loss after tail transsection, and platelet deposition and wound closure time in a micropuncture model in mesenteric veins) and ex vivo (light transmittance aggregometry, prothrombin time, and activated partial thromboplastin time) mouse models to (1) compare the TI of clopidogrel, prasugrel, and elinogrel, a reversible, competitive antagonist, with that in P2Y12(-/-) mice and (2) det. whether the bleeding consequences of the thienopyridines are attributed only to the inhibition of P2Y12.  Data indicated greater (elinogrel) and decreased (thienopyridines) TI compared with that in P2Y12(-/-) mice.  The impaired TI assocd. with the thienopyridines was not attributed to non-P2Y12 activities on platelet function or coagulation but was related to a direct effect at the vessel wall (inhibition of vascular tone).  Further anal. showed that the prasugrel off-target effect was dose- and time-dependent and of a reversible nature.  In conclusion, the TI of thienopyridines in the mouse may be decreased by P2Y12-independent off-target effects at the vessel wall, whereas that of elinogrel may be enhanced by the reversible, competitive nature of the antiplatelet agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4BcD1er_e7Vg90H21EOLACvtfcHk0lj8zumhx7aJrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D&md5=b2cd05a85e0988416608e5b2af2ea976</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178574%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DP.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DThienopyridines%252C%2520but%2520not%2520elinogrel%252C%2520result%2520in%2520off-target%2520effects%2520at%2520the%2520vessel%2520wall%2520that%2520contribute%2520to%2520bleeding%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D22%26epage%3D30%26doi%3D10.1124%2Fjpet.110.178574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Caroff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilpert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riederer, M. A.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4323</span><span class="NLM_x">–</span> <span class="NLM_lpage">4331</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.bmcl.2014.06.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4323-4331&author=E.+Caroffauthor=E.+Meyerauthor=A.+Treiberauthor=K.+Hilpertauthor=M.+A.+Riederer&title=Optimization+of+2-phenyl-pyrimidine-4-carboxamides+towards+potent%2C+orally+bioavailable+and+selective+P2Y12+antagonists+for+inhibition+of+platelet+aggregation&doi=10.1016%2Fj.bmcl.2014.06.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DRiederer%26aufirst%3DM.%2BA.%26atitle%3DOptimization%2520of%25202-phenyl-pyrimidine-4-carboxamides%2520towards%2520potent%252C%2520orally%2520bioavailable%2520and%2520selective%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4323%26epage%3D4331%26doi%3D10.1016%2Fj.bmcl.2014.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Paleo, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurrecoechea, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, H.</span><span> </span><span class="NLM_article-title">Formal Enantiospecific Synthesis of (+)-FR900482</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1021/jo0206521</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0206521" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFGhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=130-138&author=M.+R.+Paleoauthor=N.+Aurrecoecheaauthor=K.-Y.+Jungauthor=H.+Rapoport&title=Formal+Enantiospecific+Synthesis+of+%28%2B%29-FR900482&doi=10.1021%2Fjo0206521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Formal Enantiospecific Synthesis of (+)-FR900482</span></div><div class="casAuthors">Paleo, M. Rita; Aurrecoechea, Natalia; Jung, Kang-Yeoun; Rapoport, Henry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enantiospecific synthesis of FK973, and thus a formal enantiospecific synthesis of the antitumor antibiotic (+)-FR900482, is reported.  Addn. of an aniline to a chiral epoxide, prepd. from L-vinylglycine, afforded amino alc. I (R1 = CH2OMe, R2 = CO2CH2Ph).  After protection of the aliph. nitrogen with the 9-phenylfluoren-9-yl group, to preserve the acidic stereocenter from racemization, formation of the aziridine and intramol. condensation under basic conditions gave an azocinone.  Hydroxymethylation at the benzylic position was achieved by a process involving methylenation, epoxidn., and hydrogenolysis; the abs. stereochem. of the resulting alc. II (R1 = CH2OMe, R2 = SO2Ph) was detd. by X-ray crystallog. anal.  The hydroxyl group of II (R1 = CH2OMe, R2 = SO2Ph) was carbamoylated, and the arom. amine was deprotected electrochem. and then oxidized to give an unstable hydroxylamine that was immediately protected as an acetate.  Oxidn. with DMP, followed by hydrazinolysis of the acetyl group led to spontaneous closure of the resulting N-hydroxyamino ketone to hemiketal III (R1 = CH2OMe, R2 = CONH2) , which can be considered as a fully protected precursor of FR900482 and derivs.  Acid treatment to remove the protecting groups and acetylation afforded the triacetate FK973.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3-lmpWcqr7Vg90H21EOLACvtfcHk0lj8zumhx7aJrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFGhtr8%253D&md5=57f0fc325922d9b7ef512573b180f16a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo0206521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0206521%26sid%3Dliteratum%253Aachs%26aulast%3DPaleo%26aufirst%3DM.%2BR.%26aulast%3DAurrecoechea%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DK.-Y.%26aulast%3DRapoport%26aufirst%3DH.%26atitle%3DFormal%2520Enantiospecific%2520Synthesis%2520of%2520%2528%252B%2529-FR900482%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D130%26epage%3D138%26doi%3D10.1021%2Fjo0206521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">McKenna, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higa, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, M.-C.</span><span> </span><span class="NLM_article-title">The facile dealkylation of phosphonic acid dialkyl esters by bromotrimethylsilane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)92575-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS0040-4039%2801%2992575-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1977&pages=155-158&issue=2&author=C.+E.+McKennaauthor=M.+T.+Higaauthor=N.+H.+Cheungauthor=M.-C.+McKenna&title=The+facile+dealkylation+of+phosphonic+acid+dialkyl+esters+by+bromotrimethylsilane&doi=10.1016%2FS0040-4039%2801%2992575-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2992575-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252992575-4%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26aulast%3DHiga%26aufirst%3DM.%2BT.%26aulast%3DCheung%26aufirst%3DN.%2BH.%26aulast%3DMcKenna%26aufirst%3DM.-C.%26atitle%3DThe%2520facile%2520dealkylation%2520of%2520phosphonic%2520acid%2520dialkyl%2520esters%2520by%2520bromotrimethylsilane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1977%26volume%3D18%26issue%3D2%26spage%3D155%26epage%3D158%26doi%3D10.1016%2FS0040-4039%2801%2992575-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Demko, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Preparation of 5-Substituted 1<i>H</i>-Tetrazoles from Nitriles in Water</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7945</span><span class="NLM_x">–</span> <span class="NLM_lpage">7950</span><span class="refDoi"> DOI: 10.1021/jo010635w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo010635w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVCisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=7945-7950&author=Z.+P.+Demkoauthor=K.+B.+Sharpless&title=Preparation+of+5-Substituted+1H-Tetrazoles+from+Nitriles+in+Water&doi=10.1021%2Fjo010635w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of 5-Substituted 1H-Tetrazoles from Nitriles in Water</span></div><div class="casAuthors">Demko, Zachary P.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7945-7950</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The addn. of sodium azide to nitriles to give 1H-tetrazoles is shown to proceed readily in water with zinc salts as catalysts.  The scope of the reaction is quite broad; a variety of arom. nitriles, activated and unactivated alkyl nitriles, substituted vinyl nitriles, thiocyanates, and cyanamides have all been shown to be viable substrates for this reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8fxTzqdjUrVg90H21EOLACvtfcHk0ljbNakFy5Re1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVCisrc%253D&md5=c3f4e249316b4b0a52f604e3962048b2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo010635w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo010635w%26sid%3Dliteratum%253Aachs%26aulast%3DDemko%26aufirst%3DZ.%2BP.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DPreparation%2520of%25205-Substituted%25201H-Tetrazoles%2520from%2520Nitriles%2520in%2520Water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D7945%26epage%3D7950%26doi%3D10.1021%2Fjo010635w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamiya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naka, T.</span><span> </span><span class="NLM_article-title">Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">5228</span><span class="NLM_x">–</span> <span class="NLM_lpage">5235</span><span class="refDoi"> DOI: 10.1021/jm960547h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960547h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK28XntFaqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=5228-5235&author=Y.+Koharaauthor=K.+Kuboauthor=E.+Imamiyaauthor=T.+Wadaauthor=Y.+Inadaauthor=T.+Naka&title=Synthesis+and+Angiotensin+II+Receptor+Antagonistic+Activities+of+Benzimidazole+Derivatives+Bearing+Acidic+Heterocycles+as+Novel+Tetrazole+Bioisosteres&doi=10.1021%2Fjm960547h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres</span></div><div class="casAuthors">Kohara, Yasuhisa; Kubo, Keiji; Imamiya, Eiko; Wada, Takeo; Inada, Yoshiyuki; Naka, Takehiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5228-5235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. activity of benzimidazole-7-carboxylic acids bearing 5-oxo-1,2,4-oxadiazole, 5-oxo-1,2,4-thiadiazole, 5-thioxo-1,2,4-oxadiazole, and 2-oxo-1,2,3,5-oxathiadiazole rings are described.  The compds. were evaluated for in vitro and in vivo angiotensin II (AII) receptor antagonistic activities.  Most were found to have high affinity for the AT1 receptor (IC50 value, 10-6-10-7M) and to inhibit the AII-induced pressor response (more than 50% inhibition at 1 mg/kg po).  The 5-oxo-1,2,4-oxadiazole, 5-oxo-1,2,4-thiadiazole, and 5-thioxo-1,2,4-oxadiazole derivs. showed stronger inhibitory effects than the corresponding tetrazole derivs., while their binding affinities were weaker.  This might be ascribed to their improved bioavailability by increased lipophilicity.  This study showed that the 5-oxo-1,2,4-oxadiazole ring and its thio analog, the 5-oxo-1,2,4-thiadiazole ring, could be lipophilic bioisosteres for the tetrazole ring in nonpeptide AII receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoflmfjZbY2Z7Vg90H21EOLACvtfcHk0ljbNakFy5Re1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFaqsrY%253D&md5=a15b09f2dc98923ec961c3f22df99e40</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm960547h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960547h%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DImamiya%26aufirst%3DE.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DY.%26aulast%3DNaka%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Angiotensin%2520II%2520Receptor%2520Antagonistic%2520Activities%2520of%2520Benzimidazole%2520Derivatives%2520Bearing%2520Acidic%2520Heterocycles%2520as%2520Novel%2520Tetrazole%2520Bioisosteres%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D5228%26epage%3D5235%26doi%3D10.1021%2Fjm960547h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tachibana, K.; Sato, H.; Ohta, M.; Nakamura, M.; Shiraishi, T.; Imaoka, I.; Yoshino, H.; Nagamuta, M.; Kawata, H.</span><span> </span><span class="NLM_article-title">Imidazoline Derivative</span>. EP1634874, March 15,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>22 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Tachibana&author=H.+Sato&author=M.+Ohta&author=M.+Nakamura&author=T.+Shiraishi&author=I.+Imaoka&author=H.+Yoshino&author=M.+Nagamuta&author=H.+Kawata&title=Imidazoline+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DK.%26atitle%3DImidazoline%2520Derivative%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Smet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckert, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieruszeski, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landrieu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buée, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déprez, B.</span><span> </span><span class="NLM_article-title">Control of Protein–Protein Interactions: Structure-Based Discovery of Low Molecular Weight Inhibitors of the Interactions between Pin1 WW Domain and Phosphopeptides</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4815</span><span class="NLM_x">–</span> <span class="NLM_lpage">4823</span><span class="refDoi"> DOI: 10.1021/jm0500119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4815-4823&author=C.+Smetauthor=J.-F.+Duckertauthor=J.-M.+Wieruszeskiauthor=I.+Landrieuauthor=L.+Bu%C3%A9eauthor=G.+Lippensauthor=B.+D%C3%A9prez&title=Control+of+Protein%E2%80%93Protein+Interactions%3A+Structure-Based+Discovery+of+Low+Molecular+Weight+Inhibitors+of+the+Interactions+between+Pin1+WW+Domain+and+Phosphopeptides&doi=10.1021%2Fjm0500119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm0500119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500119%26sid%3Dliteratum%253Aachs%26aulast%3DSmet%26aufirst%3DC.%26aulast%3DDuckert%26aufirst%3DJ.-F.%26aulast%3DWieruszeski%26aufirst%3DJ.-M.%26aulast%3DLandrieu%26aufirst%3DI.%26aulast%3DBu%25C3%25A9e%26aufirst%3DL.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26atitle%3DControl%2520of%2520Protein%25E2%2580%2593Protein%2520Interactions%253A%2520Structure-Based%2520Discovery%2520of%2520Low%2520Molecular%2520Weight%2520Inhibitors%2520of%2520the%2520Interactions%2520between%2520Pin1%2520WW%2520Domain%2520and%2520Phosphopeptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4815%26epage%3D4823%26doi%3D10.1021%2Fjm0500119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Storer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aciro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Squaramides: physical properties, synthesis and applications</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2330</span><span class="NLM_x">–</span> <span class="NLM_lpage">2346</span><span class="refDoi"> DOI: 10.1039/c0cs00200c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1039%2Fc0cs00200c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21399835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC3MvksVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=2330-2346&author=R.+I.+Storerauthor=C.+Aciroauthor=L.+H.+Jones&title=Squaramides%3A+physical+properties%2C+synthesis+and+applications&doi=10.1039%2Fc0cs00200c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramides: physical properties, synthesis and applications</span></div><div class="casAuthors">Storer R Ian; Aciro Caroline; Jones Lyn H</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2330-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Squaramides are remarkable four-membered ring systems derived from squaric acid that are able to form up to four hydrogen bonds.  A high affinity for hydrogen bonding is driven through a concomitant increase in aromaticity of the ring.  This hydrogen bonding and aromatic switching, in combination with structural rigidity, have been exploited in many of the applications of squaramides.  Substituted squaramides can be accessed via modular synthesis under relatively mild or aqueous conditions, making them ideal units for bioconjugation and supramolecular chemistry.  In this tutorial review the fundamental electronic and structural properties of squaramides are explored to rationalise the geometry, conformation, reactivity and biological activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4YxJCB1T0gysZ1x6zOs0vfW6udTcc2eaxaLKtahmbI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvksVyntw%253D%253D&md5=503557e25e8120c895a56f78c9a19285</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fc0cs00200c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cs00200c%26sid%3Dliteratum%253Aachs%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DAciro%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSquaramides%253A%2520physical%2520properties%252C%2520synthesis%2520and%2520applications%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D2330%26epage%3D2346%26doi%3D10.1039%2Fc0cs00200c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Malachowski, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coward, J. K.</span><span> </span><span class="NLM_article-title">The Chemistry of Phosphapeptides: Investigations on the Synthesis of Phosphonamidate, Phosphonate, and Phosphinate Analogs of Glutamyl-.gamma.-glutamate</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7625</span><span class="NLM_x">–</span> <span class="NLM_lpage">7634</span><span class="refDoi"> DOI: 10.1021/jo00104a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00104a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=7625-7634&author=W.+P.+Malachowskiauthor=J.+K.+Coward&title=The+Chemistry+of+Phosphapeptides%3A+Investigations+on+the+Synthesis+of+Phosphonamidate%2C+Phosphonate%2C+and+Phosphinate+Analogs+of+Glutamyl-.gamma.-glutamate&doi=10.1021%2Fjo00104a017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00104a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00104a017%26sid%3Dliteratum%253Aachs%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DCoward%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520Chemistry%2520of%2520Phosphapeptides%253A%2520Investigations%2520on%2520the%2520Synthesis%2520of%2520Phosphonamidate%252C%2520Phosphonate%252C%2520and%2520Phosphinate%2520Analogs%2520of%2520Glutamyl-.gamma.-glutamate%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D7625%26epage%3D7634%26doi%3D10.1021%2Fjo00104a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, C. A.</span><span> </span><span class="NLM_article-title">Total syntheses of (−)-nocardicins A-G: a biogenetic approach</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1021/ja00158a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00158a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=760-770&author=G.+M.+Salituroauthor=C.+A.+Townsend&title=Total+syntheses+of+%28%E2%88%92%29-nocardicins+A-G%3A+a+biogenetic+approach&doi=10.1021%2Fja00158a040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja00158a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00158a040%26sid%3Dliteratum%253Aachs%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DTownsend%26aufirst%3DC.%2BA.%26atitle%3DTotal%2520syntheses%2520of%2520%2528%25E2%2588%2592%2529-nocardicins%2520A-G%253A%2520a%2520biogenetic%2520approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D760%26epage%3D770%26doi%3D10.1021%2Fja00158a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Yamaguchi, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, M.</span><span> </span><span class="NLM_article-title">Facile New Method for Preparation of Optically Active Protected Proline</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span><span class="refDoi"> DOI: 10.1246/cl.1996.621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1246%2Fcl.1996.621" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=621-622&author=J.-I.+Yamaguchiauthor=M.+Ueki&title=Facile+New+Method+for+Preparation+of+Optically+Active+Protected+Proline&doi=10.1246%2Fcl.1996.621"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1246%2Fcl.1996.621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1996.621%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DJ.-I.%26aulast%3DUeki%26aufirst%3DM.%26atitle%3DFacile%2520New%2520Method%2520for%2520Preparation%2520of%2520Optically%2520Active%2520Protected%2520Proline%26jtitle%3DChem.%2520Lett.%26date%3D1996%26spage%3D621%26epage%3D622%26doi%3D10.1246%2Fcl.1996.621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhIsWTzOk_yyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huryn, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span> </span><span class="NLM_article-title">Carboxylic Acid (Bio)Isosteres in Drug Design</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1002/cmdc.201200585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1002%2Fcmdc.201200585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=23361977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=385-395&author=C.+Ballatoreauthor=D.+M.+Hurynauthor=A.+B.+Smith&title=Carboxylic+Acid+%28Bio%29Isosteres+in+Drug+Design&doi=10.1002%2Fcmdc.201200585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylic Acid (Bio)Isosteres in Drug Design</span></div><div class="casAuthors">Ballatore, Carlo; Huryn, Donna M.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biol. membranes.  To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres.  The same type of strategy can also be effective for a variety other purposes, for example, to increase the selectivity of a biol. active compd. or to create new intellectual property.  Several carboxylic acid isosteres have been reported, however, the outcome of any isosteric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug-target).  As a result, screening of a panel of isosteres is typically required.  In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research.  The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEcl3NtfHu7Vg90H21EOLACvtfcHk0lhIsWTzOk_yyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D&md5=cff8233af1c386439789a0e4ebcb4331</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200585%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DCarboxylic%2520Acid%2520%2528Bio%2529Isosteres%2520in%2520Drug%2520Design%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D385%26epage%3D395%26doi%3D10.1002%2Fcmdc.201200585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">p<i>K</i><sub>a</sub> values were predicted using ACD/pKa DB software.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">Predicted p<i>K</i><sub>a</sub> values of phosphonate-containing analogs are the following: <b>30c</b> and <b>30d</b>, 1.38 and 7.39; <b>30h</b>, 2.23 and 7.81.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Baldoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruderer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueret, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astruc, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial</span> <span class="citation_source-journal">Clin. Drug Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span><span class="refDoi"> DOI: 10.1007/s40261-014-0236-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs40261-014-0236-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25331625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=807-818&author=D.+Baldoniauthor=S.+Brudererauthor=A.+Krauseauthor=M.+Gutierrezauthor=P.+Gueretauthor=B.+Astrucauthor=J.+Dingemanse&title=A+New+Reversible+and+Potent+P2Y12+Receptor+Antagonist+%28ACT-246475%29%3A+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+in+a+First-in-Man+Trial&doi=10.1007%2Fs40261-014-0236-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial</span></div><div class="casAuthors">Baldoni, Daniela; Bruderer, Shirin; Krause, Andreas; Gutierrez, Marcello; Gueret, Pierre; Astruc, Beatrice; Dingemanse, Jasper</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">807-818</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and objectives: ACT-246475 is a new reversible, selective, and potent antagonist of the platelet P2Y12 receptor.  This study was a first-in-man trial investigating the tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of ACT-246475 and its di-ester prodrug (ACT-281959) in healthy males.  Methods: The study had a double-blind, randomized, ascending single-dose design with an oral formulation F1 (i.e., ACT-281959 or placebo) (Part I) and an open-label, randomized, 3-period, crossover design comparing exploratory formulations of ACT-281959 (F2) 70 mg and ACT-246475 (dF) 50 mg to F1 70 mg (Part II).  In Part I, doses up to 1,000 mg were tested in 40 healthy subjects.  Nine healthy subjects were enrolled in Part II.  Std. safety parameters, inhibition of platelet aggregation, and ACT-246475 plasma concns. were measured.  Non-compartmental pharmacokinetic anal. was performed.  Results: All doses and formulations were well tolerated.  The most frequent adverse event was headache, whereas no events of bleeding or dyspnea were reported.  In Part I, ACT-246475 area under the plasma concn.-time curve (AUC) increased dose-proportionally whereas max. plasma concn. (Cmax) was less than dose-proportional.  The highest Cmax [geometric mean (95 % CI)] at 1,000 mg was 13.8 (9.7, 19.5) pmol/mL at 4.5 h post-dose, terminal half-life (t1/2) was ∼10 h.  ACT-246475 Cmax and AUC0-inf ratios of geometric means (90 % CI) using F1 as ref., for F2 were 8.5 (5.42, 13.35) and 3.4 (2.40, 4.82), resp., and for dF 2.2 (1.42, 3.49) and 1.5 (1.07, 2.16), resp.  Mean peak platelet inhibition was 31.0 % after F1 (1,000 mg) and 47.8 % after F2.  Conclusions: Oral doses of ACT-281959 and ACT-246475 were well tolerated.  Platelet inhibition correlated with ACT-246475 exposure.  Exploratory formulations enhanced the bioavailability and antiplatelet effect of ACT-246475.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjNomBWwqfbVg90H21EOLACvtfcHk0lhIsWTzOk_yyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrL&md5=075586f2b8a49365319bd1d1c03bdbf0</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40261-014-0236-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-014-0236-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaldoni%26aufirst%3DD.%26aulast%3DBruderer%26aufirst%3DS.%26aulast%3DKrause%26aufirst%3DA.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DGueret%26aufirst%3DP.%26aulast%3DAstruc%26aufirst%3DB.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DA%2520New%2520Reversible%2520and%2520Potent%2520P2Y12%2520Receptor%2520Antagonist%2520%2528ACT-246475%2529%253A%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520in%2520a%2520First-in-Man%2520Trial%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2014%26volume%3D34%26spage%3D807%26epage%3D818%26doi%3D10.1007%2Fs40261-014-0236-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="note"><p class="first last">The effect of the compounds on the hERG K<sup>+</sup> channel was evaluated using manual patch-clamp of HEK-hERG cells at 37 °C. Compounds were first tested near their limit of solubility in the assay solution (150 mM NaCl; 4 mM KCl; 1.2 mM CaCl<sub>2</sub>; 1 mM MgCl<sub>2</sub>; 10 mM HEPES; pH 7.4), and concentration–response curves were determined if current block exceeded 20%.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">Inhibition of the major human cytochrome P450 enzymes was investigated using human liver microsomes and P450 isoform-specific marker reactions. Diclofenac 4′-hydroxylation and dextromethorphan O-demethylation were used for CYP2C9 and CYP2D6, respectively. CYP3A4 inhibition was tested using midazolam 1′-hydroxylation and testosterone 6β-hydroxylation as markers. Inhibition experiments were performed at a single substrate concentration around the respective <i>K</i><sub>m</sub> value of each P450 marker. Eight inhibitor concentrations up to 50 μM were used and all experiments performed in duplicate under linear enzyme kinetic conditions. Organic solvent content in none of the experiments exceeded 1.1%. Sulfaphenazole, fluoxetine, and nicardipine were use as positive controls with the test compounds. Metabolite formation was monitored using liquid chromatography (Shimadzu LC-10AD VP pumps, SCL-10A VP system controller, and an HTS PAL autosampler, Shimadzu AG, Reinach, Switzerland) coupled to triple stage mass spectrometer (API2000 and API4000, AB SCIEX, Concord, Ontario, Canada, or TSQ Quantum, Thermo Electron Corporation, Waltham, MA, U.S.). Data acquisition was done using the Analyst (version 1.5 for API2000 and version 1.5.1 for API4000) or Xcalibur (TSQ Quantum, version 1.3) software packages. Data of the inhibition experiments were evaluated by plotting the inhibitor concentration (logarithmic scale) against the metabolite formation rates. IC<sub>50</sub> values were then determined from the plot by nonlinear regression using the following equation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/jm-2015-00933e_m001.gif" alt="" /></img></span>where <i>y</i> is the rate of metabolite formation, <i>x</i> is the inhibitor concentration, <i>s</i> is the slope at the point of inversion, and Top and Bottom are the maximum and minimum rates of metabolite formation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Krise, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, V. J.</span><span> </span><span class="NLM_article-title">Prodrugs of Phosphates, Phosphonates and Phosphinates</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span><span class="refDoi"> DOI: 10.1016/0169-409X(95)00111-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2F0169-409X%2895%2900111-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1996&pages=287-310&author=J.+P.+Kriseauthor=V.+J.+Stella&title=Prodrugs+of+Phosphates%2C+Phosphonates+and+Phosphinates&doi=10.1016%2F0169-409X%2895%2900111-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0169-409X%2895%2900111-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-409X%252895%252900111-J%26sid%3Dliteratum%253Aachs%26aulast%3DKrise%26aufirst%3DJ.%2BP.%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DProdrugs%2520of%2520Phosphates%252C%2520Phosphonates%2520and%2520Phosphinates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1996%26volume%3D19%26spage%3D287%26epage%3D310%26doi%3D10.1016%2F0169-409X%2895%2900111-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">He, G.-X.; Krise, J. P.; Oliyai, R.</span><span> </span><span class="NLM_article-title">Prodrugs of Phosphonates, Phosphinates, and Phosphates</span>. In  <span class="citation_source-book">Prodrugs: Challenges and Rewards Part 2</span>; <span class="NLM_contrib-group">Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J. W.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2F978-0-387-49785-3_25" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=223-264&author=G.-X.+He&author=J.+P.+Krise&author=R.+Oliyaiauthor=V.+J.+Stella&author=R.+T.+Borchardt&author=M.+J.+Hageman&author=R.+Oliyai&author=H.+Maag&author=J.+W.+Tilley&title=Prodrugs%3A+Challenges+and+Rewards+Part+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-49785-3_25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-49785-3_25%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DG.-X.%26atitle%3DProdrugs%2520of%2520Phosphonates%252C%2520Phosphinates%252C%2520and%2520Phosphates%26btitle%3DProdrugs%253A%2520Challenges%2520and%2520Rewards%2520Part%25202%26aulast%3DStella%26aufirst%3DV.%2BJ.%26pub%3DSpringer%26date%3D2007%26spage%3D223%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><div class="note"><p class="first last"><a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A:</p></div><span class="NLM_contrib-group">Rey, M.; Kramberg, M.; Cattaneo, C.; Hess, P.; Weber, E.; Ernst, R.; Haag, F.; Morrison, K.; Clozel, M.; Baumann, M.; Caroff, E.; Hubler, F.; Riederer, M. A.; Steiner, B.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Figure+5A+and+Figure+6A%3ARey%2C+M.%3B+Kramberg%2C+M.%3B+Cattaneo%2C+C.%3B+Hess%2C+P.%3B+Weber%2C+E.%3B+Ernst%2C+R.%3B+Haag%2C+F.%3B+Morrison%2C+K.%3B+Clozel%2C+M.%3B+Baumann%2C+M.%3B+Caroff%2C+E.%3B+Hubler%2C+F.%3B+Riederer%2C+M.+A.%3B+Steiner%2C+B.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Born, G. V.</span><span> </span><span class="NLM_article-title">Aggregation of blood platelets by adenosine diphosphate and its reversal</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">929</span><span class="refDoi"> DOI: 10.1038/194927b0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2F194927b0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=1962&pages=927-929&author=G.+V.+Born&title=Aggregation+of+blood+platelets+by+adenosine+diphosphate+and+its+reversal&doi=10.1038%2F194927b0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2F194927b0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F194927b0%26sid%3Dliteratum%253Aachs%26aulast%3DBorn%26aufirst%3DG.%2BV.%26atitle%3DAggregation%2520of%2520blood%2520platelets%2520by%2520adenosine%2520diphosphate%2520and%2520its%2520reversal%26jtitle%3DNature%26date%3D1962%26volume%3D194%26spage%3D927%26epage%3D929%26doi%3D10.1038%2F194927b0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Gast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschopp, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilpert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, J.</span><span> </span><span class="NLM_article-title">Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma</span> <span class="citation_source-journal">Blood Coagulation Fibrinolysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span><span class="refDoi"> DOI: 10.1097/00001721-199412000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1097%2F00001721-199412000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=7893925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK2MXktlaqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1994&pages=879-887&author=A.+Gastauthor=T.+B.+Tschoppauthor=G.+Schmidauthor=K.+Hilpertauthor=J.+Ackermann&title=Inhibition+of+clot-bound+and+free+%28fluid-phase+thrombin%29+by+a+novel+synthetic+thrombin+inhibitor+%28Ro+46-6240%29%2C+recombinant+hirudin+and+heparin+in+human+plasma&doi=10.1097%2F00001721-199412000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of clot-bound and free (fluid-phase) thrombin by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma</span></div><div class="casAuthors">Gast, A.; Tschopp, T. B.; Schmid, G.; Hilpert, K.; Ackermann, J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Coagulation & Fibrinolysis</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">879-87</span>CODEN:
                <span class="NLM_cas:coden">BLFIE7</span>;
        ISSN:<span class="NLM_cas:issn">0957-5235</span>.
    </div><div class="casAbstract">Clot-bound thrombin remains active and is less accessible to heparin-antithrombin III than fluid-phase thrombin.  To det. whether clot-bound human thrombin is more susceptible to inactivation by direct thrombin inhibitors, the activity of a novel synthetic competitive thrombin inhibitor Ro 46-6240, recombinant hirudin and unfractionated heparin were compared with fluid-phase thrombin and clot-bound thrombin.  Fibrinopeptide A generated in human plasma was used as an index of thrombin activity.  Hirudin was the most potent inhibitor of fluid-phase and clot-bound thrombin.  However, Ro 46-6240 inhibited clot-bound thrombin three times more potently than fluid-phase thrombin (IC50 19 vs. 56 ng/mL) while hirudin was two times (IC50 8 vs. 3 ng/mL) and heparin six times (IC50 1205 vs. 200 ng/mL) less active against clot-bound thrombin compared with fluid-phase thrombin.  The relative selectivity for clot-bound thrombin is not a unique property of Ro 46-6240 since two other synthetic thrombin inhibitors tested inhibited clot-bound thrombin more effectively than fluid-phase thrombin and a third was equally active against both forms of thrombin.  In contrast, the affinities of two chromogenic substrates were similar for both forms of thrombin.  This study shows that direct thrombin inhibitors inhibit clot-bound thrombin more potently than heparin and suggests that an apparent selectivity for clot-bound thrombin can be achieved with some synthetic thrombin inhibitors.  Further studies have to show whether the high potency of these direct thrombin inhibitors translates into antithrombotic efficacy in clin. situations with pre-existing clots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvG755XEMfNLVg90H21EOLACvtfcHk0liRaui6eJc2tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktlaqurw%253D&md5=23c1fe6f92488664a18f5ed1cc6fdc69</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2F00001721-199412000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001721-199412000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGast%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DT.%2BB.%26aulast%3DSchmid%26aufirst%3DG.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DAckermann%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520clot-bound%2520and%2520free%2520%2528fluid-phase%2520thrombin%2529%2520by%2520a%2520novel%2520synthetic%2520thrombin%2520inhibitor%2520%2528Ro%252046-6240%2529%252C%2520recombinant%2520hirudin%2520and%2520heparin%2520in%2520human%2520plasma%26jtitle%3DBlood%2520Coagulation%2520Fibrinolysis%26date%3D1994%26volume%3D5%26spage%3D879%26epage%3D887%26doi%3D10.1097%2F00001721-199412000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Teng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1007/s00228-009-0778-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs00228-009-0778-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=487-496&author=R.+Tengauthor=K.+Butler&title=Pharmacokinetics%2C+pharmacodynamics%2C+tolerability+and+safety+of+single+ascending+doses+of+ticagrelor%2C+a+reversibly+binding+oral+P2Y%2812%29+receptor+antagonist%2C+in+healthy+subjects&doi=10.1007%2Fs00228-009-0778-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00228-009-0778-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-009-0778-5%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DK.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%2520and%2520safety%2520of%2520single%2520ascending%2520doses%2520of%2520ticagrelor%252C%2520a%2520reversibly%2520binding%2520oral%2520P2Y%252812%2529%2520receptor%2520antagonist%252C%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D66%26spage%3D487%26epage%3D496%26doi%3D10.1007%2Fs00228-009-0778-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Kurz, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Main, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandusky, G. E.</span><span> </span><span class="NLM_article-title">Rat model of arterial thrombosis induced by ferric chloride</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1016/0049-3848(90)90106-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2F0049-3848%2890%2990106-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=2087688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1990&pages=269-280&author=K.+D.+Kurzauthor=B.+W.+Mainauthor=G.+E.+Sandusky&title=Rat+model+of+arterial+thrombosis+induced+by+ferric+chloride&doi=10.1016%2F0049-3848%2890%2990106-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Rat model of arterial thrombosis induced by ferric chloride</span></div><div class="casAuthors">Kurz, K. D.; Main, B. W.; Sandusky, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">269-80</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    </div><div class="casAbstract">The purposes of these studies were to produce a small animal model of arterial thrombosis for study of novel antithrombotic agents, to validate a simple temp. index of occlusive thrombosis, and to describe the compn. of the thrombus.  Small thermocouple transducers were fabricated from readily available materials.  A thermocouple was inserted under a carotid artery of the anesthetized rat and vessel temp. was recorded continuously.  Arterial injury was induced by FeCl3 soln. applied topically to the artery above the thermocouple.  To validate the relationship between thrombotic occlusion and vessel temp., blood flow velocity, proximal to the injury, and temp. were recorded simultaneously.  Temp. decreased rapidly when velocity averaged 24 ± 12 percent of control and velocity did not differ from zero within 20 s.  In normal vessels, av. flow velocity did not decrease significantly from control until a fixed stenosis decreased diam. by 78 percent.  Av. time to occlusion (TTO), signaled by the abrupt temp. inflection, ranged from 56 ± 4 min to 14 ± 1 min after 10 and 65 percent FeCl3 application resp.  Vessel segments were fixed at various times after FeCl3 exposure and examd. by SEM.  Endothelial damage was obsd. and was assocd. with thrombus composed of activated platelets, fibrin strands and entrapped erythrocytes.  The results demonstrate that FeCl3 dose-dependently induced formation of an occlusive mixed thrombus that was indexed by monitoring the time between FeCl3 application and a rapid temp. decrease in the carotid artery of the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLLjIq2Kf2LVg90H21EOLACvtfcHk0ljjOze4w09zxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyhsw%253D%253D&md5=896dc87d899d88e9b76f916b3245825e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0049-3848%2890%2990106-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-3848%252890%252990106-M%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DK.%2BD.%26aulast%3DMain%26aufirst%3DB.%2BW.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26atitle%3DRat%2520model%2520of%2520arterial%2520thrombosis%2520induced%2520by%2520ferric%2520chloride%26jtitle%3DThromb.%2520Res.%26date%3D1990%26volume%3D60%26spage%3D269%26epage%3D280%26doi%3D10.1016%2F0049-3848%2890%2990106-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Liu, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, H.-X.</span><span> </span><span class="NLM_article-title">Pre-treatment with puerarin affects pharmacokinetics of warfarin, but not clopidogrel, in experimental rats</span> <span class="citation_source-journal">Chin. J. Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1016/S1875-5364(15)30012-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS1875-5364%2815%2930012-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25908622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjns12qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=257-263&author=A.-C.+Liuauthor=L.-X.+Zhaoauthor=S.-W.+Yuauthor=H.-X.+Lou&title=Pre-treatment+with+puerarin+affects+pharmacokinetics+of+warfarin%2C+but+not+clopidogrel%2C+in+experimental+rats&doi=10.1016%2FS1875-5364%2815%2930012-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-treatment with puerarin affects pharmacokinetics of warfarin, but not clopidogrel, in experimental rats</span></div><div class="casAuthors">Liu An-Chang; Zhao Li-Xia; Yu Shu-Wen; Lou Hong-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Chinese journal of natural medicines</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present study was designed to determine the effects of puerarin pre-treatment on the pharmacokinetics of the oral anticoagulant agent warfarin and the antiplatelet agent clopidogrel in rats.  In the treatment group, rats was gavaged with warfarin or clopidogrel after repeated treatment with puerarin at intraperitoneal doses of 20, 60, or 200 mg·kg(-1) for 7 days, while rats in the control group were administrated only with the same dose warfarin or clopidogrel.  Plasma samples were obtained at the prescribed times and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS).  The results showed that rats treated with puerarin at all the test doses of 20, 60 and 200 mg·kg(-1) were found to affect the pharmacokinetics of warfarin, but not clopidogrel, suggesting a potential herb-drug interaction between puerarin and warfarin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfO_dqKAdP2YHWj6b1v8uTfW6udTcc2ea8cHWW3rHQhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjns12qsA%253D%253D&md5=d0edfefcbb99be77d7c1dc064df74651</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1875-5364%2815%2930012-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1875-5364%252815%252930012-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.-C.%26aulast%3DZhao%26aufirst%3DL.-X.%26aulast%3DYu%26aufirst%3DS.-W.%26aulast%3DLou%26aufirst%3DH.-X.%26atitle%3DPre-treatment%2520with%2520puerarin%2520affects%2520pharmacokinetics%2520of%2520warfarin%252C%2520but%2520not%2520clopidogrel%252C%2520in%2520experimental%2520rats%26jtitle%3DChin.%2520J.%2520Nat.%2520Med.%26date%3D2015%26volume%3D13%26spage%3D257%26epage%3D263%26doi%3D10.1016%2FS1875-5364%2815%2930012-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Descamps, M.; Radisson, J.</span><span> </span><span class="NLM_article-title">Process for the preparation of an N-phenylacetic derivative of tetrahydrothieno(3,2-c)pyridine and its chemical intermediate</span>. US5204469,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=M.+Descamps&author=J.+Radisson&title=Process+for+the+preparation+of+an+N-phenylacetic+derivative+of+tetrahydrothieno%283%2C2-c%29pyridine+and+its+chemical+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDescamps%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520preparation%2520of%2520an%2520N-phenylacetic%2520derivative%2520of%2520tetrahydrothieno%25283%252C2-c%2529pyridine%2520and%2520its%2520chemical%2520intermediate%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Fox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennon, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCague, R.</span><span> </span><span class="NLM_article-title">A Convergent Synthesis of the 11-Oxa Prostaglandin Analogue AL-12182</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1227</span><span class="NLM_x">–</span> <span class="NLM_lpage">1236</span><span class="refDoi"> DOI: 10.1021/jo048035v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo048035v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=1227-1236&author=M.+E.+Foxauthor=M.+Jacksonauthor=I.+C.+Lennonauthor=R.+McCague&title=A+Convergent+Synthesis+of+the+11-Oxa+Prostaglandin+Analogue+AL-12182&doi=10.1021%2Fjo048035v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo048035v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo048035v%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DM.%2BE.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DLennon%26aufirst%3DI.%2BC.%26aulast%3DMcCague%26aufirst%3DR.%26atitle%3DA%2520Convergent%2520Synthesis%2520of%2520the%252011-Oxa%2520Prostaglandin%2520Analogue%2520AL-12182%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D1227%26epage%3D1236%26doi%3D10.1021%2Fjo048035v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Greck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piveteau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genet, J.-P.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis of anti N-Boc-α-hydrazino-β-hydroxyesters from β-ketoesters by sequential catalytic hydrogenation and electrophilic amination</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1993</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1055/s-1993-22496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1055%2Fs-1993-22496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1993&publication_year=1993&pages=475-477&issue=7&author=C.+Greckauthor=L.+Bischoffauthor=F.+Ferreiraauthor=C.+Pinelauthor=E.+Piveteauauthor=J.-P.+Genet&title=Asymmetric+synthesis+of+anti+N-Boc-%CE%B1-hydrazino-%CE%B2-hydroxyesters+from+%CE%B2-ketoesters+by+sequential+catalytic+hydrogenation+and+electrophilic+amination&doi=10.1055%2Fs-1993-22496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1055%2Fs-1993-22496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1993-22496%26sid%3Dliteratum%253Aachs%26aulast%3DGreck%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DF.%26aulast%3DPinel%26aufirst%3DC.%26aulast%3DPiveteau%26aufirst%3DE.%26aulast%3DGenet%26aufirst%3DJ.-P.%26atitle%3DAsymmetric%2520synthesis%2520of%2520anti%2520N-Boc-%25CE%25B1-hydrazino-%25CE%25B2-hydroxyesters%2520from%2520%25CE%25B2-ketoesters%2520by%2520sequential%2520catalytic%2520hydrogenation%2520and%2520electrophilic%2520amination%26jtitle%3DSynlett%26date%3D1993%26volume%3D1993%26issue%3D7%26spage%3D475%26epage%3D477%26doi%3D10.1055%2Fs-1993-22496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bourdreux, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drouillat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greck, C.</span><span> </span><span class="NLM_article-title">Enantio- and diastereoselective syntheses of orthogonally protected anti-2-amino-1,3,4-butanetriols from an achiral β-keto ester</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1055/s-2005-871954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1055%2Fs-2005-871954" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=2086-2088&author=Y.+Bourdreuxauthor=B.+Drouillatauthor=C.+Greck&title=Enantio-+and+diastereoselective+syntheses+of+orthogonally+protected+anti-2-amino-1%2C3%2C4-butanetriols+from+an+achiral+%CE%B2-keto+ester&doi=10.1055%2Fs-2005-871954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-871954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-871954%26sid%3Dliteratum%253Aachs%26aulast%3DBourdreux%26aufirst%3DY.%26aulast%3DDrouillat%26aufirst%3DB.%26aulast%3DGreck%26aufirst%3DC.%26atitle%3DEnantio-%2520and%2520diastereoselective%2520syntheses%2520of%2520orthogonally%2520protected%2520anti-2-amino-1%252C3%252C4-butanetriols%2520from%2520an%2520achiral%2520%25CE%25B2-keto%2520ester%26jtitle%3DSynlett%26date%3D2005%26volume%3D13%26spage%3D2086%26epage%3D2088%26doi%3D10.1055%2Fs-2005-871954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Riess, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laschat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, V.</span><span> </span><span class="NLM_article-title">Evaluation of protecting groups for 3-hydroxyisoxazoles. Short access to 3-alkoxyisoxazole-5-carbaldehydes and 3-hydroxyisoxazole-5-carbaldehyde, the putative toxic metabolite of muscimol</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1998</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1002/(SICI)1099-0690(199803)1998:3<473::AID-EJOC473>3.0.CO;2-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=473-479&issue=3&author=R.+Riessauthor=M.+Schoenauthor=S.+Laschatauthor=V.+Jaeger&title=Evaluation+of+protecting+groups+for+3-hydroxyisoxazoles.+Short+access+to+3-alkoxyisoxazole-5-carbaldehydes+and+3-hydroxyisoxazole-5-carbaldehyde%2C+the+putative+toxic+metabolite+of+muscimol&doi=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-0690%2528199803%25291998%253A3%253C473%253A%253AAID-EJOC473%253E3.0.CO%253B2-V%26sid%3Dliteratum%253Aachs%26aulast%3DRiess%26aufirst%3DR.%26aulast%3DSchoen%26aufirst%3DM.%26aulast%3DLaschat%26aufirst%3DS.%26aulast%3DJaeger%26aufirst%3DV.%26atitle%3DEvaluation%2520of%2520protecting%2520groups%2520for%25203-hydroxyisoxazoles.%2520Short%2520access%2520to%25203-alkoxyisoxazole-5-carbaldehydes%2520and%25203-hydroxyisoxazole-5-carbaldehyde%252C%2520the%2520putative%2520toxic%2520metabolite%2520of%2520muscimol%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D1998%26volume%3D1998%26issue%3D3%26spage%3D473%26epage%3D479%26doi%3D10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Ornstein, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleisch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borromeo, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugar, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">leander, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Structure–Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2232</span><span class="NLM_x">–</span> <span class="NLM_lpage">2244</span><span class="refDoi"> DOI: 10.1021/jm950913h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950913h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2232-2244&author=P.+L.+Ornsteinauthor=M.+B.+Arnoldauthor=N.+K.+Allenauthor=T.+Bleischauthor=P.+S.+Borromeoauthor=C.+W.+Lugarauthor=J.+D.+leanderauthor=D.+Lodgeauthor=D.+D.+Schoepp&title=Structure%E2%80%93Activity+Studies+of+6-Substituted+Decahydroisoquinoline-3-carboxylic+Acid+AMPA+Receptor+Antagonists.+2.+Effects+of+Distal+Acid+Bioisosteric+Substitution%2C+Absolute+Stereochemical+Preferences%2C+and+in+Vivo+Activity&doi=10.1021%2Fjm950913h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm950913h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950913h%26sid%3Dliteratum%253Aachs%26aulast%3DOrnstein%26aufirst%3DP.%2BL.%26aulast%3DArnold%26aufirst%3DM.%2BB.%26aulast%3DAllen%26aufirst%3DN.%2BK.%26aulast%3DBleisch%26aufirst%3DT.%26aulast%3DBorromeo%26aufirst%3DP.%2BS.%26aulast%3DLugar%26aufirst%3DC.%2BW.%26aulast%3Dleander%26aufirst%3DJ.%2BD.%26aulast%3DLodge%26aufirst%3DD.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DStructure%25E2%2580%2593Activity%2520Studies%2520of%25206-Substituted%2520Decahydroisoquinoline-3-carboxylic%2520Acid%2520AMPA%2520Receptor%2520Antagonists.%25202.%2520Effects%2520of%2520Distal%2520Acid%2520Bioisosteric%2520Substitution%252C%2520Absolute%2520Stereochemical%2520Preferences%252C%2520and%2520in%2520Vivo%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2232%26epage%3D2244%26doi%3D10.1021%2Fjm950913h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Croce, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzatti, E.</span><span> </span><span class="NLM_article-title">Stereoselective synthesis of 3-heteroaromatic-substituted alanines</span> <span class="citation_source-journal">Tetrahedron: Asymmetry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2642</span><span class="refDoi"> DOI: 10.1016/S0957-4166(00)00223-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS0957-4166%2800%2900223-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=2635-2642&author=P.+D.+Croceauthor=C.+La+Rosaauthor=E.+Pizzatti&title=Stereoselective+synthesis+of+3-heteroaromatic-substituted+alanines&doi=10.1016%2FS0957-4166%2800%2900223-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0957-4166%2800%2900223-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0957-4166%252800%252900223-8%26sid%3Dliteratum%253Aachs%26aulast%3DCroce%26aufirst%3DP.%2BD.%26aulast%3DLa%2BRosa%26aufirst%3DC.%26aulast%3DPizzatti%26aufirst%3DE.%26atitle%3DStereoselective%2520synthesis%2520of%25203-heteroaromatic-substituted%2520alanines%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2000%26volume%3D11%26spage%3D2635%26epage%3D2642%26doi%3D10.1016%2FS0957-4166%2800%2900223-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Baudy, R. B.; Butera, J. A.</span><span> </span><span class="NLM_article-title">Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as N-methyl-D-aspartate (NMDA) receptor antagonists</span>. WO 2004/092189,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>21 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=R.+B.+Baudy&author=J.+A.+Butera&title=Derivatives+of+2-%288%2C9-dioxo-2%2C6-diazabicyclo%285.2.0%29non-1%287%29-en-2-yl%29alkyl+phosphonic+acid+and+their+use+as+N-methyl-D-aspartate+%28NMDA%29+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaudy%26aufirst%3DR.%2BB.%26atitle%3DDerivatives%2520of%25202-%25288%252C9-dioxo-2%252C6-diazabicyclo%25285.2.0%2529non-1%25287%2529-en-2-yl%2529alkyl%2520phosphonic%2520acid%2520and%2520their%2520use%2520as%2520N-methyl-D-aspartate%2520%2528NMDA%2529%2520receptor%2520antagonists%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Serafinowska, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harnden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, D.</span><span> </span><span class="NLM_article-title">Synthesis and in Vivo Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy) ethoxy]adenine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1372</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1021/jm00008a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1372-1379&author=H.+T.+Serafinowskaauthor=R.+J.+Ashtonauthor=S.+Baileyauthor=M.+R.+Harndenauthor=S.+M.+Jacksonauthor=D.+Sutton&title=Synthesis+and+in+Vivo+Evaluation+of+Prodrugs+of+9-%5B2-%28Phosphonomethoxy%29+ethoxy%5Dadenine&doi=10.1021%2Fjm00008a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a015%26sid%3Dliteratum%253Aachs%26aulast%3DSerafinowska%26aufirst%3DH.%2BT.%26aulast%3DAshton%26aufirst%3DR.%2BJ.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DHarnden%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DSutton%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Prodrugs%2520of%25209-%255B2-%2528Phosphonomethoxy%2529%2520ethoxy%255Dadenine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1372%26epage%3D1379%26doi%3D10.1021%2Fjm00008a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':[],'ref42':[],'ref43':['cit43'],'ref44':[],'ref45':[],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56a','cit56b'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 28 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yu Lei, Bing Zhang, Dan Liu, Jian Zhao, Xiwen Dai, Jun Gao, Qing Mao, Yao Feng, Jiaxing Zhao, Fengwei Lin, Yulin Duan, Yan Zhang, Ziyang Bao, Yuwei Yang, Yanhua Mou, <span class="NLM_string-name hlFld-ContribAuthor">Shaojie Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15752-15772. <a href="https://doi.org/10.1021/acs.jmedchem.0c01524" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01524</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01524%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSwitching%252Ba%252BXanthine%252BOxidase%252BInhibitor%252Bto%252Ba%252BDual-Target%252BAntagonist%252Bof%252BP2Y1%252Band%252BP2Y12%252Bas%252Ban%252BOral%252BAntiplatelet%252BAgent%252Bwith%252Ba%252BWider%252BTherapeutic%252BWindow%252Bin%252BRats%252Bthan%252BTicagrelor%26aulast%3DLei%26aufirst%3DYu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01092020%26date%3D12122020%26volume%3D63%26issue%3D24%26spage%3D15752%26epage%3D15772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Deyu Kong, Tao Xue, Bin Guo, Jianjun Cheng, Shunyin Liu, Jianhai Wei, Zhengyu Lu, Haoran Liu, Guoqing Gong, Tian Lan, Wenhao Hu, <span class="NLM_string-name hlFld-ContribAuthor">Yushe Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3088-3106. <a href="https://doi.org/10.1021/acs.jmedchem.8b01971" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01971</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252BP2Y12%252BAntagonist%252BEthyl%252B6-%2525284-%252528%252528Benzylsulfonyl%252529carbamoyl%252529piperidin-1-yl%252529-5-cyano-2-methylnicotinate%252B%252528AZD1283%252529%252BLed%252Bto%252Bthe%252BDiscovery%252Bof%252Ban%252BOral%252BAntiplatelet%252BAgent%252Bwith%252BImproved%252BDruglike%252BProperties%26aulast%3DKong%26aufirst%3DDeyu%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D17122018%26date%3D19032019%26date%3D07032019%26volume%3D62%26issue%3D6%26spage%3D3088%26epage%3D3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dahye Kang, Taehwan Kim, Hyunpyo Lee, <span class="NLM_string-name hlFld-ContribAuthor">Sungwoo Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Regiodivergent Ring-Opening Cross-Coupling of Vinyl Aziridines with Phosphorus Nucleophiles: Access to Phosphorus-Containing Amino Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (23)
                                     , 7571-7575. <a href="https://doi.org/10.1021/acs.orglett.8b03309" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03309%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRegiodivergent%252BRing-Opening%252BCross-Coupling%252Bof%252BVinyl%252BAziridines%252Bwith%252BPhosphorus%252BNucleophiles%25253A%252BAccess%252Bto%252BPhosphorus-Containing%252BAmino%252BAcid%252BDerivatives%26aulast%3DKang%26aufirst%3DDahye%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16102018%26date%3D02112018%26volume%3D20%26issue%3D23%26spage%3D7571%26epage%3D7575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark A. T.  Blaskovich</span>  . </span><span class="cited-content_cbyCitation_article-title">Unusual Amino Acids in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (24)
                                     , 10807-10836. <a href="https://doi.org/10.1021/acs.jmedchem.6b00319" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00319%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnusual%252BAmino%252BAcids%252Bin%252BMedicinal%252BChemistry%26aulast%3DBlaskovich%26aufirst%3DMark%2BA.%2BT.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D02032016%26date%3D30092016%26date%3D22122016%26date%3D02092016%26volume%3D59%26issue%3D24%26spage%3D10807%26epage%3D10836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean  Conroy</span>, <span class="hlFld-ContribAuthor ">Nicholas  Kindon</span>, <span class="hlFld-ContribAuthor ">Barrie  Kellam</span>, and <span class="hlFld-ContribAuthor ">Michael J.  Stocks</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug-like Antagonists of P2Y Receptors—From Lead Identification to Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 9981-10005. <a href="https://doi.org/10.1021/acs.jmedchem.5b01972" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01972%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug-like%252BAntagonists%252Bof%252BP2Y%252BReceptors%2525E2%252580%252594From%252BLead%252BIdentification%252Bto%252BDrug%252BDevelopment%26aulast%3DConroy%26aufirst%3DSean%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D21122015%26date%3D01082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D9981%26epage%3D10005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lydie  Crescence</span>, <span class="hlFld-ContribAuthor ">Roxane  Darbousset</span>, <span class="hlFld-ContribAuthor ">Eva  Caroff</span>, <span class="hlFld-ContribAuthor ">Francis  Hubler</span>, <span class="hlFld-ContribAuthor ">Markus A.  Riederer</span>, <span class="hlFld-ContribAuthor ">Laurence  Panicot-Dubois</span>, <span class="hlFld-ContribAuthor ">Christophe  Dubois</span>. </span><span class="cited-content_cbyCitation_article-title">Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model. </span><span class="cited-content_cbyCitation_journal-name">Thrombosis Research</span><span> <strong>2021,</strong> <em>200 </em>, 133-140. <a href="https://doi.org/10.1016/j.thromres.2021.01.026" title="DOI URL">https://doi.org/10.1016/j.thromres.2021.01.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.thromres.2021.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.thromres.2021.01.026%26sid%3Dliteratum%253Aachs%26jtitle%3DThrombosis%2520Research%26atitle%3DSelatogrel%25252C%252Ba%252Breversible%252BP2Y12%252Breceptor%252Bantagonist%25252C%252Bhas%252Breduced%252Boff-target%252Binterference%252Bwith%252Bhaemostatic%252Bfactors%252Bin%252Ba%252Bmouse%252Bthrombosis%252Bmodel%26aulast%3DCrescence%26aufirst%3DLydie%26date%3D2021%26volume%3D200%26spage%3D133%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martine  Baumann</span>, <span class="hlFld-ContribAuthor ">Benoît  Lack</span>, <span class="hlFld-ContribAuthor ">Isabelle  Guillaumat</span>, <span class="hlFld-ContribAuthor ">Mark J.  Murphy</span>, <span class="hlFld-ContribAuthor ">Markus A.  Riederer</span>. </span><span class="cited-content_cbyCitation_article-title">The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2021,</strong> <em> </em>, 1-10. <a href="https://doi.org/10.1080/09537104.2020.1869711" title="DOI URL">https://doi.org/10.1080/09537104.2020.1869711</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1869711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1869711%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DThe%252Bpotency%252Bof%252Bselatogrel%25252C%252Ba%252Breversible%252Bantagonist%252Bof%252Bthe%252BP2Y12%252Breceptor%25252C%252Bis%252Baffected%252Bby%252Bcalcium%252Bconcentration%26aulast%3DBaumann%26aufirst%3DMartine%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A. E.  Parker</span>, <span class="hlFld-ContribAuthor ">Robert F.  Storey</span>. </span><span class="cited-content_cbyCitation_article-title">Novel approaches to P2Y
              12
              inhibition and aspirin dosing. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2021,</strong> <em>32 </em>
                                    (1)
                                     , 7-14. <a href="https://doi.org/10.1080/09537104.2020.1714574" title="DOI URL">https://doi.org/10.1080/09537104.2020.1714574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1714574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1714574%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DNovel%252Bapproaches%252Bto%252BP2Y%252B12%252Binhibition%252Band%252Baspirin%252Bdosing%26aulast%3DParker%26aufirst%3DWilliam%2BA.%2BE.%26date%3D2021%26date%3D2020%26volume%3D32%26issue%3D1%26spage%3D7%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paulo Anastácio Furtado  Pacheco</span>, <span class="hlFld-ContribAuthor ">Roberta Tosta  Diogo</span>, <span class="hlFld-ContribAuthor ">Betina Quintanilha  Magalhães</span>, <span class="hlFld-ContribAuthor ">Robson Xavier  Faria</span>. </span><span class="cited-content_cbyCitation_article-title">Plant natural products as source of new P2 receptors ligands. </span><span class="cited-content_cbyCitation_journal-name">Fitoterapia</span><span> <strong>2020,</strong> <em>146 </em>, 104709. <a href="https://doi.org/10.1016/j.fitote.2020.104709" title="DOI URL">https://doi.org/10.1016/j.fitote.2020.104709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fitote.2020.104709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fitote.2020.104709%26sid%3Dliteratum%253Aachs%26jtitle%3DFitoterapia%26atitle%3DPlant%252Bnatural%252Bproducts%252Bas%252Bsource%252Bof%252Bnew%252BP2%252Breceptors%252Bligands%26aulast%3DPacheco%26aufirst%3DPaulo%2BAnast%25C3%25A1cio%2BFurtado%26date%3D2020%26volume%3D146%26spage%3D104709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert F  Storey</span>, <span class="hlFld-ContribAuthor ">Paul A  Gurbel</span>, <span class="hlFld-ContribAuthor ">Jurrien  ten Berg</span>, <span class="hlFld-ContribAuthor ">Corine  Bernaud</span>, <span class="hlFld-ContribAuthor ">George D  Dangas</span>, <span class="hlFld-ContribAuthor ">Jean-Marie  Frenoux</span>, <span class="hlFld-ContribAuthor ">Diana A  Gorog</span>, <span class="hlFld-ContribAuthor ">Abdel  Hmissi</span>, <span class="hlFld-ContribAuthor ">Vijay  Kunadian</span>, <span class="hlFld-ContribAuthor ">Stefan K  James</span>, <span class="hlFld-ContribAuthor ">Jean-Francois  Tanguay</span>, <span class="hlFld-ContribAuthor ">Henry  Tran</span>, <span class="hlFld-ContribAuthor ">Dietmar  Trenk</span>, <span class="hlFld-ContribAuthor ">Mike  Ufer</span>, <span class="hlFld-ContribAuthor ">Pim  Van der Harst</span>, <span class="hlFld-ContribAuthor ">Arnoud W J  Van't Hof</span>, <span class="hlFld-ContribAuthor ">Dominick J  Angiolillo</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. </span><span class="cited-content_cbyCitation_journal-name">European Heart Journal</span><span> <strong>2020,</strong> <em>41 </em>
                                    (33)
                                     , 3132-3140. <a href="https://doi.org/10.1093/eurheartj/ehz807" title="DOI URL">https://doi.org/10.1093/eurheartj/ehz807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/eurheartj/ehz807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Feurheartj%2Fehz807%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Heart%2520Journal%26atitle%3DPharmacodynamics%25252C%252Bpharmacokinetics%25252C%252Band%252Bsafety%252Bof%252Bsingle-dose%252Bsubcutaneous%252Badministration%252Bof%252Bselatogrel%25252C%252Ba%252Bnovel%252BP2Y12%252Breceptor%252Bantagonist%25252C%252Bin%252Bpatients%252Bwith%252Bchronic%252Bcoronary%252Bsyndromes%26aulast%3DStorey%26aufirst%3DRobert%2BF%26date%3D2020%26date%3D2019%26volume%3D41%26issue%3D33%26spage%3D3132%26epage%3D3140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rocco P.  Milluzzo</span>, <span class="hlFld-ContribAuthor ">Gabriele A.  Franchina</span>, <span class="hlFld-ContribAuthor ">Davide  Capodanno</span>, <span class="hlFld-ContribAuthor ">Dominick J.  Angiolillo</span>. </span><span class="cited-content_cbyCitation_article-title">Selatogrel, a novel P2Y
              12
              inhibitor: a review of the pharmacology and clinical development. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (6)
                                     , 537-546. <a href="https://doi.org/10.1080/13543784.2020.1764533" title="DOI URL">https://doi.org/10.1080/13543784.2020.1764533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1764533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1764533%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DSelatogrel%25252C%252Ba%252Bnovel%252BP2Y%252B12%252Binhibitor%25253A%252Ba%252Breview%252Bof%252Bthe%252Bpharmacology%252Band%252Bclinical%252Bdevelopment%26aulast%3DMilluzzo%26aufirst%3DRocco%2BP.%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D6%26spage%3D537%26epage%3D546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Esmerilda G.  Delicado</span>, <span class="hlFld-ContribAuthor ">Christian  Gachet</span>, <span class="hlFld-ContribAuthor ">Charles  Kennedy</span>, <span class="hlFld-ContribAuthor ">Ivar  Kügelgen</span>, <span class="hlFld-ContribAuthor ">Beibei  Li</span>, <span class="hlFld-ContribAuthor ">M. Teresa  Miras‐Portugal</span>, <span class="hlFld-ContribAuthor ">Ivana  Novak</span>, <span class="hlFld-ContribAuthor ">Torsten  Schöneberg</span>, <span class="hlFld-ContribAuthor ">Raquel  Perez‐Sen</span>, <span class="hlFld-ContribAuthor ">Doreen  Thor</span>, <span class="hlFld-ContribAuthor ">Beili  Wu</span>, <span class="hlFld-ContribAuthor ">Zhenlin  Yang</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Update of P2Y receptor pharmacology: IUPHAR Review 27. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>
                                    (11)
                                     , 2413-2433. <a href="https://doi.org/10.1111/bph.15005" title="DOI URL">https://doi.org/10.1111/bph.15005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15005%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DUpdate%252Bof%252BP2Y%252Breceptor%252Bpharmacology%25253A%252BIUPHAR%252BReview%252B27%26aulast%3DJacobson%26aufirst%3DKenneth%2BA.%26date%3D2020%26date%3D2020%26volume%3D177%26issue%3D11%26spage%3D2413%26epage%3D2433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raphael  Oeschger</span>, <span class="hlFld-ContribAuthor ">Bo  Su</span>, <span class="hlFld-ContribAuthor ">Isaac  Yu</span>, <span class="hlFld-ContribAuthor ">Christian  Ehinger</span>, <span class="hlFld-ContribAuthor ">Erik  Romero</span>, <span class="hlFld-ContribAuthor ">Sam  He</span>, <span class="hlFld-ContribAuthor ">John  Hartwig</span>. </span><span class="cited-content_cbyCitation_article-title">Diverse functionalization of strong alkyl C–H bonds by undirected borylation. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2020,</strong> <em>368 </em>
                                    (6492)
                                     , 736-741. <a href="https://doi.org/10.1126/science.aba6146" title="DOI URL">https://doi.org/10.1126/science.aba6146</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aba6146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aba6146%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DDiverse%252Bfunctionalization%252Bof%252Bstrong%252Balkyl%252BC%2525E2%252580%252593H%252Bbonds%252Bby%252Bundirected%252Bborylation%26aulast%3DOeschger%26aufirst%3DRaphael%26date%3D2020%26date%3D2020%26volume%3D368%26issue%3D6492%26spage%3D736%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uta  Schilling</span>, <span class="hlFld-ContribAuthor ">Jasper  Dingemanse</span>, <span class="hlFld-ContribAuthor ">Mike  Ufer</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacokinetics</span><span> <strong>2020,</strong> <em>59 </em>
                                    (5)
                                     , 545-566. <a href="https://doi.org/10.1007/s40262-020-00864-4" title="DOI URL">https://doi.org/10.1007/s40262-020-00864-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40262-020-00864-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40262-020-00864-4%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacokinetics%26atitle%3DPharmacokinetics%252Band%252BPharmacodynamics%252Bof%252BApproved%252Band%252BInvestigational%252BP2Y12%252BReceptor%252BAntagonists%26aulast%3DSchilling%26aufirst%3DUta%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D5%26spage%3D545%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximilian  Tscharre</span>, <span class="hlFld-ContribAuthor ">Alan D.  Michelson</span>, <span class="hlFld-ContribAuthor ">Thomas  Gremmel</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Antiplatelet Agents in Cardiovascular Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cardiovascular Pharmacology and Therapeutics</span><span> <strong>2020,</strong> <em>25 </em>
                                    (3)
                                     , 191-200. <a href="https://doi.org/10.1177/1074248419899314" title="DOI URL">https://doi.org/10.1177/1074248419899314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1074248419899314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1074248419899314%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cardiovascular%2520Pharmacology%2520and%2520Therapeutics%26atitle%3DNovel%252BAntiplatelet%252BAgents%252Bin%252BCardiovascular%252BDisease%26aulast%3DTscharre%26aufirst%3DMaximilian%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D3%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mike  Ufer</span>, <span class="hlFld-ContribAuthor ">Christine  Huynh</span>, <span class="hlFld-ContribAuthor ">Jan Jaap  van Lier</span>, <span class="hlFld-ContribAuthor ">Eva  Caroff</span>, <span class="hlFld-ContribAuthor ">Hartmut  Fischer</span>, <span class="hlFld-ContribAuthor ">Jasper  Dingemanse</span>. </span><span class="cited-content_cbyCitation_article-title">Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2020,</strong> <em>50 </em>
                                    (4)
                                     , 427-434. <a href="https://doi.org/10.1080/00498254.2019.1646440" title="DOI URL">https://doi.org/10.1080/00498254.2019.1646440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2019.1646440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2019.1646440%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DAbsorption%25252C%252Bdistribution%25252C%252Bmetabolism%252Band%252Bexcretion%252Bof%252Bthe%252BP2Y12%252Breceptor%252Bantagonist%252Bselatogrel%252Bafter%252Bsubcutaneous%252Badministration%252Bin%252Bhealthy%252Bsubjects%26aulast%3DUfer%26aufirst%3DMike%26date%3D2020%26date%3D2019%26volume%3D50%26issue%3D4%26spage%3D427%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anas  Najjar</span>, <span class="hlFld-ContribAuthor ">Abderrahman  Najjar</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>. </span><span class="cited-content_cbyCitation_article-title">Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 884. <a href="https://doi.org/10.3390/molecules25040884" title="DOI URL">https://doi.org/10.3390/molecules25040884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25040884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25040884%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNewly%252BDeveloped%252BProdrugs%252Band%252BProdrugs%252Bin%252BDevelopment%25253B%252Ban%252BInsight%252Bof%252Bthe%252BRecent%252BYears%26aulast%3DNajjar%26aufirst%3DAnas%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A. E.  Parker</span>, <span class="hlFld-ContribAuthor ">Robert F.  Storey</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y
              12
              receptor antagonist. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 1-6. <a href="https://doi.org/10.1080/14728214.2020.1729121" title="DOI URL">https://doi.org/10.1080/14728214.2020.1729121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2020.1729121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2020.1729121%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DPharmacology%252Band%252Bpotential%252Brole%252Bof%252Bselatogrel%25252C%252Ba%252Bsubcutaneous%252Bplatelet%252BP2Y%252B12%252Breceptor%252Bantagonist%26aulast%3DParker%26aufirst%3DWilliam%2BA.%2BE.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D1%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacology of P2Y receptors. </span><span class="cited-content_cbyCitation_journal-name">Brain Research Bulletin</span><span> <strong>2019,</strong> <em>151 </em>, 12-24. <a href="https://doi.org/10.1016/j.brainresbull.2019.03.010" title="DOI URL">https://doi.org/10.1016/j.brainresbull.2019.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.brainresbull.2019.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.brainresbull.2019.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%2520Research%2520Bulletin%26atitle%3DPharmacology%252Bof%252BP2Y%252Breceptors%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DIvar%26date%3D2019%26volume%3D151%26spage%3D12%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre‐Eric  Juif</span>, <span class="hlFld-ContribAuthor ">Margaux  Boehler</span>, <span class="hlFld-ContribAuthor ">Michael  Dobrow</span>, <span class="hlFld-ContribAuthor ">Mike  Ufer</span>, <span class="hlFld-ContribAuthor ">Jasper  Dingemanse</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Pharmacology of the Reversible and Potent P2Y
              12
              Receptor Antagonist ACT‐246475 After Single Subcutaneous Administration in Healthy Male Subjects. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Pharmacology</span><span> <strong>2019,</strong> <em>59 </em>
                                    (1)
                                     , 123-130. <a href="https://doi.org/10.1002/jcph.1296" title="DOI URL">https://doi.org/10.1002/jcph.1296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcph.1296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcph.1296%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DClinical%252BPharmacology%252Bof%252Bthe%252BReversible%252Band%252BPotent%252BP2Y%252B12%252BReceptor%252BAntagonist%252BACT%2525E2%252580%252590246475%252BAfter%252BSingle%252BSubcutaneous%252BAdministration%252Bin%252BHealthy%252BMale%252BSubjects%26aulast%3DJuif%26aufirst%3DPierre%25E2%2580%2590Eric%26date%3D2019%26date%3D2018%26volume%3D59%26issue%3D1%26spage%3D123%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kumaran  Kolandaivelu</span>, <span class="hlFld-ContribAuthor ">Deepak L.  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Antiplatelet Therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 991-1015. <a href="https://doi.org/10.1016/B978-0-12-813456-6.00055-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-813456-6.00055-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813456-6.00055-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813456-6.00055-2%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%252BAntiplatelet%252BTherapies%26aulast%3DKolandaivelu%26aufirst%3DKumaran%26date%3D2019%26spage%3D991%26epage%3D1015%26pub%3DElsevier%26atitle%3DPlatelets%26date%3D2019%26volume%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Younis  Baqi</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (1)
                                     , 325-333. <a href="https://doi.org/10.1016/j.drudis.2018.09.021" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.09.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.09.021%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAntithrombotic%252BP2Y12%252Breceptor%252Bantagonists%25253A%252Brecent%252Bdevelopments%252Bin%252Bdrug%252Bdiscovery%26aulast%3DBaqi%26aufirst%3DYounis%26date%3D2019%26volume%3D24%26issue%3D1%26spage%3D325%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imadul  Islam</span>, <span class="hlFld-ContribAuthor ">Shendong  Yuan</span>, <span class="hlFld-ContribAuthor ">Robert G.  Wei</span>, <span class="hlFld-ContribAuthor ">Wei  Xu</span>, <span class="hlFld-ContribAuthor ">Michael  Morrissey</span>, <span class="hlFld-ContribAuthor ">Raju  Mohan</span>, <span class="hlFld-ContribAuthor ">Dewan  Zheng</span>, <span class="hlFld-ContribAuthor ">Andrea  DiMella</span>, <span class="hlFld-ContribAuthor ">Laura  Dunning</span>, <span class="hlFld-ContribAuthor ">Michael  Snider</span>, <span class="hlFld-ContribAuthor ">Babu  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Jih-Lie  Tseng</span>, <span class="hlFld-ContribAuthor ">Judi A.  Bryant</span>, <span class="hlFld-ContribAuthor ">Brad O.  Buckman</span>. </span><span class="cited-content_cbyCitation_article-title">Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (9)
                                     , 1459-1463. <a href="https://doi.org/10.1016/j.bmcl.2018.03.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReversible%25252C%252Borally%252Bavailable%252BADP%252Breceptor%252B%252528P2Y12%252529%252Bantagonists%252BPart%252BI%25253A%252BHit%252Bto%252Blead%252Bprocess%26aulast%3DIslam%26aufirst%3DImadul%26date%3D2018%26volume%3D28%26issue%3D9%26spage%3D1459%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Markus  Rey</span>, <span class="hlFld-ContribAuthor ">Markus  Kramberg</span>, <span class="hlFld-ContribAuthor ">Patrick  Hess</span>, <span class="hlFld-ContribAuthor ">Keith  Morrison</span>, <span class="hlFld-ContribAuthor ">Roland  Ernst</span>, <span class="hlFld-ContribAuthor ">Franck  Haag</span>, <span class="hlFld-ContribAuthor ">Edgar  Weber</span>, <span class="hlFld-ContribAuthor ">Martine  Clozel</span>, <span class="hlFld-ContribAuthor ">Martine  Baumann</span>, <span class="hlFld-ContribAuthor ">Eva  Caroff</span>, <span class="hlFld-ContribAuthor ">Francis  Hubler</span>, <span class="hlFld-ContribAuthor ">Markus A.  Riederer</span>, <span class="hlFld-ContribAuthor ">Beat  Steiner</span>. </span><span class="cited-content_cbyCitation_article-title">The reversible P2Y
              12
              antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2017,</strong> <em>5 </em>
                                    (5)
                                     , e00338. <a href="https://doi.org/10.1002/prp2.338" title="DOI URL">https://doi.org/10.1002/prp2.338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.338%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DThe%252Breversible%252BP2Y%252B12%252Bantagonist%252BACT-246475%252Bcauses%252Bsignificantly%252Bless%252Bblood%252Bloss%252Bthan%252Bticagrelor%252Bat%252Bequivalent%252Bantithrombotic%252Befficacy%252Bin%252Brat%26aulast%3DRey%26aufirst%3DMarkus%26date%3D2017%26date%3D2017%26volume%3D5%26issue%3D5%26spage%3De00338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryo  Yoshino</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Tokairin</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of fully protected (2 R ,3 R ,4 S )-4-amino-7-guanidino-2,3-dihydroxy heptanoic acid. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (16)
                                     , 1604-1606. <a href="https://doi.org/10.1016/j.tetlet.2017.03.025" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.03.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.03.025%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Bfully%252Bprotected%252B%2525282%252BR%252B%25252C3%252BR%252B%25252C4%252BS%252B%252529-4-amino-7-guanidino-2%25252C3-dihydroxy%252Bheptanoic%252Bacid%26aulast%3DYoshino%26aufirst%3DRyo%26date%3D2017%26volume%3D58%26issue%3D16%26spage%3D1604%26epage%3D1606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivar  von Kügelgen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 123-138. <a href="https://doi.org/10.1007/5584_2017_98" title="DOI URL">https://doi.org/10.1007/5584_2017_98</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/5584_2017_98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F5584_2017_98%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%25252C%252BPharmacology%252Band%252BRoles%252Bin%252BPhysiology%252Bof%252Bthe%252BP2Y12%252BReceptor%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DIvar%26date%3D2017%26date%3D2017%26spage%3D123%26epage%3D138%26pub%3DSpringer%2520Singapore%26atitle%3DProtein%252BReviews%26aulast%3DAtassi%26aufirst%3DM.%2BZouhair%26date%3D2017%26volume%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.A.  Meyer</span>, <span class="hlFld-ContribAuthor ">E.  Caroff</span>, <span class="hlFld-ContribAuthor ">M.A.  Riederer</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Antiplatelet Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 556-599. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12431-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12431-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12431-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12431-X%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252BAntiplatelet%252BAgents%26aulast%3DMeyer%26aufirst%3DE.A.%26date%3D2017%26spage%3D556%26epage%3D599%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fredrik  Zetterberg</span>, <span class="hlFld-ContribAuthor ">Peder  Svensson</span>. </span><span class="cited-content_cbyCitation_article-title">State of affairs: Design and structure–activity relationships of reversible P2Y 12 receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (12)
                                     , 2739-2754. <a href="https://doi.org/10.1016/j.bmcl.2016.04.030" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.030%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DState%252Bof%252Baffairs%25253A%252BDesign%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Breversible%252BP2Y%252B12%252Breceptor%252Bantagonists%26aulast%3DZetterberg%26aufirst%3DFredrik%26date%3D2016%26volume%3D26%26issue%3D12%26spage%3D2739%26epage%3D2754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Previous work: 2-phenylpyrimidine-4-carboxamide analogs <b>1</b> and <b>2</b> where the central core was set as <span class="smallcaps smallerCapital">l</span>-glutamic acid. (b) This disclosure: general structure of (<i>S</i>)-6-(3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamide analogs. R<sup>1</sup> is ethyl or <i>n</i>-butyl. R<sup>2</sup> and stereochemistry at the α carbon of the amino acid core are detailed in the tables.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Building Block <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) see ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>, 4 steps, 51%; (b) BOC<sub>2</sub>O, Et<sub>3</sub>N, DCM, 100% (crude); (c) NaH, MeI, THF, 93% (crude); (d) HCl in EA, 95%; (e) DIPEA, THF, 60 °C, 4 days, 93%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of P2Y<sub>12</sub> Antagonist Analogs <b>13</b>–<b>22</b>, <b>28</b>, <b>29a</b>–<b>f</b>, <b>30a</b>–<b>k</b>, <b>31a</b>,<b>b</b>, <b>32a</b>,<b>b</b>, <b>33–37</b>, and <b>38a</b>,<b>b</b> (for R<sup>1</sup> and R<sup>2</sup>, See <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HOBt/EDC-Cl or HATU or PyBOP, DIPEA, DCM or DCM/THF, rt. (b) PG = BOC: TFA/DCM, rt, or HCl in EA or EA/dioxane. PG = Cbz: Pd/C (wet, 5%), H<sub>2</sub>, EtOH or EtOH/AcOH, rt. PG = Fmoc: Et<sub>2</sub>NH, DCM, rt. (c) <b>8</b>, similar conditions as described in (a); (d) TFA, DCM, rt, 22–100%; (e) TMSBr, MeCN, 0 °C to rt overnight, then DCM, water, rt, 1 h, 17–98%; (f) 4 M HCl in dioxane, rt, 30 min, 99–100%; (g) ZnBr<sub>2</sub>, NaN<sub>3</sub>, H<sub>2</sub>O, 100 °C, 20 h, 22% (<b>32a</b>,<b>b</b>), or NH<sub>2</sub>OH–HCl, NaHCO<sub>3</sub>, MeOH, 70 °C, 24 h, then CDI, DBU, dioxane, 105 °C, 2 h, 2% (<b>33</b>); (h) Me<sub>4</sub>NCl, DMF, 150 °C, overnight, 23%; (i) trichloroacetyl isocyanate, EtOH, 0 °C, 20 min, then NaBH<sub>4</sub>, EtOH, 0 °C to rt overnight, 5%; (j) SOCl<sub>2</sub>, rt, 1 h, then Et<sub>3</sub>N, CF<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub>, DCM, rt, overnight, 6% (<b>35</b>), or MeSO<sub>2</sub>NH<sub>2</sub>, DCC, DMAP, DCM, 0 °C, 1 h, then rt, 20 h, 36% (<b>36</b>); (k) CF<sub>3</sub>SO<sub>2</sub>Cl, Et<sub>3</sub>N, THF, 0 °C to rt, overnight, 11%; (l) 3,4-diethoxy-3-cyclobutene-1,2-dione, Et<sub>3</sub>N, EtOH, rt, overnight, 52–65%, then 4 M HCl in dioxane, THF, 50 °C, 2 days, 52–56%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Intermediates <b>10a</b>–<b>g</b> for the Synthesis of Phosphonic Acid-Containing Analogs <b>30a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) isobutyl chloroformate, NMM, THF, −15 °C, 14 h, then NaBH<sub>4</sub>, MeOH, −10 °C, 100% (crude) (<b>41f</b>–<b>g</b>); (b) CBr<sub>4</sub>, PS–PPh<sub>3</sub>, DCM, 0 °C, 2–3 h, 25–52% (<b>40d</b>–<b>e</b>), or imidazole, PPh<sub>3</sub>, I<sub>2</sub>, THF, 0 °C to rt, 11 h, 65–100% (<b>40f</b>–<b>g</b>); (c) P(OEt)<sub>3</sub>, 120–130 °C, overnight, 57–100% (crude); (d) LiOH, MeOH, EtOH, H<sub>2</sub>O, 0 °C, 1 h, 100% (<b>10a</b>), or rt, 3 h to overnight, 48–100% (<b>10e</b>–<b>g</b>), or LiOH, THF, H<sub>2</sub>O, rt, 3 h to overnight, 72–100% (<b>10b</b>–<b>d</b>).</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of (A) clopidogrel, (B) compound <b>1</b>, and (C) compound <b>30d</b> on thrombotic occlusion after FeCl<sub>3</sub>-induced arterial injury in anesthetized Wistar rats (<i>n</i> = 3–4 per group (A), <i>n</i> = 5–11 per group (B), and <i>n</i> = 3–11 per group (C)). Doses are in mg/kg. Thrombotic occlusion is defined as % reduction in blood flow velocity from baseline, 30 min after arterial injury. Data are presented as the mean ± SEM. (A) Vehicle and clopidogrel were administered orally as single dose 2 h before arterial injury. Vehicle was saline 9 g/L, pH adjusted to 2.5 with 3 M HCl. (B, C) Vehicle and compounds <b>1</b> and <b>30d</b> were administered as intravenous bolus injection 5 min before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of (A) clopidogrel and (B) compounds <b>1</b> and <b>30d</b> on surgical blood loss after spleen puncture in anesthetized Wistar rats (<i>n</i> = 8–14 per group (A) or <i>n</i> = 5–20 per group (B)). Surgical blood loss was measured 30 min after spleen puncture. Data are presented as the mean ± SEM. (A) Vehicle and clopidogrel were administered orally as single dose 2 h before spleen puncture. Vehicle was saline 9 g/L, pH adjusted to 2.5 with 3 M HCl. Open bar = vehicle. Hatched bar = clopidogrel at 30 mg/kg. (B) Vehicle and compounds <b>1</b> and <b>30d</b> were administered as intravenous bolus injection 5 min before spleen puncture. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4. Open bar = vehicle. Gray bar = compound <b>1</b> at 1 mg/kg. Black bar = compound <b>30d</b> at 0.1 mg/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>45</b>, bis((isopropoxycarbonyl)oxy)methyl ester prodrug of <b>30d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of (A) compound <b>30d</b> and (B) compound <b>45</b> on thrombotic occlusion after FeCl<sub>3</sub>-induced arterial injury in anesthetized Wistar rats (<i>n</i> = 10–35 per group (A) or <i>n</i> = 6 per group (B)). Thrombotic occlusion is defined as % reduction in blood flow velocity from baseline, 30 min after arterial injury. Data are presented as the mean ± SEM. (A) Vehicle and compound <b>30d</b> were administered as continuous intravenous infusion over 50 min at the rate of 1 (mL/kg)/20 min, starting 20 min before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), phosphate buffer, pH = 7.4. (B) Vehicle and compound <b>45</b> were administered orally as single dose 1 h before arterial injury. Vehicle was PEG 400 (7.5%), PG (7.5%), Cremophor (5%), water, 5 mL/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/medium/jm-2015-00933e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma concentrations of the active drug <b>30d</b> (A) at 20 and 50 min after starting iv infusion of <b>30d</b> in the experiment described in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and (B) at 60 and 90 min after oral gavage of <b>45</b> in the experiment described in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B. Plasma was obtained from arterial blood sampling (EDTA). Experimental details are given in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/large/jm-2015-00933e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00933&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Davies, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hangartner, J. R.</span><span> </span><span class="NLM_article-title">Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1161/01.CIR.73.3.418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1161%2F01.CIR.73.3.418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1986&pages=418-427&author=M.+J.+Daviesauthor=A.+C.+Thomasauthor=P.+A.+Knapmanauthor=J.+R.+Hangartner&title=Intramyocardial+platelet+aggregation+in+patients+with+unstable+angina+suffering+sudden+ischemic+cardiac+death&doi=10.1161%2F01.CIR.73.3.418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.73.3.418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.73.3.418%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BJ.%26aulast%3DThomas%26aufirst%3DA.%2BC.%26aulast%3DKnapman%26aufirst%3DP.%2BA.%26aulast%3DHangartner%26aufirst%3DJ.%2BR.%26atitle%3DIntramyocardial%2520platelet%2520aggregation%2520in%2520patients%2520with%2520unstable%2520angina%2520suffering%2520sudden%2520ischemic%2520cardiac%2520death%26jtitle%3DCirculation%26date%3D1986%26volume%3D73%26spage%3D418%26epage%3D427%26doi%3D10.1161%2F01.CIR.73.3.418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Davì, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrono, C.</span><span> </span><span class="NLM_article-title">Platelet activation and atherothrombosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2482</span><span class="NLM_x">–</span> <span class="NLM_lpage">2494</span><span class="refDoi"> DOI: 10.1056/NEJMra071014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMra071014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=18077812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVemurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2482-2494&author=G.+Dav%C3%ACauthor=C.+Patrono&title=Platelet+activation+and+atherothrombosis&doi=10.1056%2FNEJMra071014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">.Mechanisms of disease: platelet activation and atherothrombosis</span></div><div class="casAuthors">Davi, Giovanni; Patrono, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2482-2494</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The role of thrombin and protease-activated receptors in platelet-activated mechanism in atherothrombosis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ9gf2beAZ_LVg90H21EOLACvtfcHk0lhzZDtHc16AoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVemurrL&md5=b24fcd4b4aff95fb8fa9487881d76d33</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra071014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra071014%26sid%3Dliteratum%253Aachs%26aulast%3DDav%25C3%25AC%26aufirst%3DG.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DPlatelet%2520activation%2520and%2520atherothrombosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2482%26epage%3D2494%26doi%3D10.1056%2FNEJMra071014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Michelson, A. D.</span><span> </span><span class="NLM_article-title">Antiplatelet therapies for the treatment of cardiovascular disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1038/nrd2957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnrd2957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=20118963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=154-169&author=A.+D.+Michelson&title=Antiplatelet+therapies+for+the+treatment+of+cardiovascular+disease&doi=10.1038%2Fnrd2957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet therapies for the treatment of cardiovascular disease</span></div><div class="casAuthors">Michelson, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-169</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antiplatelet therapy was successful in reducing mortality and morbidity in acute myocardial infarction.  Recent advances in understanding the mol. basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity.  This article reviews the role of platelets in hemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Jl1XbcNzGrVg90H21EOLACvtfcHk0lhzZDtHc16AoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yns7c%253D&md5=aef13552bb92d3311c04a2e9505442ad</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2957%26sid%3Dliteratum%253Aachs%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26atitle%3DAntiplatelet%2520therapies%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D154%26epage%3D169%26doi%3D10.1038%2Fnrd2957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Andre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaRocca, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">398</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span><span class="refDoi"> DOI: 10.1172/JCI17864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1172%2FJCI17864" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=398-406&author=P.+Andreauthor=S.+M.+Delaneyauthor=T.+LaRoccaauthor=D.+Vincentauthor=F.+DeGuzmanauthor=M.+Jurekauthor=B.+Kollerauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=P2Y12+regulates+platelet+adhesion%2Factivation%2C+thrombus+growth%2C+and+thrombus+stability+in+injured+arteries&doi=10.1172%2FJCI17864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI17864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI17864%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDelaney%26aufirst%3DS.%2BM.%26aulast%3DLaRocca%26aufirst%3DT.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DJurek%26aufirst%3DM.%26aulast%3DKoller%26aufirst%3DB.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DP2Y12%2520regulates%2520platelet%2520adhesion%252Factivation%252C%2520thrombus%2520growth%252C%2520and%2520thrombus%2520stability%2520in%2520injured%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D112%26spage%3D398%26epage%3D406%26doi%3D10.1172%2FJCI17864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Dorsam, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunapuli, S. P.</span><span> </span><span class="NLM_article-title">Central role of the P2Y12 receptor in platelet activation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span><span class="refDoi"> DOI: 10.1172/JCI20986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1172%2FJCI20986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=14755328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation&doi=10.1172%2FJCI20986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Central role of the P2Y12 receptor in platelet activation</span></div><div class="casAuthors">Dorsam, Robert T.; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Platelet activation occurs in response to vessel injury and is important for the arrest of bleeding.  Platelet activation during disease states leads to vascular occlusion and ischemic damage.  The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y12 receptor antagonists that have proven therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjFviIpPpTLVg90H21EOLACvtfcHk0ljV7YWs0clvKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D&md5=a0a6e94419e76fe78d2cef969ece6274</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI20986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI20986%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345%26doi%3D10.1172%2FJCI20986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gachet, C.</span><span> </span><span class="NLM_article-title">Antiplatelet drugs: which targets for which treatments?</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S313</span><span class="NLM_x">–</span> <span class="NLM_lpage">S322</span><span class="refDoi"> DOI: 10.1111/jth.12947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1111%2Fjth.12947" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=S313-S322&issue=Suppl.+1&author=C.+Gachet&title=Antiplatelet+drugs%3A+which+targets+for+which+treatments%3F&doi=10.1111%2Fjth.12947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fjth.12947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12947%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DAntiplatelet%2520drugs%253A%2520which%2520targets%2520for%2520which%2520treatments%253F%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2015%26volume%3D13%26issue%3DSuppl.%25201%26spage%3DS313%26epage%3DS322%26doi%3D10.1111%2Fjth.12947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Steg, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badano, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomstrom Lundqvist, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Mario, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducrocq, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Aviles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gershlick, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannuzzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halvorsen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastrati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuuti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenzen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahaffey, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valgimigli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van’t Hof, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widimsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bax, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceconi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funck-Brentano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasdai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchhof, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knuuti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonagh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popescu, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiner, Ž.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechtem, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirnes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tendera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vahanian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasdai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åström-Olsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collet, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustiene, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancellotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkely, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piepoli, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Werf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheugt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span> </span><span class="NLM_article-title">ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2569</span><span class="NLM_x">–</span> <span class="NLM_lpage">2619</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehs215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehs215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=22922416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFektbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2569-2619&author=P.+G.+Stegauthor=S.+K.+Jamesauthor=D.+Atarauthor=L.+P.+Badanoauthor=C.+Blomstrom+Lundqvistauthor=M.+A.+Borgerauthor=C.+Di+Marioauthor=K.+Dicksteinauthor=G.+Ducrocqauthor=F.+Fernandez-Avilesauthor=A.+H.+Gershlickauthor=P.+Giannuzziauthor=S.+Halvorsenauthor=K.+Huberauthor=P.+Juniauthor=A.+Kastratiauthor=J.+Knuutiauthor=M.+J.+Lenzenauthor=K.+W.+Mahaffeyauthor=M.+Valgimigliauthor=A.+van%E2%80%99t+Hofauthor=P.+Widimskyauthor=D.+Zahgerauthor=J.+J.+Baxauthor=H.+Baumgartnerauthor=C.+Ceconiauthor=V.+Deanauthor=C.+Deatonauthor=R.+Fagardauthor=C.+Funck-Brentanoauthor=D.+Hasdaiauthor=A.+Hoesauthor=P.+Kirchhofauthor=J.+Knuutiauthor=P.+Kolhauthor=T.+McDonaghauthor=C.+Moulinauthor=B.+A.+Popescuauthor=%C5%BD.+Reinerauthor=U.+Sechtemauthor=P.+A.+Sirnesauthor=M.+Tenderaauthor=A.+Torbickiauthor=A.+Vahanianauthor=S.+Windeckerauthor=D.+Hasdaiauthor=F.+Astinauthor=K.+%C3%85str%C3%B6m-Olssonauthor=A.+Budajauthor=P.+Clemmensenauthor=J.-P.+Colletauthor=K.+A.+Foxauthor=A.+Fuatauthor=O.+Gustieneauthor=C.+W.+Hammauthor=P.+Kalaauthor=P.+Lancellottiauthor=A.+P.+Maggioniauthor=B.+Merkelyauthor=F.-J.+Neumannauthor=M.+F.+Piepoliauthor=F.+Van+de+Werfauthor=F.+Verheugtauthor=L.+Wallentin&title=ESC+Guidelines+for+the+management+of+acute+myocardial+infarction+in+patients+presenting+with+ST-segment+elevation%3A+The+Task+Force+on+the+management+of+ST-segment+elevation+acute+myocardial+infarction+of+the+European+Society+of+Cardiology+%28ESC%29&doi=10.1093%2Feurheartj%2Fehs215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</span></div><div class="casAuthors">Steg, Ph. Gabriel; James, Stefan K.; Atar, Dan; Badano, Luigi P.; Lundqvist, Carina Blomstrom; Borger, Michael A.; Di Mario, Carlo; Dickstein, Kenneth; Ducrocq, Gregory; Fernandez-Aviles, Francisco; Gershlick, Anthony H.; Giannuzzi, Pantaleo; Halvorsen, Sigrun; Huber, Kurt; Juni, Peter; Kastrati, Adnan; Knuuti, Juhani; Lenzen, Mattie J.; Mahaffey, Kenneth W.; Valgimigli, Marco; van't Hof, Arnoud; Widimsky, Petr; Zahger, Doron; Bax, Jeroen J.; Baumgartner, Helmut; Ceconi, Claudio; Dean, Veronica; Deaton, Christi; Fagard, Robert; Funck-Brentano, Christian; Hasdai, David; Hoes, Arno; Kirchhof, Paulus; Knuuti, Juhani; Kolh, Philippe; McDonagh, Theresa; Moulin, Cyril; Popescu, Bogdan A.; Reiner, Zeljko; Sechtem, Udo; Sirnes, Per Anton; Tendera, Michal; Torbicki, Adam; Vahanian, Alec; Windecker, Stephan; Hasdai, David; Astin, Felicity; Aastroem-Olsson, Karin; Budaj, Andrzej; Clemmensen, Peter; Collet, Jean-Philippe; Fox, Keith A.; Fuat, Ahmet; Gustiene, Olivija; Hamm, Christian W.; Kala, Petr; Lancellotti, Patrizio; Maggioni, Aldo Pietro; Merkely, Bela; Neumann, Franz-Josef; Piepoli, Massimo F.; Van de Werf, Frans; Verheugt, Freek; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2569-2619</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The present guidelines pertain to the management of acute myocardial infarction in patients presenting with ischemic symptoms and persistent ST-segment elevation on the ECG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroXU4uG_IjH7Vg90H21EOLACvtfcHk0ljFM_5KzHwMLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFektbrE&md5=96241715be7c10947e6b691dd76b4b9a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehs215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehs215%26sid%3Dliteratum%253Aachs%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DJames%26aufirst%3DS.%2BK.%26aulast%3DAtar%26aufirst%3DD.%26aulast%3DBadano%26aufirst%3DL.%2BP.%26aulast%3DBlomstrom%2BLundqvist%26aufirst%3DC.%26aulast%3DBorger%26aufirst%3DM.%2BA.%26aulast%3DDi%2BMario%26aufirst%3DC.%26aulast%3DDickstein%26aufirst%3DK.%26aulast%3DDucrocq%26aufirst%3DG.%26aulast%3DFernandez-Aviles%26aufirst%3DF.%26aulast%3DGershlick%26aufirst%3DA.%2BH.%26aulast%3DGiannuzzi%26aufirst%3DP.%26aulast%3DHalvorsen%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DJuni%26aufirst%3DP.%26aulast%3DKastrati%26aufirst%3DA.%26aulast%3DKnuuti%26aufirst%3DJ.%26aulast%3DLenzen%26aufirst%3DM.%2BJ.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DValgimigli%26aufirst%3DM.%26aulast%3Dvan%25E2%2580%2599t%2BHof%26aufirst%3DA.%26aulast%3DWidimsky%26aufirst%3DP.%26aulast%3DZahger%26aufirst%3DD.%26aulast%3DBax%26aufirst%3DJ.%2BJ.%26aulast%3DBaumgartner%26aufirst%3DH.%26aulast%3DCeconi%26aufirst%3DC.%26aulast%3DDean%26aufirst%3DV.%26aulast%3DDeaton%26aufirst%3DC.%26aulast%3DFagard%26aufirst%3DR.%26aulast%3DFunck-Brentano%26aufirst%3DC.%26aulast%3DHasdai%26aufirst%3DD.%26aulast%3DHoes%26aufirst%3DA.%26aulast%3DKirchhof%26aufirst%3DP.%26aulast%3DKnuuti%26aufirst%3DJ.%26aulast%3DKolh%26aufirst%3DP.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DMoulin%26aufirst%3DC.%26aulast%3DPopescu%26aufirst%3DB.%2BA.%26aulast%3DReiner%26aufirst%3D%25C5%25BD.%26aulast%3DSechtem%26aufirst%3DU.%26aulast%3DSirnes%26aufirst%3DP.%2BA.%26aulast%3DTendera%26aufirst%3DM.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DVahanian%26aufirst%3DA.%26aulast%3DWindecker%26aufirst%3DS.%26aulast%3DHasdai%26aufirst%3DD.%26aulast%3DAstin%26aufirst%3DF.%26aulast%3D%25C3%2585str%25C3%25B6m-Olsson%26aufirst%3DK.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DCollet%26aufirst%3DJ.-P.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DFuat%26aufirst%3DA.%26aulast%3DGustiene%26aufirst%3DO.%26aulast%3DHamm%26aufirst%3DC.%2BW.%26aulast%3DKala%26aufirst%3DP.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMerkely%26aufirst%3DB.%26aulast%3DNeumann%26aufirst%3DF.-J.%26aulast%3DPiepoli%26aufirst%3DM.%2BF.%26aulast%3DVan%2Bde%2BWerf%26aufirst%3DF.%26aulast%3DVerheugt%26aufirst%3DF.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DESC%2520Guidelines%2520for%2520the%2520management%2520of%2520acute%2520myocardial%2520infarction%2520in%2520patients%2520presenting%2520with%2520ST-segment%2520elevation%253A%2520The%2520Task%2520Force%2520on%2520the%2520management%2520of%2520ST-segment%2520elevation%2520acute%2520myocardial%2520infarction%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2012%26volume%3D33%26spage%3D2569%26epage%3D2619%26doi%3D10.1093%2Feurheartj%2Fehs215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">O’Gara, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascheim, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, D. E.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lemos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesmire, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krumholz, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linderbaum, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newby, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornato, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamis-Holland, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommaso, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, D. X.</span><span> </span><span class="NLM_article-title">2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">e78</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1016/j.jacc.2012.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.jacc.2012.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=23256914" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=e78-140&author=P.+T.+O%E2%80%99Garaauthor=F.+G.+Kushnerauthor=D.+D.+Ascheimauthor=D.+E.+Caseyauthor=M.+K.+Chungauthor=J.+A.+de+Lemosauthor=S.+M.+Ettingerauthor=J.+C.+Fangauthor=F.+M.+Fesmireauthor=B.+A.+Franklinauthor=C.+B.+Grangerauthor=H.+M.+Krumholzauthor=J.+A.+Linderbaumauthor=D.+A.+Morrowauthor=L.+K.+Newbyauthor=J.+P.+Ornatoauthor=N.+Ouauthor=M.+J.+Radfordauthor=J.+E.+Tamis-Hollandauthor=C.+L.+Tommasoauthor=C.+M.+Tracyauthor=Y.+J.+Wooauthor=D.+X.+Zhao&title=2013+ACCF%2FAHA+Guideline+for+the+Management+of+ST-Elevation+Myocardial+Infarction%3A+A+Report+of+the+American+College+of+Cardiology+Foundation%2FAmerican+Heart+Association+Task+Force+on+Practice+Guidelines&doi=10.1016%2Fj.jacc.2012.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Gara%26aufirst%3DP.%2BT.%26aulast%3DKushner%26aufirst%3DF.%2BG.%26aulast%3DAscheim%26aufirst%3DD.%2BD.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DChung%26aufirst%3DM.%2BK.%26aulast%3Dde%2BLemos%26aufirst%3DJ.%2BA.%26aulast%3DEttinger%26aufirst%3DS.%2BM.%26aulast%3DFang%26aufirst%3DJ.%2BC.%26aulast%3DFesmire%26aufirst%3DF.%2BM.%26aulast%3DFranklin%26aufirst%3DB.%2BA.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DKrumholz%26aufirst%3DH.%2BM.%26aulast%3DLinderbaum%26aufirst%3DJ.%2BA.%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DNewby%26aufirst%3DL.%2BK.%26aulast%3DOrnato%26aufirst%3DJ.%2BP.%26aulast%3DOu%26aufirst%3DN.%26aulast%3DRadford%26aufirst%3DM.%2BJ.%26aulast%3DTamis-Holland%26aufirst%3DJ.%2BE.%26aulast%3DTommaso%26aufirst%3DC.%2BL.%26aulast%3DTracy%26aufirst%3DC.%2BM.%26aulast%3DWoo%26aufirst%3DY.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%2BX.%26atitle%3D2013%2520ACCF%252FAHA%2520Guideline%2520for%2520the%2520Management%2520of%2520ST-Elevation%2520Myocardial%2520Infarction%253A%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%2520Foundation%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Practice%2520Guidelines%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D61%26spage%3De78%26epage%3D140%26doi%3D10.1016%2Fj.jacc.2012.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">King, S. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirshfeld, J. W.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. O.</span><span> </span><span class="NLM_article-title">2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=261-295&author=S.+B.+Kingauthor=S.+C.+Smithauthor=J.+W.+Hirshfeldauthor=A.+K.+Jacobsauthor=D.+A.+Morrisonauthor=D.+O.+Williams&title=2007+Focused+Update+of+the+ACC%2FAHA%2FSCAI+2005+Guideline+Update+for+Percutaneous+Coronary+Intervention.+A+Report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Practice+Guidelines%3A+2007+Writing+Group+to+Review+New+Evidence+and+Update+the+ACC%2FAHA%2FSCAI+2005+Guideline+Update+for+Percutaneous+Coronary+Intervention%2C+Writing+on+Behalf+of+the+2005+Writing+Committee"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DS.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DHirshfeld%26aufirst%3DJ.%2BW.%26aulast%3DJacobs%26aufirst%3DA.%2BK.%26aulast%3DMorrison%26aufirst%3DD.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BO.%26atitle%3D2007%2520Focused%2520Update%2520of%2520the%2520ACC%252FAHA%252FSCAI%25202005%2520Guideline%2520Update%2520for%2520Percutaneous%2520Coronary%2520Intervention.%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Practice%2520Guidelines%253A%25202007%2520Writing%2520Group%2520to%2520Review%2520New%2520Evidence%2520and%2520Update%2520the%2520ACC%252FAHA%252FSCAI%25202005%2520Guideline%2520Update%2520for%2520Percutaneous%2520Coronary%2520Intervention%252C%2520Writing%2520on%2520Behalf%2520of%2520the%25202005%2520Writing%2520Committee%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D261%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrolavicius, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. K.</span><span> </span><span class="NLM_article-title">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1056/NEJMoa010746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa010746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=11519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=494-502&author=S.+Yusufauthor=F.+Zhaoauthor=S.+R.+Mehtaauthor=S.+Chrolaviciusauthor=G.+Tognoniauthor=K.+K.+Fox&title=Effects+of+clopidogrel+in+addition+to+aspirin+in+patients+with+acute+coronary+syndromes+without+ST-segment+elevation&doi=10.1056%2FNEJMoa010746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</span></div><div class="casAuthors">Yusuf, Salim; Zhao, Feng; Mehta, Shamir R.; Chrolavicius, Susan; Tognoni, Gianni; Fox, Keith K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">494-502</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events.  We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.  We randomly assigned 12,562 patients who had presented within 24 h after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addn. to aspirin for 3 to 12 mo.  The first primary outcome - a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001).  The second primary outcome - the first primary outcome or refractory ischemia - occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001).  The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel.  There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.  The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.  However, the risk of major bleeding is increased among patients treated with clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihXPVAbDPg7Vg90H21EOLACvtfcHk0li2iVDZ8ZBnhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXms1arsrY%253D&md5=3ddc47281ccad90f046038a4c3f98a21</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa010746%26sid%3Dliteratum%253Aachs%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DMehta%26aufirst%3DS.%2BR.%26aulast%3DChrolavicius%26aufirst%3DS.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DFox%26aufirst%3DK.%2BK.%26atitle%3DEffects%2520of%2520clopidogrel%2520in%2520addition%2520to%2520aspirin%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%2520without%2520ST-segment%2520elevation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D494%26epage%3D502%26doi%3D10.1056%2FNEJMoa010746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakkis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gersh, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span> </span><span class="NLM_article-title">Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1202</span><span class="NLM_x">–</span> <span class="NLM_lpage">1208</span><span class="refDoi"> DOI: 10.1161/01.CIR.0000140675.85342.1B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1161%2F01.CIR.0000140675.85342.1B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=15313956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=1202-1208&author=K.+A.+Foxauthor=S.+R.+Mehtaauthor=R.+Petersauthor=F.+Zhaoauthor=N.+Lakkisauthor=B.+J.+Gershauthor=S.+Yusuf&title=Benefits+and+risks+of+the+combination+of+clopidogrel+and+aspirin+in+patients+undergoing+surgical+revascularization+for+non-ST-elevation+acute+coronary+syndrome%3A+the+Clopidogrel+in+Unstable+angina+to+prevent+Recurrent+ischemic+Events+%28CURE%29+Trial&doi=10.1161%2F01.CIR.0000140675.85342.1B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits and risks of the combination of Clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome</span></div><div class="casAuthors">Fox, Keith A. A.; Mehta, Shamir R.; Peters, Ron; Zhao, Feng; Lakkis, Nasser; Gersh, Bernard J.; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1202-1208</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding.  In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12,562 patients were randomized to clopidogrel or placebo in addn. to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke.  The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9.6% for clopidogrel, 13.2% for placebo; relative risk (RR), 0.72; 95% CI, 0.57-0.90], coronary artery bypass grafting (CABG) surgery (14.5% for clopidogrel 16.2% for placebo; RR, 0.89; 95% CI, 0.71-1.11), and medical therapy only (8.1% for clopidogrel, 10.0% for placebo; RR, 0.80; 95% CI, 0.69-0.92; test for interaction among strata, 0.53).  For CABG during the initial hospitalization (530 for placebo, 485 for clopidogrel), the frequency of CV death, MI or stroke before CABG was 4.7% for placebo and 2.9% for clopidogrel (RR, 0.56; 95% CI, 0.29-1.08).  For the entire study, there was a 1% excess of major bleeding but no significant excess of life-threatening bleeding.  Among patients undergoing CABG, the rates of life-threatening bleeding were 5.6% for clopidogrel and 4.2% for placebo (RR, 1.30; 95% CI, 0.91-1.95; both nonsignificant).  The benefits vs. risks of early and long-term clopidogrel therapy (freedom from CV death, MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization (CABG or PCI) and in the study population as a whole.  Overall, the benefits of starting clopidogrel on admission appear to outweigh the risks, even among those who proceed to CABG during the initial hospitalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot-5k67TQzCrVg90H21EOLACvtfcHk0li2iVDZ8ZBnhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSksL8%253D&md5=404fadafe6de6dcd91c5a49e8722c95f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000140675.85342.1B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000140675.85342.1B%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DMehta%26aufirst%3DS.%2BR.%26aulast%3DPeters%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DLakkis%26aufirst%3DN.%26aulast%3DGersh%26aufirst%3DB.%2BJ.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DBenefits%2520and%2520risks%2520of%2520the%2520combination%2520of%2520clopidogrel%2520and%2520aspirin%2520in%2520patients%2520undergoing%2520surgical%2520revascularization%2520for%2520non-ST-elevation%2520acute%2520coronary%2520syndrome%253A%2520the%2520Clopidogrel%2520in%2520Unstable%2520angina%2520to%2520prevent%2520Recurrent%2520ischemic%2520Events%2520%2528CURE%2529%2520Trial%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26spage%3D1202%26epage%3D1208%26doi%3D10.1161%2F01.CIR.0000140675.85342.1B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Snoep, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hovens, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eikenboom, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Bom, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jukema, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, M. V.</span><span> </span><span class="NLM_article-title">Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.ahj.2007.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.ahj.2007.04.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2007&pages=221-231&author=J.+D.+Snoepauthor=M.+M.+Hovensauthor=J.+C.+Eikenboomauthor=J.+G.+van+der+Bomauthor=J.+W.+Jukemaauthor=M.+V.+Huisman&title=Clopidogrel+nonresponsiveness+in+patients+undergoing+percutaneous+coronary+intervention+with+stenting%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2Fj.ahj.2007.04.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2007.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2007.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSnoep%26aufirst%3DJ.%2BD.%26aulast%3DHovens%26aufirst%3DM.%2BM.%26aulast%3DEikenboom%26aufirst%3DJ.%2BC.%26aulast%3Dvan%2Bder%2BBom%26aufirst%3DJ.%2BG.%26aulast%3DJukema%26aufirst%3DJ.%2BW.%26aulast%3DHuisman%26aufirst%3DM.%2BV.%26atitle%3DClopidogrel%2520nonresponsiveness%2520in%2520patients%2520undergoing%2520percutaneous%2520coronary%2520intervention%2520with%2520stenting%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2007%26volume%3D154%26spage%3D221%26epage%3D231%26doi%3D10.1016%2Fj.ahj.2007.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">O’Connor, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cayla, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collet, J. P.</span><span> </span><span class="NLM_article-title">Pharmacogenetics of Clopidogrel</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5309</span><span class="NLM_x">–</span> <span class="NLM_lpage">5327</span><span class="refDoi"> DOI: 10.2174/138161212803251880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.2174%2F138161212803251880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=22724417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ont7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5309-5327&author=S.+A.+O%E2%80%99Connorauthor=J.+S.+Hulotauthor=J.+Silvainauthor=G.+Caylaauthor=G.+Montalescotauthor=J.+P.+Collet&title=Pharmacogenetics+of+Clopidogrel&doi=10.2174%2F138161212803251880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics of clopidogrel</span></div><div class="casAuthors">O'Connor, Stephen A.; Hulot, Jean-Sebastien; Silvain, Johanne; Cayla, Guillaume; Montalescot, Gilles; Collet, Jean-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5309-5327</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clopidogrel used in conjunction with aspirin has a central role in the treatment of patients with an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI).  The pharmacokinetic and pharmacodynamic responses to this drug are highly variable leaving up to one third of patients with inadequate platelet inhibition or high on-treatment platelet reactivity (HPR), and subsequent increased ischemic cardiovascular events.  Genetic variability in drug absorption and metab. is a key factor responsible for the inefficient generation of the active drug metabolite.  The two-step hepatic cytochrome P 450 (CYP)-dependant oxidative metab. of the prodrug appears to be of particular importance.  Pharmacogenomic analyses have identified loss-of-function variant alleles of CYP 2C19 and specifically the 2C19*2 allele, to be the predominant genetic mediators of the antiplatelet effect of clopidogrel.  Carriers were have been shown to have lower active metabolite levels of clopidogrel, higher platelet reactivity and assocd. poorer outcomes.  Rapid and accurate point-of-care genetic tests to identify these alleles are currently in development but several questions about the role of such testing remain such as patient selection and whether personalized treatment based on genotype has a pos. impact on clin. outcome.  At present, genetic testing cannot be recommended in routine clin. practice due to insufficient prospective data.  However, the significant body of research published to date suggests a likely role when used in combination with platelet function anal. in ACS patients undergoing stenting who have other known risk factors for recurrent ischemic events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaOK_TFTLbebVg90H21EOLACvtfcHk0li2iVDZ8ZBnhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ont7nF&md5=91cbc50c058a5646530d8ff072c6fea4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F138161212803251880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212803251880%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BA.%26aulast%3DHulot%26aufirst%3DJ.%2BS.%26aulast%3DSilvain%26aufirst%3DJ.%26aulast%3DCayla%26aufirst%3DG.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DCollet%26aufirst%3DJ.%2BP.%26atitle%3DPharmacogenetics%2520of%2520Clopidogrel%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D5309%26epage%3D5327%26doi%3D10.2174%2F138161212803251880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Schrör, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siller-Matula, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetic basis of the antiplatelet action of prasugrel</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1111/j.1472-8206.2011.00986.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1111%2Fj.1472-8206.2011.00986.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21895761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC387isFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=39-46&author=K.+Schr%C3%B6rauthor=J.+M.+Siller-Matulaauthor=K.+Huber&title=Pharmacokinetic+basis+of+the+antiplatelet+action+of+prasugrel&doi=10.1111%2Fj.1472-8206.2011.00986.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic basis of the antiplatelet action of prasugrel</span></div><div class="casAuthors">Schror Karsten; Siller-Matula Jolanta M; Huber Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & clinical pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prasugrel is the most recent development of thienopyridine-type antiplatelet drugs.  Like the earlier-generation thienopyridines, i.e. ticlopidine and clopidogrel, prasugrel is also an inactive prodrug that requires metabolic processing in vivo to generate the active antiplatelet metabolite.  The efficacy of this bioactivation is the key determinant for the pharmacodynamic potency of the compound, i.e. the irreversible blockade of the platelet P2Y12-ADP receptor.  Prasugrel is rapidly absorbed from the gut.  After oral administration of standard-loading doses of 60 mg, maximum plasma levels of the active metabolite are achieved within 1 h, effective, maximum inhibition of platelet aggregation at 1-2 h.  Bioconversion of prasugrel into the active metabolite requires two metabolic steps that occur in sequence.  The first is the generation of a thiolactone-intermediate, mainly by carboxyesterases-2 in the intestine, the second the cytochrome (CYP)-dependent conversion of the thiolactone into the active metabolite.  This second step involves several cytochromes, most notably CYP3A4, CYP2C19, CYP2B6, and CYP2C9.  The enzymatic generation of the active metabolite of prasugrel is much more effective than that of clopidogrel where only about 5% of oral clopidogrel is transformed into the active compound by two-step CYP-dependent procedures.  About 70% of prasugrel metabolites are excreted in the urine and 30% in the feces.  The molar potency of the respective active metabolites of prasugrel and clopidogrel is identical.  Thus, the more rapid onset, higher potency and lower interindividual variability of antiplatelet effects of prasugrel as compared to clopidogrel in vivo are entirely because of its more efficient pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0mErGQHcRnQxyojvcjibhfW6udTcc2eYb1mlkgiFuJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387isFCktQ%253D%253D&md5=6973f63544f4e80cc9c624f4217548f8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1472-8206.2011.00986.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1472-8206.2011.00986.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6r%26aufirst%3DK.%26aulast%3DSiller-Matula%26aufirst%3DJ.%2BM.%26aulast%3DHuber%26aufirst%3DK.%26atitle%3DPharmacokinetic%2520basis%2520of%2520the%2520antiplatelet%2520action%2520of%2520prasugrel%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D26%26spage%3D39%26epage%3D46%26doi%3D10.1111%2Fj.1472-8206.2011.00986.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Jernberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naganuma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span> </span><span class="NLM_article-title">Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1173</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehi877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehi877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=16621870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Crt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=1166-1173&author=T.+Jernbergauthor=C.+D.+Payneauthor=K.+J.+Wintersauthor=C.+Darsteinauthor=J.+T.+Brandtauthor=J.+A.+Jakubowskiauthor=H.+Naganumaauthor=A.+Siegbahnauthor=L.+Wallentin&title=Prasugrel+achieves+greater+inhibition+of+platelet+aggregation+and+a+lower+rate+of+non-responders+compared+with+clopidogrel+in+aspirin-treated+patients+with+stable+coronary+artery+disease&doi=10.1093%2Feurheartj%2Fehi877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease</span></div><div class="casAuthors">Jernberg, Tomas; Payne, Christopher D.; Winters, Kenneth J.; Darstein, Christelle; Brandt, John T.; Jakubowski, Joseph A.; Naganuma, Hideo; Siegbahn, Agneta; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1166-1173</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD).  Methods and results: Subjects (n = 101) were randomly assigned to the following loading dose (LD) (day 1)/maintenance dose (MD) (days 2-28) combinations: prasugrel, 40 mg/5 mg; 40 mg/7.5 mg; 60 mg/10 mg; 60 mg/15 mg; or clopidogrel, 300 mg/75 mg.  Turbidometric platelet aggregation was measured at multiple timepoints during the study.  At 4 h after dosing, with 20 μM ADP, both prasugrel LDs achieved significantly higher mean IPA levels (60.6% and 68.4 vs. 30.0%, resp.; all P < 0.0001) and lower percentage (3 vs. 52%, P < 0.0001) of pharmacodynamic non-responders (defined as IPA <20%) than clopidogrel.  Prasugrel 10 and 15 mg MDs achieved consistently higher mean IPA than clopidogrel 75 mg at day 28 (all P < 0.0001).  At pre-MD on day 28, there were no non-responders in the 10 and 15 mg prasugrel group, compared with 45% in the clopidogrel group (P = 0.0007).  Conclusion: In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekrzLKAa5jbVg90H21EOLACvtfcHk0lhs6AlI54vv4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Crt7g%253D&md5=62bd6495d6bbf8b2cf1a2953a8507ad9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehi877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehi877%26sid%3Dliteratum%253Aachs%26aulast%3DJernberg%26aufirst%3DT.%26aulast%3DPayne%26aufirst%3DC.%2BD.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DDarstein%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DJ.%2BT.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DNaganuma%26aufirst%3DH.%26aulast%3DSiegbahn%26aufirst%3DA.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DPrasugrel%2520achieves%2520greater%2520inhibition%2520of%2520platelet%2520aggregation%2520and%2520a%2520lower%2520rate%2520of%2520non-responders%2520compared%2520with%2520clopidogrel%2520in%2520aspirin-treated%2520patients%2520with%2520stable%2520coronary%2520artery%2520disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2006%26volume%3D27%26spage%3D1166%26epage%3D1173%26doi%3D10.1093%2Feurheartj%2Fehi877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varenhorst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubowski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugidachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span> </span><span class="NLM_article-title">Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1093/eurheartj/ehm545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1093%2Feurheartj%2Fehm545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=18055486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Sqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=21-30&author=L.+Wallentinauthor=C.+Varenhorstauthor=S.+Jamesauthor=D.+Erlingeauthor=O.+O.+Braunauthor=J.+A.+Jakubowskiauthor=A.+Sugidachiauthor=K.+J.+Wintersauthor=A.+Siegbahn&title=Prasugrel+achieves+greater+and+faster+P2Y12+receptor-mediated+platelet+inhibition+than+clopidogrel+due+to+more+efficient+generation+of+its+active+metabolite+in+aspirin-treated+patients+with+coronary+artery+disease&doi=10.1093%2Feurheartj%2Fehm545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease</span></div><div class="casAuthors">Wallentin, Lars; Varenhorst, Christoph; James, Stefan; Erlinge, David; Braun, Oscar Oe; Jakubowski, Joseph A.; Sugidachi, Atsuhiro; Winters, Kenneth J.; Siegbahn, Agneta</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: P2Y12 receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease.  Methods and results: One hundred and ten aspirin treated subjects were randomized to double-blind treatment with clopidogrel (n = 55) 600 mg loading dose (LD) and 75 mg maintenance dose (MD) or prasugrel (n = 55) 60 mg LD and 10 mg MD for 28 days.  Concns. of prasugrel and clopidogrel active metabolites were detd.  Platelet aggregation to 20 μM ADP, measured by light transmission aggregometry, was reported as maximal platelet aggregation (MPA).  P2Y12 function was assessed by the vasodilator-stimulated phosphoprotein assay and reported as platelet reactivity index (PRI).  The same pharmacodynamic measurements were performed after ex vivo addn. of clopidogrel's active metabolite.  At 2 h post-LD, mean MPA was 31 vs. 55%, and mean PRI 8.3 vs. 55.9% for prasugrel and clopidogrel, resp. (P < 0.001).  During MD on day 14 and 28, mean MPA was 42 vs. 54% and mean PRI was 25 vs. 51%, resp. (P < 0.001).  Peak level of the active metabolite and P2Y12 inhibition occurred earlier and was greater with prasugrel (P < 0.001).  Mean area under the time-concn. curve (AUC; μM/h) of the resp. active metabolite was higher with prasugrel vs. clopidogrel post-LD (1.11 vs. 0.24) and post-MD (0.16 vs. 0.062).  Ex vivo addn. of clopidogrel's active metabolite further reduced PRI in all patients whose platelets were not already maximally inhibited.  Conclusion: In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y12 receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrDYed-6tQALVg90H21EOLACvtfcHk0lhs6AlI54vv4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Sqtr8%253D&md5=1c02df46b20b6345d6df9cffea4b4a89</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehm545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehm545%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DVarenhorst%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DBraun%26aufirst%3DO.%2BO.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DSiegbahn%26aufirst%3DA.%26atitle%3DPrasugrel%2520achieves%2520greater%2520and%2520faster%2520P2Y12%2520receptor-mediated%2520platelet%2520inhibition%2520than%2520clopidogrel%2520due%2520to%2520more%2520efficient%2520generation%2520of%2520its%2520active%2520metabolite%2520in%2520aspirin-treated%2520patients%2520with%2520coronary%2520artery%2520disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2008%26volume%3D29%26spage%3D21%26epage%3D30%26doi%3D10.1093%2Feurheartj%2Fehm545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wiviott, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braunwald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzyllo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardissino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Servi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riesmeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerakkody, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antman, E. M.</span><span> </span><span class="NLM_article-title">Prasugrel versus clopidogrel in patients with acute coronary syndromes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2001</span><span class="NLM_x">–</span> <span class="NLM_lpage">2015</span><span class="refDoi"> DOI: 10.1056/NEJMoa0706482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa0706482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=17982182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWis7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2001-2015&author=S.+D.+Wiviottauthor=E.+Braunwaldauthor=C.+H.+McCabeauthor=G.+Montalescotauthor=W.+Ruzylloauthor=S.+Gottliebauthor=F.+J.+Neumannauthor=D.+Ardissinoauthor=S.+De+Serviauthor=S.+A.+Murphyauthor=J.+Riesmeyerauthor=G.+Weerakkodyauthor=C.+M.+Gibsonauthor=E.+M.+Antman&title=Prasugrel+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0706482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wiviott, Stephen D.; Bruanwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzylio, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antmann, Elliott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2001-2015</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.  METHODS To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 mo.  The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.  The key safety end point was major bleeding.  RESULTS The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P < 0.001).  We also found significant redns. in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P < 0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P < 0.001), and stent thrombosis (2.4% vs. 1.1%; P < 0.001).  Major bleeding was obsd. in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P = 0.03).  Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P = 0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P = 0.23) and fatal bleeding (0.4% vs. 0.1%; P = 0.002).  CONCLUSIONS In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was assocd. with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.  Overall mortality did not differ significantly between treatment groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetj1787mjK7Vg90H21EOLACvtfcHk0lhuMUAQnLjoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWis7rN&md5=dd3d3362a7c48f897a94a517cfdc06cd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706482%26sid%3Dliteratum%253Aachs%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DMcCabe%26aufirst%3DC.%2BH.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DGottlieb%26aufirst%3DS.%26aulast%3DNeumann%26aufirst%3DF.%2BJ.%26aulast%3DArdissino%26aufirst%3DD.%26aulast%3DDe%2BServi%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26aulast%3DRiesmeyer%26aufirst%3DJ.%26aulast%3DWeerakkody%26aufirst%3DG.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DAntman%26aufirst%3DE.%2BM.%26atitle%3DPrasugrel%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2001%26epage%3D2015%26doi%3D10.1056%2FNEJMoa0706482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budaj, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuelsson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Held, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahaffey, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scirica, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steg, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storey, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freij, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsén, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PLATO Investigators.</span><span> </span><span class="NLM_article-title">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1056%2FNEJMoa0904327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=19717846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1045-1057&author=L.+Wallentinauthor=R.+C.+Beckerauthor=A.+Budajauthor=C.+P.+Cannonauthor=H.+Emanuelssonauthor=C.+Heldauthor=J.+Horrowauthor=S.+Hustedauthor=S.+Jamesauthor=H.+Katusauthor=K.+W.+Mahaffeyauthor=B.+M.+Sciricaauthor=A.+Skeneauthor=P.+G.+Stegauthor=R.+F.+Storeyauthor=R.+A.+Harringtonauthor=A.+Freijauthor=M.+Thors%C3%A9nauthor=PLATO+Investigators.&title=Ticagrelor+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0904327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wallentin, Lars; Becker, Richard C.; Budaj, Andrej; Cannon, Christopher P.; Emanuelsson, Hakan; Held, Claes; Horrow, Jay; Husted, Steen; James, Stefan; Katus, Hugo; Mahaffey, Kenneth W.; Scirica, Benjamin M.; Skene, Allan; Steg, Philppe Gabriel; Storey, Robert F.; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1045-1057</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ticagrelor is an oral, reversible, direct-acting inhibitor of the ADP receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.  In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg. loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.  At 12 mo, the primary end point - a composite of death from vascular causes, myocardial infarction, or stroke - had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P < 0.001).  Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P = 0.005) and death from vascular causes (4.0% vs. 5.1%0/, P = 0.001) but not stroke alone (1.5% vs. 1.3%, P = 0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P < 0.001).  No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, resp.; P = 0.43), but ticagrelor was assocd. with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P = 0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.  In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTdvlM1dfTz7Vg90H21EOLACvtfcHk0lhuMUAQnLjoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ&md5=9c215c4ceeb6dd14d406ab26e2db25d5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904327%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DEmanuelsson%26aufirst%3DH.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DHorrow%26aufirst%3DJ.%26aulast%3DHusted%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DKatus%26aufirst%3DH.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSkene%26aufirst%3DA.%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DFreij%26aufirst%3DA.%26aulast%3DThors%25C3%25A9n%26aufirst%3DM.%26aulast%3D%26atitle%3DTicagrelor%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1045%26epage%3D1057%26doi%3D10.1056%2FNEJMoa0904327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Reny, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, P.</span><span> </span><span class="NLM_article-title">Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1517/14656566.2015.993608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1517%2F14656566.2015.993608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25495963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisl2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=449-452&author=J.+L.+Renyauthor=P.+Fontana&title=Antiplatelet+drugs+and+platelet+reactivity%3A+is+it+time+to+halt+clinical+research+on+tailored+strategies%3F&doi=10.1517%2F14656566.2015.993608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?</span></div><div class="casAuthors">Reny, Jean-Luc; Fontana, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-452</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Personalized medicine of antiplatelet drugs in cardiovascular patients has led to a significant enthusiasm.  Indeed, numerous longitudinal studies showed an assocn. between high platelet reactivity and the recurrence of ischemic events.  The first small randomized trials of P2Y12 blockers tailored to each patient's platelet reactivity yielded encouraging redns. of coronary stent thrombosis in high-risk populations.  The discovery of genetic variants contributing to the pharmacodynamic effect of clopidogrel has then paved the way toward a personalized antiplatelet therapy based on reliable and stable genetic tests.  This enthusiasm was soon tempered by large interventional trials demonstrating that a platelet function testing-based strategy did not improve clin. outcome and that genetic variants discovered up to now only explained a small part of the pharmacodynamic effect of clopidogrel, thus limiting its clin. use.  Looking back to the most recent trials, their target populations and the type of clin. setting, it seems that the one-size-fits all policy regarding antiplatelet drugs may be well acceptable for low-risk patients.  On the contrary, integration of the clin. setting as well as other risk factors may help to identify subgroups of patients who could derive a benefit from a truly personalized management of antiplatelet therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeSPA04O2Y0rVg90H21EOLACvtfcHk0lhuMUAQnLjoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisl2msbY%253D&md5=cde4d30f2be3202bc91c20a2c1b211fa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.993608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.993608%26sid%3Dliteratum%253Aachs%26aulast%3DReny%26aufirst%3DJ.%2BL.%26aulast%3DFontana%26aufirst%3DP.%26atitle%3DAntiplatelet%2520drugs%2520and%2520platelet%2520reactivity%253A%2520is%2520it%2520time%2520to%2520halt%2520clinical%2520research%2520on%2520tailored%2520strategies%253F%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D449%26epage%3D452%26doi%3D10.1517%2F14656566.2015.993608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burney, m. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Case, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiebsch, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapp, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerndle, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ennis, M. D.</span><span> </span><span class="NLM_article-title">Piperazinyl Glutamate Pyridines as Potent Orally Bioavailable P2Y12 Antagonists for Inhibition of Platelet Aggregation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2010</span><span class="NLM_x">–</span> <span class="NLM_lpage">2037</span><span class="refDoi"> DOI: 10.1021/jm901518t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901518t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2010-2037&author=J.+J.+Parlowauthor=m.+W.+Burneyauthor=B.+L.+Caseauthor=T.+J.+Girardauthor=K.+A.+Hallauthor=P.+K.+Harrisauthor=R.+R.+Hiebschauthor=R.+M.+Huffauthor=R.+M.+Lachanceauthor=D.+A.+Mischkeauthor=S.+R.+Rappauthor=R.+S.+Woerndleauthor=M.+D.+Ennis&title=Piperazinyl+Glutamate+Pyridines+as+Potent+Orally+Bioavailable+P2Y12+Antagonists+for+Inhibition+of+Platelet+Aggregation&doi=10.1021%2Fjm901518t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Fjm901518t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901518t%26sid%3Dliteratum%253Aachs%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DBurney%26aufirst%3Dm.%2BW.%26aulast%3DCase%26aufirst%3DB.%2BL.%26aulast%3DGirard%26aufirst%3DT.%2BJ.%26aulast%3DHall%26aufirst%3DK.%2BA.%26aulast%3DHarris%26aufirst%3DP.%2BK.%26aulast%3DHiebsch%26aufirst%3DR.%2BR.%26aulast%3DHuff%26aufirst%3DR.%2BM.%26aulast%3DLachance%26aufirst%3DR.%2BM.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DWoerndle%26aufirst%3DR.%2BS.%26aulast%3DEnnis%26aufirst%3DM.%2BD.%26atitle%3DPiperazinyl%2520Glutamate%2520Pyridines%2520as%2520Potent%2520Orally%2520Bioavailable%2520P2Y12%2520Antagonists%2520for%2520Inhibition%2520of%2520Platelet%2520Aggregation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2010%26epage%3D2037%26doi%3D10.1021%2Fjm901518t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zech, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Just, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czechtizky, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Görlitzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazaré, M.</span><span> </span><span class="NLM_article-title">Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8615</span><span class="NLM_x">–</span> <span class="NLM_lpage">8629</span><span class="refDoi"> DOI: 10.1021/jm300771j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300771j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8615-8629&author=G.+Zechauthor=G.+Hesslerauthor=A.+Eversauthor=T.+Weissauthor=P.+Florianauthor=M.+Justauthor=J.+Czechauthor=W.+Czechtizkyauthor=J.+G%C3%B6rlitzerauthor=S.+Rufauthor=M.+Kohlmannauthor=M.+Nazar%C3%A9&title=Identification+of+High-Affinity+P2Y12+Antagonists+Based+on+a+Phenylpyrazole+Glutamic+Acid+Piperazine+Backbone&doi=10.1021%2Fjm300771j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm300771j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300771j%26sid%3Dliteratum%253Aachs%26aulast%3DZech%26aufirst%3DG.%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DWeiss%26aufirst%3DT.%26aulast%3DFlorian%26aufirst%3DP.%26aulast%3DJust%26aufirst%3DM.%26aulast%3DCzech%26aufirst%3DJ.%26aulast%3DCzechtizky%26aufirst%3DW.%26aulast%3DG%25C3%25B6rlitzer%26aufirst%3DJ.%26aulast%3DRuf%26aufirst%3DS.%26aulast%3DKohlmann%26aufirst%3DM.%26aulast%3DNazar%25C3%25A9%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520High-Affinity%2520P2Y12%2520Antagonists%2520Based%2520on%2520a%2520Phenylpyrazole%2520Glutamic%2520Acid%2520Piperazine%2520Backbone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8615%26epage%3D8629%26doi%3D10.1021%2Fjm300771j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bach, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bylund, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Björkman, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Österlund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordanetto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giezen, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachrisson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, F.</span><span> </span><span class="NLM_article-title">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7015</span><span class="NLM_x">–</span> <span class="NLM_lpage">7024</span><span class="refDoi"> DOI: 10.1021/jm400820m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400820m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7015-7024&author=P.+Bachauthor=T.+Antonssonauthor=R.+Bylundauthor=J.-A.+Bj%C3%B6rkmanauthor=K.+%C3%96sterlundauthor=F.+Giordanettoauthor=J.+J.+J.+van+Giezenauthor=S.+M.+Andersenauthor=H.+Zachrissonauthor=F.+Zetterberg&title=Lead+Optimization+of+Ethyl+6-Aminonicotinate+Acyl+Sulfonamides+as+Antagonists+of+the+P2Y12+Receptor.+Separation+of+the+Antithrombotic+Effect+and+Bleeding+for+Candidate+Drug+AZD1283&doi=10.1021%2Fjm400820m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span></div><div class="casAuthors">Bach, Peter; Antonsson, Thomas; Bylund, Ruth; Bjoerkman, Jan-Arne; Oesterlund, Krister; Giordanetto, Fabrizio; van Giezen, J. J. J.; Andersen, Soeren M.; Zachrisson, Helen; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7015-7024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationships of Et 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented.  Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay.  Evaluation of PK parameters in vivo in dog for six compds. showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines.  In a modified Folts model in dog, both piperidine (I) and azetidine (II) dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, resp.  The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for I and II, resp.  Thus, the therapeutic index (TI) was ≥10 for both compds.  On the basis of these data, compd. I was progressed into human clin. trials as candidate drug AZD1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmCuB-1CBurVg90H21EOLACvtfcHk0lgGgxySPKmaMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP&md5=3810ed67647a776b9ad8bdb165f715e7</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fjm400820m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400820m%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DAntonsson%26aufirst%3DT.%26aulast%3DBylund%26aufirst%3DR.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DJ.-A.%26aulast%3D%25C3%2596sterlund%26aufirst%3DK.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DLead%2520Optimization%2520of%2520Ethyl%25206-Aminonicotinate%2520Acyl%2520Sulfonamides%2520as%2520Antagonists%2520of%2520the%2520P2Y12%2520Receptor.%2520Separation%2520of%2520the%2520Antithrombotic%2520Effect%2520and%2520Bleeding%2520for%2520Candidate%2520Drug%2520AZD1283%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7015%26epage%3D7024%26doi%3D10.1021%2Fjm400820m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Boldron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordes, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tissandié, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yvon, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badorc, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseaux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barré, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meneyrol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflieger, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet-Lignon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hérault, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassalle, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delesque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bono, F.</span><span> </span><span class="NLM_article-title">N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7293</span><span class="NLM_x">–</span> <span class="NLM_lpage">7316</span><span class="refDoi"> DOI: 10.1021/jm500588w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500588w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7293-7316&author=C.+Boldronauthor=A.+Besseauthor=M.-F.+Bordesauthor=S.+Tissandi%C3%A9author=X.+Yvonauthor=B.+Gauauthor=A.+Badorcauthor=T.+Rousseauxauthor=G.+Barr%C3%A9author=J.+Meneyrolauthor=G.+Zechauthor=M.+Nazareauthor=V.+Fosseyauthor=A.-M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=C.+Briotauthor=F.+Dolauthor=J.-P.+H%C3%A9raultauthor=P.+Saviauthor=G.+Lassalleauthor=N.+Delesqueauthor=J.-M.+Herbertauthor=F.+Bono&title=N-%5B6-%284-Butanoyl-5-methyl-1H-pyrazol-1-yl%29pyridazin-3-yl%5D-5-chloro-1-%5B2-%284-methylpiperazin-1-yl%29-2-oxoethyl%5D-1H-indole-3-carboxamide+%28SAR216471%29%2C+a+Novel+Intravenous+and+Oral%2C+Reversible%2C+and+Directly+Acting+P2Y12+Antagonist&doi=10.1021%2Fjm500588w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Fjm500588w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500588w%26sid%3Dliteratum%253Aachs%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBordes%26aufirst%3DM.-F.%26aulast%3DTissandi%25C3%25A9%26aufirst%3DS.%26aulast%3DYvon%26aufirst%3DX.%26aulast%3DGau%26aufirst%3DB.%26aulast%3DBadorc%26aufirst%3DA.%26aulast%3DRousseaux%26aufirst%3DT.%26aulast%3DBarr%25C3%25A9%26aufirst%3DG.%26aulast%3DMeneyrol%26aufirst%3DJ.%26aulast%3DZech%26aufirst%3DG.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DFossey%26aufirst%3DV.%26aulast%3DPflieger%26aufirst%3DA.-M.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DBriot%26aufirst%3DC.%26aulast%3DDol%26aufirst%3DF.%26aulast%3DH%25C3%25A9rault%26aufirst%3DJ.-P.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DHerbert%26aufirst%3DJ.-M.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DN-%255B6-%25284-Butanoyl-5-methyl-1H-pyrazol-1-yl%2529pyridazin-3-yl%255D-5-chloro-1-%255B2-%25284-methylpiperazin-1-yl%2529-2-oxoethyl%255D-1H-indole-3-carboxamide%2520%2528SAR216471%2529%252C%2520a%2520Novel%2520Intravenous%2520and%2520Oral%252C%2520Reversible%252C%2520and%2520Directly%2520Acting%2520P2Y12%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7293%26epage%3D7316%26doi%3D10.1021%2Fjm500588w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenalti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span> </span><span class="NLM_article-title">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">509</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/nature13083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnature13083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=24670650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=115-118&author=K.+Zhangauthor=J.+Zhangauthor=Z.+G.+Gaoauthor=D.+Zhangauthor=L.+Zhuauthor=G.+W.+Hanauthor=S.+M.+Mossauthor=S.+Paolettaauthor=E.+Kiselevauthor=W.+Luauthor=G.+Fenaltiauthor=W.+Zhangauthor=C.+E.+M%C3%BCllerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Structure+of+the+human+P2Y12+receptor+in+complex+with+an+antithrombotic+drug&doi=10.1038%2Fnature13083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span></div><div class="casAuthors">Zhang, Kaihua; Zhang, Jin; Gao, Zhan-Guo; Zhang, Dandan; Zhu, Lan; Han, Gye Won; Moss, Steven M.; Paoletta, Silvia; Kiselev, Evgeny; Lu, Weizhen; Fenalti, Gustavo; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides.  There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.  Their ligands are generally charged mols. with relatively low bioavailability and stability in vivo, which limits the authors' understanding of this receptor family.  P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R-including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analog ticagrelor (Brilinta) that acts directly on the receptor-have been approved for the prevention of stroke and myocardial infarction.  However, limitations of these drugs (for example, a very long half-life of clopidogrel action and a characteristic adverse effect profile of ticagrelor) suggest that there is an unfulfilled medical need for developing a new generation of P2Y12R inhibitors.  Here the authors report the 2.6 Å resoln. crystal structure of human P2Y12R in complex with a non-nucleotide reversible antagonist, AZD1283.  The structure reveals a distinct straight conformation of helix V, which sets P2Y12R apart from all other known class A GPCR structures.  With AZD1283 bound, the highly conserved disulfide bridge in GPCRs between helix III and extracellular loop 2 is not obsd. and appears to be dynamic.  Along with the details of the AZD1283-binding site, anal. of the extracellular interface reveals an adjacent ligand-binding region and suggests that both pockets could be required for dinucleotide binding.  The structure provides essential insights for the development of improved P2Y12R ligands and allosteric modulators as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY06VN4D76bVg90H21EOLACvtfcHk0ljbuXyNe6q-Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D&md5=539bb91325c547737bc98baf59f3ff26</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature13083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13083%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DMoss%26aufirst%3DS.%2BM.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520P2Y12%2520receptor%2520in%2520complex%2520with%2520an%2520antithrombotic%2520drug%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature13083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span> </span><span class="NLM_article-title">Agonist-bound structure of the human P2Y12 receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">509</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1038/nature13288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2Fnature13288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=24784220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=119-122&author=J.+Zhangauthor=K.+Zhangauthor=Z.+G.+Gaoauthor=S.+Paolettaauthor=D.+Zhangauthor=G.+W.+Hanauthor=T.+Liauthor=L.+Maauthor=W.+Zhangauthor=C.+E.+M%C3%BCllerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Agonist-bound+structure+of+the+human+P2Y12+receptor&doi=10.1038%2Fnature13288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound structure of the human P2Y12 receptor</span></div><div class="casAuthors">Zhang, Jin; Zhang, Kaihua; Gao, Zhan-Guo; Paoletta, Silvia; Zhang, Dandan; Han, Gye Won; Li, Tingting; Ma, Limin; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The P2Y12 receptor (P2Y12R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clin. drug targets for inhibition of platelet aggregation.  Although mutagenesis and modeling studies of the P2Y12R provided useful insights into ligand binding, the agonist and antagonist recognition and function at the P2Y12R remain poorly understood at the mol. level.  Here we report the structures of the human P2Y12R in complex with the full agonist 2-methylthio-adenosine-5'-diphosphate (2MeSADP, a close analog of endogenous agonist ADP) at 2.5 Å resoln., and the corresponding ATP deriv. 2-methylthio-adenosine-5'-triphosphate (2MeSATP) at 3.1 Å resoln.  These structures, together with the structure of the P2Y12R with antagonist Et 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283), reveal striking conformational changes between nucleotide and non-nucleotide ligand complexes in the extracellular regions.  Further anal. of these changes provides insight into a distinct ligand binding landscape in the δ-group of class A G-protein-coupled receptors (GPCRs).  Agonist and non-nucleotide antagonist adopt different orientations in the P2Y12R, with only partially overlapped binding pockets.  The agonist-bound P2Y12R structure answers long-standing questions surrounding P2Y12R-agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding.  As a first example, to our knowledge, of a GPCR in which agonist access to the binding pocket requires large-scale rearrangements in the highly malleable extracellular region, the structural and docking studies will therefore provide invaluable insight into the pharmacol. and mechanisms of action of agonists and different classes of antagonists for the P2Y12R and potentially for other closely related P2YRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJkF4VbScbarVg90H21EOLACvtfcHk0ljbuXyNe6q-Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyis7k%253D&md5=7fdb421ab2f3757a7e7134d586de84bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature13288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13288%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DAgonist-bound%2520structure%2520of%2520the%2520human%2520P2Y12%2520receptor%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D119%26epage%3D122%26doi%3D10.1038%2Fnature13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbadin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Kügelgen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelrahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straßburger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baqi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">756</span><span class="refDoi"> DOI: 10.1007/s10822-015-9858-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs10822-015-9858-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=26194851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=737-756&author=S.+Paolettaauthor=S.+Sabbadinauthor=I.+von+K%C3%BCgelgenauthor=S.+Hinzauthor=V.+Katritchauthor=K.+Hoffmannauthor=A.+Abdelrahmanauthor=J.+Stra%C3%9Fburgerauthor=Y.+Baqiauthor=Q.+Zhaoauthor=R.+C.+Stevensauthor=S.+Moroauthor=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Modeling+ligand+recognition+at+the+P2Y12+receptor+in+light+of+X-ray+structural+information&doi=10.1007%2Fs10822-015-9858-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span></div><div class="casAuthors">Paoletta, Silvia; Sabbadin, Davide; von Kugelgen, Ivar; Hinz, Sonja; Katritch, Vsevolod; Hoffmann, Kristina; Abdelrahman, Aliaa; Strassburger, Jens; Baqi, Younis; Zhao, Qiang; Stevens, Raymond C.; Moro, Stefano; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery.  Its recently solved, highly divergent crystallog. structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition.  Therefore, we performed extensive mol. modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported.  Various nucleotide derivs. docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6.  Supervised mol. dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites.  Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R.  Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets.  Thus, our structure-based approach consistently rationalized the main structure-activity relationships within each ligand class, giving useful information for designing improved ligands.  Graphical Abstr.: [Figure not available: see full text.].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QHrDrSpB57Vg90H21EOLACvtfcHk0ljbuXyNe6q-Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J&md5=f6d2128d8067de9a9e0aed5dd1a375d7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9858-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9858-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DSabbadin%26aufirst%3DS.%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DStra%25C3%259Fburger%26aufirst%3DJ.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DModeling%2520ligand%2520recognition%2520at%2520the%2520P2Y12%2520receptor%2520in%2520light%2520of%2520X-ray%2520structural%2520information%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D737%26epage%3D756%26doi%3D10.1007%2Fs10822-015-9858-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tantry, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesheff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bliden, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span> </span><span class="NLM_article-title">Resistance to antiplatelet drugs: what progress has been made?</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2553</span><span class="NLM_x">–</span> <span class="NLM_lpage">2564</span><span class="refDoi"> DOI: 10.1517/14656566.2014.968126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1517%2F14656566.2014.968126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25297833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=2553-2564&author=U.+S.+Tantryauthor=M.+Gesheffauthor=F.+Liuauthor=K.+P.+Blidenauthor=P.+A.+Gurbel&title=Resistance+to+antiplatelet+drugs%3A+what+progress+has+been+made%3F&doi=10.1517%2F14656566.2014.968126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to antiplatelet drugs: what progress has been made?</span></div><div class="casAuthors">Tantry, Udaya S.; Gesheff, Martin; Liu, Fang; Bliden, Kevin P.; Gurbel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2553-2564</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel.  The latter observation stimulated the close scrutiny of the pharmacodynamic effects of clopidogrel and revealed the 'wide variability' and the phenomenon of 'antiplatelet resistance'.  High on-treatment platelet reactivity to ADP (HPR) during clopidogrel therapy is an independent risk factor for ischemic event occurrences in post-percutaneous coronary intervention (post-PCI) patients.  Recent observational studies demonstrated a link between low on-treatment platelet reactivity to bleeding.  The concept of a 'therapeutic window' of P2Y12 receptor reactivity assocd. with both ischemic event occurrence (upper threshold) and bleeding risk (lower threshold) has been proposed.  Areas covered: An update on and a brief review of the current knowledge on antiplatelet resistance were presented.  Evidence available from studies evaluating aspirin resistance and high and low on-treatment platelet reactivity to ADP during P2Y12 receptor blocker therapy was collected from a selective literature search.  Expert opinion: The available evidence indicates that HPR is an independent risk factor for post-PCI ischemic event occurrences.  The therapeutic window concept for the P2Y12 receptor blocker therapy may facilitate the balance between reducing ischemic events and avoiding bleeding events, thereby improving net clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnOqEOVeDYN7Vg90H21EOLACvtfcHk0lh3ewfk_HIFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsrzK&md5=5705156905244abf22cb4608b300bde1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.968126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.968126%26sid%3Dliteratum%253Aachs%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DGesheff%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DBliden%26aufirst%3DK.%2BP.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DResistance%2520to%2520antiplatelet%2520drugs%253A%2520what%2520progress%2520has%2520been%2520made%253F%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D2553%26epage%3D2564%26doi%3D10.1517%2F14656566.2014.968126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">van Giezen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berntsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zachrisson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkman, J. A.</span><span> </span><span class="NLM_article-title">Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1016/j.thromres.2009.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.thromres.2009.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=19692114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2009&pages=565-571&author=J.+J.+van+Giezenauthor=P.+Berntssonauthor=H.+Zachrissonauthor=J.+A.+Bjorkman&title=Comparison+of+ticagrelor+and+thienopyridine+P2Y%2812%29+binding+characteristics+and+antithrombotic+and+bleeding+effects+in+rat+and+dog+models+of+thrombosis%2Fhemostasis&doi=10.1016%2Fj.thromres.2009.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis</span></div><div class="casAuthors">van Giezen, J. J. J.; Berntsson, Pia; Zachrisson, Helen; Bjoerkman, Jan-Arne</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ticagrelor (AZD6140), the first reversibly binding oral P2Y12 receptor antagonist, blocks ADP-induced platelet aggregation via a mode of action distinct from that of thienopyridine antiplatelet agents.  The latter must be metabolically activated and binds irreversibly to P2Y12 for the life of the platelet, precluding restoration of hemostatic function without the generation of new platelets.  In in vitro studies comparing binding characteristics of ticagrelor and compd. 105, a chem. compd. indistinguishable from the active metabolite of prasugrel, ticagrelor exhibited (1) an approx. 100-fold higher affinity for P2Y12 and rapid achievement of equil. (vs no equil. reached with compd. 105) as assessed by radioligand displacement in a receptor filtration binding assay, (2) 48-fold greater potency in a functional receptor assay using recombinant human P2Y12, and (3) 63-fold greater potency in inhibiting ADP-induced aggregation in washed human platelets.  In rat and dog models of thrombosis/hemostasis, there was greater sepn. between doses that provided antithrombotic effect and those that increased bleeding for ticagrelor compared with clopidogrel and compd. 072, a chem. compd. indistinguishable from the prasugrel parent compd.  The ratio of dose resulting in 3-fold increase in bleeding time to dose resulting in 50% restoration of blood flow in rats was 9.7 for ticagrelor compared with 2.0 for clopidogrel and 1.4 for compd. 072.  Similar results were obsd. in dogs.  Our findings suggest that reversibility of P2Y12 binding with ticagrelor may account for the greater sepn. between antithrombotic effects and increased bleeding compared with the irreversible binding of clopidogrel and prasugrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi34tt_gTEe7Vg90H21EOLACvtfcHk0lh3ewfk_HIFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yls7jK&md5=65a2a28bed4e31c6109f37fc9d34ab50</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2009.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2009.06.029%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DBerntsson%26aufirst%3DP.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520ticagrelor%2520and%2520thienopyridine%2520P2Y%252812%2529%2520binding%2520characteristics%2520and%2520antithrombotic%2520and%2520bleeding%2520effects%2520in%2520rat%2520and%2520dog%2520models%2520of%2520thrombosis%252Fhemostasis%26jtitle%3DThromb.%2520Res.%26date%3D2009%26volume%3D124%26spage%3D565%26epage%3D571%26doi%3D10.1016%2Fj.thromres.2009.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Becker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbel, P. A.</span><span> </span><span class="NLM_article-title">Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies</span> <span class="citation_source-journal">Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1160/TH09-07-0491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1160%2FTH09-07-0491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=20135066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=535-544&author=R.+C.+Beckerauthor=P.+A.+Gurbel&title=Platelet+P2Y12+receptor+antagonist+pharmacokinetics+and+pharmacodynamics%3A+A+foundation+for+distinguishing+mechanisms+of+bleeding+and+anticipated+risk+for+platelet-directed+therapies&doi=10.1160%2FTH09-07-0491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies</span></div><div class="casAuthors">Becker, Richard C.; Gurbel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">535-544</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">A review.  The platelet P2Y12 receptor is involved in all aspects of arterial thrombosis, including adhesion, activation, aggregation, secretion and development of a stable aggregate on which coagulation proteins can assemble and fibrin strands can mesh.  Inhibition of the P2Y12 receptor has been shown convincingly to reduce cardiovascular events among patients with acute coronary syndromes (ACS) and in patients undergoing percutaneous intervention (PCI).  Current studies are exploring whether there is a threshold of platelet aggregation below which only more bleeding occurs, without a concomitant redn. in clin. events.  The following review considers the potential relevance of reversible and irreversible mechanisms of P2Y12 inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y12 receptor is inhibited that dets. the attributable safety profile".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr199vMChfdcbVg90H21EOLACvtfcHk0lh3ewfk_HIFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKrsLw%253D&md5=9d1c9b9adfda85293d450bd1c537cc19</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1160%2FTH09-07-0491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1160%252FTH09-07-0491%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DPlatelet%2520P2Y12%2520receptor%2520antagonist%2520pharmacokinetics%2520and%2520pharmacodynamics%253A%2520A%2520foundation%2520for%2520distinguishing%2520mechanisms%2520of%2520bleeding%2520and%2520anticipated%2520risk%2520for%2520platelet-directed%2520therapies%26jtitle%3DThromb.%2520Haemostasis%26date%3D2010%26volume%3D103%26spage%3D535%26epage%3D544%26doi%3D10.1160%2FTH09-07-0491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">André, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberstock-Debic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pak, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1124/jpet.110.178574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1124%2Fjpet.110.178574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21447613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=22-30&author=P.+Andr%C3%A9author=F.+DeGuzmanauthor=H.+Haberstock-Debicauthor=S.+Millsauthor=Y.+Pakauthor=M.+Inagakiauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=Thienopyridines%2C+but+not+elinogrel%2C+result+in+off-target+effects+at+the+vessel+wall+that+contribute+to+bleeding&doi=10.1124%2Fjpet.110.178574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span></div><div class="casAuthors">Andre, Patrick; DeGuzman, Francis; Haberstock-Debic, Helena; Mills, Scott; Pak, Yvonne; Inagaki, Mayuko; Pandey, Anjali; Hollenbach, Stanley; Phillips, David R.; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. studies with clopidogrel or prasugrel show that although increased inhibition of P2Y12 and platelet function improves efficacy, bleeding is also increased.  Other preclin. and clin. studies have suggested a greater therapeutic index (TI) with reversible inhibitors and disproportionate effects of thienopyridines on bleeding at high doses.  We used multiple in vivo (FeCl3-induced arterial thrombosis in mesenteric arteries, blood loss after tail transsection, and platelet deposition and wound closure time in a micropuncture model in mesenteric veins) and ex vivo (light transmittance aggregometry, prothrombin time, and activated partial thromboplastin time) mouse models to (1) compare the TI of clopidogrel, prasugrel, and elinogrel, a reversible, competitive antagonist, with that in P2Y12(-/-) mice and (2) det. whether the bleeding consequences of the thienopyridines are attributed only to the inhibition of P2Y12.  Data indicated greater (elinogrel) and decreased (thienopyridines) TI compared with that in P2Y12(-/-) mice.  The impaired TI assocd. with the thienopyridines was not attributed to non-P2Y12 activities on platelet function or coagulation but was related to a direct effect at the vessel wall (inhibition of vascular tone).  Further anal. showed that the prasugrel off-target effect was dose- and time-dependent and of a reversible nature.  In conclusion, the TI of thienopyridines in the mouse may be decreased by P2Y12-independent off-target effects at the vessel wall, whereas that of elinogrel may be enhanced by the reversible, competitive nature of the antiplatelet agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4BcD1er_e7Vg90H21EOLACvtfcHk0lhNaCr9K92szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D&md5=b2cd05a85e0988416608e5b2af2ea976</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178574%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DP.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DThienopyridines%252C%2520but%2520not%2520elinogrel%252C%2520result%2520in%2520off-target%2520effects%2520at%2520the%2520vessel%2520wall%2520that%2520contribute%2520to%2520bleeding%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D22%26epage%3D30%26doi%3D10.1124%2Fjpet.110.178574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Caroff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilpert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riederer, M. A.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4323</span><span class="NLM_x">–</span> <span class="NLM_lpage">4331</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2Fj.bmcl.2014.06.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4323-4331&author=E.+Caroffauthor=E.+Meyerauthor=A.+Treiberauthor=K.+Hilpertauthor=M.+A.+Riederer&title=Optimization+of+2-phenyl-pyrimidine-4-carboxamides+towards+potent%2C+orally+bioavailable+and+selective+P2Y12+antagonists+for+inhibition+of+platelet+aggregation&doi=10.1016%2Fj.bmcl.2014.06.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DRiederer%26aufirst%3DM.%2BA.%26atitle%3DOptimization%2520of%25202-phenyl-pyrimidine-4-carboxamides%2520towards%2520potent%252C%2520orally%2520bioavailable%2520and%2520selective%2520P2Y12%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4323%26epage%3D4331%26doi%3D10.1016%2Fj.bmcl.2014.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Paleo, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurrecoechea, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, H.</span><span> </span><span class="NLM_article-title">Formal Enantiospecific Synthesis of (+)-FR900482</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1021/jo0206521</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0206521" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFGhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=130-138&author=M.+R.+Paleoauthor=N.+Aurrecoecheaauthor=K.-Y.+Jungauthor=H.+Rapoport&title=Formal+Enantiospecific+Synthesis+of+%28%2B%29-FR900482&doi=10.1021%2Fjo0206521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Formal Enantiospecific Synthesis of (+)-FR900482</span></div><div class="casAuthors">Paleo, M. Rita; Aurrecoechea, Natalia; Jung, Kang-Yeoun; Rapoport, Henry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enantiospecific synthesis of FK973, and thus a formal enantiospecific synthesis of the antitumor antibiotic (+)-FR900482, is reported.  Addn. of an aniline to a chiral epoxide, prepd. from L-vinylglycine, afforded amino alc. I (R1 = CH2OMe, R2 = CO2CH2Ph).  After protection of the aliph. nitrogen with the 9-phenylfluoren-9-yl group, to preserve the acidic stereocenter from racemization, formation of the aziridine and intramol. condensation under basic conditions gave an azocinone.  Hydroxymethylation at the benzylic position was achieved by a process involving methylenation, epoxidn., and hydrogenolysis; the abs. stereochem. of the resulting alc. II (R1 = CH2OMe, R2 = SO2Ph) was detd. by X-ray crystallog. anal.  The hydroxyl group of II (R1 = CH2OMe, R2 = SO2Ph) was carbamoylated, and the arom. amine was deprotected electrochem. and then oxidized to give an unstable hydroxylamine that was immediately protected as an acetate.  Oxidn. with DMP, followed by hydrazinolysis of the acetyl group led to spontaneous closure of the resulting N-hydroxyamino ketone to hemiketal III (R1 = CH2OMe, R2 = CONH2) , which can be considered as a fully protected precursor of FR900482 and derivs.  Acid treatment to remove the protecting groups and acetylation afforded the triacetate FK973.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3-lmpWcqr7Vg90H21EOLACvtfcHk0lhNaCr9K92szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFGhtr8%253D&md5=57f0fc325922d9b7ef512573b180f16a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo0206521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0206521%26sid%3Dliteratum%253Aachs%26aulast%3DPaleo%26aufirst%3DM.%2BR.%26aulast%3DAurrecoechea%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DK.-Y.%26aulast%3DRapoport%26aufirst%3DH.%26atitle%3DFormal%2520Enantiospecific%2520Synthesis%2520of%2520%2528%252B%2529-FR900482%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D130%26epage%3D138%26doi%3D10.1021%2Fjo0206521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">McKenna, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higa, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenna, M.-C.</span><span> </span><span class="NLM_article-title">The facile dealkylation of phosphonic acid dialkyl esters by bromotrimethylsilane</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)92575-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS0040-4039%2801%2992575-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1977&pages=155-158&issue=2&author=C.+E.+McKennaauthor=M.+T.+Higaauthor=N.+H.+Cheungauthor=M.-C.+McKenna&title=The+facile+dealkylation+of+phosphonic+acid+dialkyl+esters+by+bromotrimethylsilane&doi=10.1016%2FS0040-4039%2801%2992575-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2992575-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252992575-4%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenna%26aufirst%3DC.%2BE.%26aulast%3DHiga%26aufirst%3DM.%2BT.%26aulast%3DCheung%26aufirst%3DN.%2BH.%26aulast%3DMcKenna%26aufirst%3DM.-C.%26atitle%3DThe%2520facile%2520dealkylation%2520of%2520phosphonic%2520acid%2520dialkyl%2520esters%2520by%2520bromotrimethylsilane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1977%26volume%3D18%26issue%3D2%26spage%3D155%26epage%3D158%26doi%3D10.1016%2FS0040-4039%2801%2992575-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Demko, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">Preparation of 5-Substituted 1<i>H</i>-Tetrazoles from Nitriles in Water</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7945</span><span class="NLM_x">–</span> <span class="NLM_lpage">7950</span><span class="refDoi"> DOI: 10.1021/jo010635w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo010635w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVCisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=7945-7950&author=Z.+P.+Demkoauthor=K.+B.+Sharpless&title=Preparation+of+5-Substituted+1H-Tetrazoles+from+Nitriles+in+Water&doi=10.1021%2Fjo010635w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of 5-Substituted 1H-Tetrazoles from Nitriles in Water</span></div><div class="casAuthors">Demko, Zachary P.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7945-7950</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The addn. of sodium azide to nitriles to give 1H-tetrazoles is shown to proceed readily in water with zinc salts as catalysts.  The scope of the reaction is quite broad; a variety of arom. nitriles, activated and unactivated alkyl nitriles, substituted vinyl nitriles, thiocyanates, and cyanamides have all been shown to be viable substrates for this reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8fxTzqdjUrVg90H21EOLACvtfcHk0lhNaCr9K92szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVCisrc%253D&md5=c3f4e249316b4b0a52f604e3962048b2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjo010635w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo010635w%26sid%3Dliteratum%253Aachs%26aulast%3DDemko%26aufirst%3DZ.%2BP.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DPreparation%2520of%25205-Substituted%25201H-Tetrazoles%2520from%2520Nitriles%2520in%2520Water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D7945%26epage%3D7950%26doi%3D10.1021%2Fjo010635w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamiya, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naka, T.</span><span> </span><span class="NLM_article-title">Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">5228</span><span class="NLM_x">–</span> <span class="NLM_lpage">5235</span><span class="refDoi"> DOI: 10.1021/jm960547h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960547h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK28XntFaqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=5228-5235&author=Y.+Koharaauthor=K.+Kuboauthor=E.+Imamiyaauthor=T.+Wadaauthor=Y.+Inadaauthor=T.+Naka&title=Synthesis+and+Angiotensin+II+Receptor+Antagonistic+Activities+of+Benzimidazole+Derivatives+Bearing+Acidic+Heterocycles+as+Novel+Tetrazole+Bioisosteres&doi=10.1021%2Fjm960547h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres</span></div><div class="casAuthors">Kohara, Yasuhisa; Kubo, Keiji; Imamiya, Eiko; Wada, Takeo; Inada, Yoshiyuki; Naka, Takehiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5228-5235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. activity of benzimidazole-7-carboxylic acids bearing 5-oxo-1,2,4-oxadiazole, 5-oxo-1,2,4-thiadiazole, 5-thioxo-1,2,4-oxadiazole, and 2-oxo-1,2,3,5-oxathiadiazole rings are described.  The compds. were evaluated for in vitro and in vivo angiotensin II (AII) receptor antagonistic activities.  Most were found to have high affinity for the AT1 receptor (IC50 value, 10-6-10-7M) and to inhibit the AII-induced pressor response (more than 50% inhibition at 1 mg/kg po).  The 5-oxo-1,2,4-oxadiazole, 5-oxo-1,2,4-thiadiazole, and 5-thioxo-1,2,4-oxadiazole derivs. showed stronger inhibitory effects than the corresponding tetrazole derivs., while their binding affinities were weaker.  This might be ascribed to their improved bioavailability by increased lipophilicity.  This study showed that the 5-oxo-1,2,4-oxadiazole ring and its thio analog, the 5-oxo-1,2,4-thiadiazole ring, could be lipophilic bioisosteres for the tetrazole ring in nonpeptide AII receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoflmfjZbY2Z7Vg90H21EOLACvtfcHk0lhYW7-xG7sOkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntFaqsrY%253D&md5=a15b09f2dc98923ec961c3f22df99e40</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm960547h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960547h%26sid%3Dliteratum%253Aachs%26aulast%3DKohara%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DImamiya%26aufirst%3DE.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DY.%26aulast%3DNaka%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Angiotensin%2520II%2520Receptor%2520Antagonistic%2520Activities%2520of%2520Benzimidazole%2520Derivatives%2520Bearing%2520Acidic%2520Heterocycles%2520as%2520Novel%2520Tetrazole%2520Bioisosteres%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D5228%26epage%3D5235%26doi%3D10.1021%2Fjm960547h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tachibana, K.; Sato, H.; Ohta, M.; Nakamura, M.; Shiraishi, T.; Imaoka, I.; Yoshino, H.; Nagamuta, M.; Kawata, H.</span><span> </span><span class="NLM_article-title">Imidazoline Derivative</span>. EP1634874, March 15,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>22 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=K.+Tachibana&author=H.+Sato&author=M.+Ohta&author=M.+Nakamura&author=T.+Shiraishi&author=I.+Imaoka&author=H.+Yoshino&author=M.+Nagamuta&author=H.+Kawata&title=Imidazoline+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DK.%26atitle%3DImidazoline%2520Derivative%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Smet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckert, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieruszeski, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landrieu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buée, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déprez, B.</span><span> </span><span class="NLM_article-title">Control of Protein–Protein Interactions: Structure-Based Discovery of Low Molecular Weight Inhibitors of the Interactions between Pin1 WW Domain and Phosphopeptides</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4815</span><span class="NLM_x">–</span> <span class="NLM_lpage">4823</span><span class="refDoi"> DOI: 10.1021/jm0500119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4815-4823&author=C.+Smetauthor=J.-F.+Duckertauthor=J.-M.+Wieruszeskiauthor=I.+Landrieuauthor=L.+Bu%C3%A9eauthor=G.+Lippensauthor=B.+D%C3%A9prez&title=Control+of+Protein%E2%80%93Protein+Interactions%3A+Structure-Based+Discovery+of+Low+Molecular+Weight+Inhibitors+of+the+Interactions+between+Pin1+WW+Domain+and+Phosphopeptides&doi=10.1021%2Fjm0500119"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm0500119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500119%26sid%3Dliteratum%253Aachs%26aulast%3DSmet%26aufirst%3DC.%26aulast%3DDuckert%26aufirst%3DJ.-F.%26aulast%3DWieruszeski%26aufirst%3DJ.-M.%26aulast%3DLandrieu%26aufirst%3DI.%26aulast%3DBu%25C3%25A9e%26aufirst%3DL.%26aulast%3DLippens%26aufirst%3DG.%26aulast%3DD%25C3%25A9prez%26aufirst%3DB.%26atitle%3DControl%2520of%2520Protein%25E2%2580%2593Protein%2520Interactions%253A%2520Structure-Based%2520Discovery%2520of%2520Low%2520Molecular%2520Weight%2520Inhibitors%2520of%2520the%2520Interactions%2520between%2520Pin1%2520WW%2520Domain%2520and%2520Phosphopeptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4815%26epage%3D4823%26doi%3D10.1021%2Fjm0500119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Storer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aciro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Squaramides: physical properties, synthesis and applications</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2330</span><span class="NLM_x">–</span> <span class="NLM_lpage">2346</span><span class="refDoi"> DOI: 10.1039/c0cs00200c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1039%2Fc0cs00200c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=21399835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC3MvksVyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=2330-2346&author=R.+I.+Storerauthor=C.+Aciroauthor=L.+H.+Jones&title=Squaramides%3A+physical+properties%2C+synthesis+and+applications&doi=10.1039%2Fc0cs00200c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramides: physical properties, synthesis and applications</span></div><div class="casAuthors">Storer R Ian; Aciro Caroline; Jones Lyn H</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2330-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Squaramides are remarkable four-membered ring systems derived from squaric acid that are able to form up to four hydrogen bonds.  A high affinity for hydrogen bonding is driven through a concomitant increase in aromaticity of the ring.  This hydrogen bonding and aromatic switching, in combination with structural rigidity, have been exploited in many of the applications of squaramides.  Substituted squaramides can be accessed via modular synthesis under relatively mild or aqueous conditions, making them ideal units for bioconjugation and supramolecular chemistry.  In this tutorial review the fundamental electronic and structural properties of squaramides are explored to rationalise the geometry, conformation, reactivity and biological activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4YxJCB1T0gysZ1x6zOs0vfW6udTcc2ebq3AwYKGgXqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvksVyntw%253D%253D&md5=503557e25e8120c895a56f78c9a19285</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fc0cs00200c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cs00200c%26sid%3Dliteratum%253Aachs%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DAciro%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DSquaramides%253A%2520physical%2520properties%252C%2520synthesis%2520and%2520applications%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D2330%26epage%3D2346%26doi%3D10.1039%2Fc0cs00200c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Malachowski, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coward, J. K.</span><span> </span><span class="NLM_article-title">The Chemistry of Phosphapeptides: Investigations on the Synthesis of Phosphonamidate, Phosphonate, and Phosphinate Analogs of Glutamyl-.gamma.-glutamate</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7625</span><span class="NLM_x">–</span> <span class="NLM_lpage">7634</span><span class="refDoi"> DOI: 10.1021/jo00104a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00104a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1994&pages=7625-7634&author=W.+P.+Malachowskiauthor=J.+K.+Coward&title=The+Chemistry+of+Phosphapeptides%3A+Investigations+on+the+Synthesis+of+Phosphonamidate%2C+Phosphonate%2C+and+Phosphinate+Analogs+of+Glutamyl-.gamma.-glutamate&doi=10.1021%2Fjo00104a017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00104a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00104a017%26sid%3Dliteratum%253Aachs%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DCoward%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520Chemistry%2520of%2520Phosphapeptides%253A%2520Investigations%2520on%2520the%2520Synthesis%2520of%2520Phosphonamidate%252C%2520Phosphonate%252C%2520and%2520Phosphinate%2520Analogs%2520of%2520Glutamyl-.gamma.-glutamate%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1994%26volume%3D59%26spage%3D7625%26epage%3D7634%26doi%3D10.1021%2Fjo00104a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, C. A.</span><span> </span><span class="NLM_article-title">Total syntheses of (−)-nocardicins A-G: a biogenetic approach</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span><span class="refDoi"> DOI: 10.1021/ja00158a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00158a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=760-770&author=G.+M.+Salituroauthor=C.+A.+Townsend&title=Total+syntheses+of+%28%E2%88%92%29-nocardicins+A-G%3A+a+biogenetic+approach&doi=10.1021%2Fja00158a040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja00158a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00158a040%26sid%3Dliteratum%253Aachs%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DTownsend%26aufirst%3DC.%2BA.%26atitle%3DTotal%2520syntheses%2520of%2520%2528%25E2%2588%2592%2529-nocardicins%2520A-G%253A%2520a%2520biogenetic%2520approach%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D760%26epage%3D770%26doi%3D10.1021%2Fja00158a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Yamaguchi, J.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, M.</span><span> </span><span class="NLM_article-title">Facile New Method for Preparation of Optically Active Protected Proline</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span><span class="refDoi"> DOI: 10.1246/cl.1996.621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1246%2Fcl.1996.621" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=621-622&author=J.-I.+Yamaguchiauthor=M.+Ueki&title=Facile+New+Method+for+Preparation+of+Optically+Active+Protected+Proline&doi=10.1246%2Fcl.1996.621"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1246%2Fcl.1996.621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1996.621%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DJ.-I.%26aulast%3DUeki%26aufirst%3DM.%26atitle%3DFacile%2520New%2520Method%2520for%2520Preparation%2520of%2520Optically%2520Active%2520Protected%2520Proline%26jtitle%3DChem.%2520Lett.%26date%3D1996%26spage%3D621%26epage%3D622%26doi%3D10.1246%2Fcl.1996.621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgYhIDXZqWOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huryn, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span> </span><span class="NLM_article-title">Carboxylic Acid (Bio)Isosteres in Drug Design</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1002/cmdc.201200585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1002%2Fcmdc.201200585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=23361977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=385-395&author=C.+Ballatoreauthor=D.+M.+Hurynauthor=A.+B.+Smith&title=Carboxylic+Acid+%28Bio%29Isosteres+in+Drug+Design&doi=10.1002%2Fcmdc.201200585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylic Acid (Bio)Isosteres in Drug Design</span></div><div class="casAuthors">Ballatore, Carlo; Huryn, Donna M.; Smith, Amos B.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biol. membranes.  To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres.  The same type of strategy can also be effective for a variety other purposes, for example, to increase the selectivity of a biol. active compd. or to create new intellectual property.  Several carboxylic acid isosteres have been reported, however, the outcome of any isosteric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug-target).  As a result, screening of a panel of isosteres is typically required.  In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research.  The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVEcl3NtfHu7Vg90H21EOLACvtfcHk0lgYhIDXZqWOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCms7g%253D&md5=cff8233af1c386439789a0e4ebcb4331</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200585%26sid%3Dliteratum%253Aachs%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26atitle%3DCarboxylic%2520Acid%2520%2528Bio%2529Isosteres%2520in%2520Drug%2520Design%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D385%26epage%3D395%26doi%3D10.1002%2Fcmdc.201200585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">p<i>K</i><sub>a</sub> values were predicted using ACD/pKa DB software.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">Predicted p<i>K</i><sub>a</sub> values of phosphonate-containing analogs are the following: <b>30c</b> and <b>30d</b>, 1.38 and 7.39; <b>30h</b>, 2.23 and 7.81.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Baldoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruderer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueret, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astruc, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial</span> <span class="citation_source-journal">Clin. Drug Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">818</span><span class="refDoi"> DOI: 10.1007/s40261-014-0236-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs40261-014-0236-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25331625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=807-818&author=D.+Baldoniauthor=S.+Brudererauthor=A.+Krauseauthor=M.+Gutierrezauthor=P.+Gueretauthor=B.+Astrucauthor=J.+Dingemanse&title=A+New+Reversible+and+Potent+P2Y12+Receptor+Antagonist+%28ACT-246475%29%3A+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+in+a+First-in-Man+Trial&doi=10.1007%2Fs40261-014-0236-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial</span></div><div class="casAuthors">Baldoni, Daniela; Bruderer, Shirin; Krause, Andreas; Gutierrez, Marcello; Gueret, Pierre; Astruc, Beatrice; Dingemanse, Jasper</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">807-818</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and objectives: ACT-246475 is a new reversible, selective, and potent antagonist of the platelet P2Y12 receptor.  This study was a first-in-man trial investigating the tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of ACT-246475 and its di-ester prodrug (ACT-281959) in healthy males.  Methods: The study had a double-blind, randomized, ascending single-dose design with an oral formulation F1 (i.e., ACT-281959 or placebo) (Part I) and an open-label, randomized, 3-period, crossover design comparing exploratory formulations of ACT-281959 (F2) 70 mg and ACT-246475 (dF) 50 mg to F1 70 mg (Part II).  In Part I, doses up to 1,000 mg were tested in 40 healthy subjects.  Nine healthy subjects were enrolled in Part II.  Std. safety parameters, inhibition of platelet aggregation, and ACT-246475 plasma concns. were measured.  Non-compartmental pharmacokinetic anal. was performed.  Results: All doses and formulations were well tolerated.  The most frequent adverse event was headache, whereas no events of bleeding or dyspnea were reported.  In Part I, ACT-246475 area under the plasma concn.-time curve (AUC) increased dose-proportionally whereas max. plasma concn. (Cmax) was less than dose-proportional.  The highest Cmax [geometric mean (95 % CI)] at 1,000 mg was 13.8 (9.7, 19.5) pmol/mL at 4.5 h post-dose, terminal half-life (t1/2) was ∼10 h.  ACT-246475 Cmax and AUC0-inf ratios of geometric means (90 % CI) using F1 as ref., for F2 were 8.5 (5.42, 13.35) and 3.4 (2.40, 4.82), resp., and for dF 2.2 (1.42, 3.49) and 1.5 (1.07, 2.16), resp.  Mean peak platelet inhibition was 31.0 % after F1 (1,000 mg) and 47.8 % after F2.  Conclusions: Oral doses of ACT-281959 and ACT-246475 were well tolerated.  Platelet inhibition correlated with ACT-246475 exposure.  Exploratory formulations enhanced the bioavailability and antiplatelet effect of ACT-246475.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjNomBWwqfbVg90H21EOLACvtfcHk0lgYhIDXZqWOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrL&md5=075586f2b8a49365319bd1d1c03bdbf0</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40261-014-0236-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-014-0236-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaldoni%26aufirst%3DD.%26aulast%3DBruderer%26aufirst%3DS.%26aulast%3DKrause%26aufirst%3DA.%26aulast%3DGutierrez%26aufirst%3DM.%26aulast%3DGueret%26aufirst%3DP.%26aulast%3DAstruc%26aufirst%3DB.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DA%2520New%2520Reversible%2520and%2520Potent%2520P2Y12%2520Receptor%2520Antagonist%2520%2528ACT-246475%2529%253A%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520in%2520a%2520First-in-Man%2520Trial%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2014%26volume%3D34%26spage%3D807%26epage%3D818%26doi%3D10.1007%2Fs40261-014-0236-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="note"><p class="first last">The effect of the compounds on the hERG K<sup>+</sup> channel was evaluated using manual patch-clamp of HEK-hERG cells at 37 °C. Compounds were first tested near their limit of solubility in the assay solution (150 mM NaCl; 4 mM KCl; 1.2 mM CaCl<sub>2</sub>; 1 mM MgCl<sub>2</sub>; 10 mM HEPES; pH 7.4), and concentration–response curves were determined if current block exceeded 20%.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">Inhibition of the major human cytochrome P450 enzymes was investigated using human liver microsomes and P450 isoform-specific marker reactions. Diclofenac 4′-hydroxylation and dextromethorphan O-demethylation were used for CYP2C9 and CYP2D6, respectively. CYP3A4 inhibition was tested using midazolam 1′-hydroxylation and testosterone 6β-hydroxylation as markers. Inhibition experiments were performed at a single substrate concentration around the respective <i>K</i><sub>m</sub> value of each P450 marker. Eight inhibitor concentrations up to 50 μM were used and all experiments performed in duplicate under linear enzyme kinetic conditions. Organic solvent content in none of the experiments exceeded 1.1%. Sulfaphenazole, fluoxetine, and nicardipine were use as positive controls with the test compounds. Metabolite formation was monitored using liquid chromatography (Shimadzu LC-10AD VP pumps, SCL-10A VP system controller, and an HTS PAL autosampler, Shimadzu AG, Reinach, Switzerland) coupled to triple stage mass spectrometer (API2000 and API4000, AB SCIEX, Concord, Ontario, Canada, or TSQ Quantum, Thermo Electron Corporation, Waltham, MA, U.S.). Data acquisition was done using the Analyst (version 1.5 for API2000 and version 1.5.1 for API4000) or Xcalibur (TSQ Quantum, version 1.3) software packages. Data of the inhibition experiments were evaluated by plotting the inhibitor concentration (logarithmic scale) against the metabolite formation rates. IC<sub>50</sub> values were then determined from the plot by nonlinear regression using the following equation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b00933/20151204/images/jm-2015-00933e_m001.gif" alt="" /></img></span>where <i>y</i> is the rate of metabolite formation, <i>x</i> is the inhibitor concentration, <i>s</i> is the slope at the point of inversion, and Top and Bottom are the maximum and minimum rates of metabolite formation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Krise, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, V. J.</span><span> </span><span class="NLM_article-title">Prodrugs of Phosphates, Phosphonates and Phosphinates</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span><span class="refDoi"> DOI: 10.1016/0169-409X(95)00111-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2F0169-409X%2895%2900111-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1996&pages=287-310&author=J.+P.+Kriseauthor=V.+J.+Stella&title=Prodrugs+of+Phosphates%2C+Phosphonates+and+Phosphinates&doi=10.1016%2F0169-409X%2895%2900111-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0169-409X%2895%2900111-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-409X%252895%252900111-J%26sid%3Dliteratum%253Aachs%26aulast%3DKrise%26aufirst%3DJ.%2BP.%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DProdrugs%2520of%2520Phosphates%252C%2520Phosphonates%2520and%2520Phosphinates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1996%26volume%3D19%26spage%3D287%26epage%3D310%26doi%3D10.1016%2F0169-409X%2895%2900111-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">He, G.-X.; Krise, J. P.; Oliyai, R.</span><span> </span><span class="NLM_article-title">Prodrugs of Phosphonates, Phosphinates, and Phosphates</span>. In  <span class="citation_source-book">Prodrugs: Challenges and Rewards Part 2</span>; <span class="NLM_contrib-group">Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J. W.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2F978-0-387-49785-3_25" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=223-264&author=G.-X.+He&author=J.+P.+Krise&author=R.+Oliyaiauthor=V.+J.+Stella&author=R.+T.+Borchardt&author=M.+J.+Hageman&author=R.+Oliyai&author=H.+Maag&author=J.+W.+Tilley&title=Prodrugs%3A+Challenges+and+Rewards+Part+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-49785-3_25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-49785-3_25%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DG.-X.%26atitle%3DProdrugs%2520of%2520Phosphonates%252C%2520Phosphinates%252C%2520and%2520Phosphates%26btitle%3DProdrugs%253A%2520Challenges%2520and%2520Rewards%2520Part%25202%26aulast%3DStella%26aufirst%3DV.%2BJ.%26pub%3DSpringer%26date%3D2007%26spage%3D223%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><div class="note"><p class="first last"><a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A and <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A:</p></div><span class="NLM_contrib-group">Rey, M.; Kramberg, M.; Cattaneo, C.; Hess, P.; Weber, E.; Ernst, R.; Haag, F.; Morrison, K.; Clozel, M.; Baumann, M.; Caroff, E.; Hubler, F.; Riederer, M. A.; Steiner, B.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Figure+5A+and+Figure+6A%3ARey%2C+M.%3B+Kramberg%2C+M.%3B+Cattaneo%2C+C.%3B+Hess%2C+P.%3B+Weber%2C+E.%3B+Ernst%2C+R.%3B+Haag%2C+F.%3B+Morrison%2C+K.%3B+Clozel%2C+M.%3B+Baumann%2C+M.%3B+Caroff%2C+E.%3B+Hubler%2C+F.%3B+Riederer%2C+M.+A.%3B+Steiner%2C+B.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Born, G. V.</span><span> </span><span class="NLM_article-title">Aggregation of blood platelets by adenosine diphosphate and its reversal</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">929</span><span class="refDoi"> DOI: 10.1038/194927b0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1038%2F194927b0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=1962&pages=927-929&author=G.+V.+Born&title=Aggregation+of+blood+platelets+by+adenosine+diphosphate+and+its+reversal&doi=10.1038%2F194927b0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2F194927b0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F194927b0%26sid%3Dliteratum%253Aachs%26aulast%3DBorn%26aufirst%3DG.%2BV.%26atitle%3DAggregation%2520of%2520blood%2520platelets%2520by%2520adenosine%2520diphosphate%2520and%2520its%2520reversal%26jtitle%3DNature%26date%3D1962%26volume%3D194%26spage%3D927%26epage%3D929%26doi%3D10.1038%2F194927b0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Gast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschopp, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilpert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackermann, J.</span><span> </span><span class="NLM_article-title">Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma</span> <span class="citation_source-journal">Blood Coagulation Fibrinolysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span><span class="refDoi"> DOI: 10.1097/00001721-199412000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1097%2F00001721-199412000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=7893925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK2MXktlaqurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1994&pages=879-887&author=A.+Gastauthor=T.+B.+Tschoppauthor=G.+Schmidauthor=K.+Hilpertauthor=J.+Ackermann&title=Inhibition+of+clot-bound+and+free+%28fluid-phase+thrombin%29+by+a+novel+synthetic+thrombin+inhibitor+%28Ro+46-6240%29%2C+recombinant+hirudin+and+heparin+in+human+plasma&doi=10.1097%2F00001721-199412000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of clot-bound and free (fluid-phase) thrombin by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma</span></div><div class="casAuthors">Gast, A.; Tschopp, T. B.; Schmid, G.; Hilpert, K.; Ackermann, J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Coagulation & Fibrinolysis</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">879-87</span>CODEN:
                <span class="NLM_cas:coden">BLFIE7</span>;
        ISSN:<span class="NLM_cas:issn">0957-5235</span>.
    </div><div class="casAbstract">Clot-bound thrombin remains active and is less accessible to heparin-antithrombin III than fluid-phase thrombin.  To det. whether clot-bound human thrombin is more susceptible to inactivation by direct thrombin inhibitors, the activity of a novel synthetic competitive thrombin inhibitor Ro 46-6240, recombinant hirudin and unfractionated heparin were compared with fluid-phase thrombin and clot-bound thrombin.  Fibrinopeptide A generated in human plasma was used as an index of thrombin activity.  Hirudin was the most potent inhibitor of fluid-phase and clot-bound thrombin.  However, Ro 46-6240 inhibited clot-bound thrombin three times more potently than fluid-phase thrombin (IC50 19 vs. 56 ng/mL) while hirudin was two times (IC50 8 vs. 3 ng/mL) and heparin six times (IC50 1205 vs. 200 ng/mL) less active against clot-bound thrombin compared with fluid-phase thrombin.  The relative selectivity for clot-bound thrombin is not a unique property of Ro 46-6240 since two other synthetic thrombin inhibitors tested inhibited clot-bound thrombin more effectively than fluid-phase thrombin and a third was equally active against both forms of thrombin.  In contrast, the affinities of two chromogenic substrates were similar for both forms of thrombin.  This study shows that direct thrombin inhibitors inhibit clot-bound thrombin more potently than heparin and suggests that an apparent selectivity for clot-bound thrombin can be achieved with some synthetic thrombin inhibitors.  Further studies have to show whether the high potency of these direct thrombin inhibitors translates into antithrombotic efficacy in clin. situations with pre-existing clots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvG755XEMfNLVg90H21EOLACvtfcHk0ljfubrzW5K59g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktlaqurw%253D&md5=23c1fe6f92488664a18f5ed1cc6fdc69</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2F00001721-199412000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001721-199412000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGast%26aufirst%3DA.%26aulast%3DTschopp%26aufirst%3DT.%2BB.%26aulast%3DSchmid%26aufirst%3DG.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DAckermann%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520clot-bound%2520and%2520free%2520%2528fluid-phase%2520thrombin%2529%2520by%2520a%2520novel%2520synthetic%2520thrombin%2520inhibitor%2520%2528Ro%252046-6240%2529%252C%2520recombinant%2520hirudin%2520and%2520heparin%2520in%2520human%2520plasma%26jtitle%3DBlood%2520Coagulation%2520Fibrinolysis%26date%3D1994%26volume%3D5%26spage%3D879%26epage%3D887%26doi%3D10.1097%2F00001721-199412000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Teng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1007/s00228-009-0778-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1007%2Fs00228-009-0778-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=487-496&author=R.+Tengauthor=K.+Butler&title=Pharmacokinetics%2C+pharmacodynamics%2C+tolerability+and+safety+of+single+ascending+doses+of+ticagrelor%2C+a+reversibly+binding+oral+P2Y%2812%29+receptor+antagonist%2C+in+healthy+subjects&doi=10.1007%2Fs00228-009-0778-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00228-009-0778-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-009-0778-5%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DK.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%2520and%2520safety%2520of%2520single%2520ascending%2520doses%2520of%2520ticagrelor%252C%2520a%2520reversibly%2520binding%2520oral%2520P2Y%252812%2529%2520receptor%2520antagonist%252C%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D66%26spage%3D487%26epage%3D496%26doi%3D10.1007%2Fs00228-009-0778-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Kurz, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Main, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandusky, G. E.</span><span> </span><span class="NLM_article-title">Rat model of arterial thrombosis induced by ferric chloride</span> <span class="citation_source-journal">Thromb. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1016/0049-3848(90)90106-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2F0049-3848%2890%2990106-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=2087688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1990&pages=269-280&author=K.+D.+Kurzauthor=B.+W.+Mainauthor=G.+E.+Sandusky&title=Rat+model+of+arterial+thrombosis+induced+by+ferric+chloride&doi=10.1016%2F0049-3848%2890%2990106-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Rat model of arterial thrombosis induced by ferric chloride</span></div><div class="casAuthors">Kurz, K. D.; Main, B. W.; Sandusky, G. E.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">269-80</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    </div><div class="casAbstract">The purposes of these studies were to produce a small animal model of arterial thrombosis for study of novel antithrombotic agents, to validate a simple temp. index of occlusive thrombosis, and to describe the compn. of the thrombus.  Small thermocouple transducers were fabricated from readily available materials.  A thermocouple was inserted under a carotid artery of the anesthetized rat and vessel temp. was recorded continuously.  Arterial injury was induced by FeCl3 soln. applied topically to the artery above the thermocouple.  To validate the relationship between thrombotic occlusion and vessel temp., blood flow velocity, proximal to the injury, and temp. were recorded simultaneously.  Temp. decreased rapidly when velocity averaged 24 ± 12 percent of control and velocity did not differ from zero within 20 s.  In normal vessels, av. flow velocity did not decrease significantly from control until a fixed stenosis decreased diam. by 78 percent.  Av. time to occlusion (TTO), signaled by the abrupt temp. inflection, ranged from 56 ± 4 min to 14 ± 1 min after 10 and 65 percent FeCl3 application resp.  Vessel segments were fixed at various times after FeCl3 exposure and examd. by SEM.  Endothelial damage was obsd. and was assocd. with thrombus composed of activated platelets, fibrin strands and entrapped erythrocytes.  The results demonstrate that FeCl3 dose-dependently induced formation of an occlusive mixed thrombus that was indexed by monitoring the time between FeCl3 application and a rapid temp. decrease in the carotid artery of the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLLjIq2Kf2LVg90H21EOLACvtfcHk0ljfubrzW5K59g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyhsw%253D%253D&md5=896dc87d899d88e9b76f916b3245825e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0049-3848%2890%2990106-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0049-3848%252890%252990106-M%26sid%3Dliteratum%253Aachs%26aulast%3DKurz%26aufirst%3DK.%2BD.%26aulast%3DMain%26aufirst%3DB.%2BW.%26aulast%3DSandusky%26aufirst%3DG.%2BE.%26atitle%3DRat%2520model%2520of%2520arterial%2520thrombosis%2520induced%2520by%2520ferric%2520chloride%26jtitle%3DThromb.%2520Res.%26date%3D1990%26volume%3D60%26spage%3D269%26epage%3D280%26doi%3D10.1016%2F0049-3848%2890%2990106-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Liu, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, H.-X.</span><span> </span><span class="NLM_article-title">Pre-treatment with puerarin affects pharmacokinetics of warfarin, but not clopidogrel, in experimental rats</span> <span class="citation_source-journal">Chin. J. Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1016/S1875-5364(15)30012-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS1875-5364%2815%2930012-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=25908622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjns12qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=257-263&author=A.-C.+Liuauthor=L.-X.+Zhaoauthor=S.-W.+Yuauthor=H.-X.+Lou&title=Pre-treatment+with+puerarin+affects+pharmacokinetics+of+warfarin%2C+but+not+clopidogrel%2C+in+experimental+rats&doi=10.1016%2FS1875-5364%2815%2930012-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-treatment with puerarin affects pharmacokinetics of warfarin, but not clopidogrel, in experimental rats</span></div><div class="casAuthors">Liu An-Chang; Zhao Li-Xia; Yu Shu-Wen; Lou Hong-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Chinese journal of natural medicines</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present study was designed to determine the effects of puerarin pre-treatment on the pharmacokinetics of the oral anticoagulant agent warfarin and the antiplatelet agent clopidogrel in rats.  In the treatment group, rats was gavaged with warfarin or clopidogrel after repeated treatment with puerarin at intraperitoneal doses of 20, 60, or 200 mg·kg(-1) for 7 days, while rats in the control group were administrated only with the same dose warfarin or clopidogrel.  Plasma samples were obtained at the prescribed times and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS).  The results showed that rats treated with puerarin at all the test doses of 20, 60 and 200 mg·kg(-1) were found to affect the pharmacokinetics of warfarin, but not clopidogrel, suggesting a potential herb-drug interaction between puerarin and warfarin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfO_dqKAdP2YHWj6b1v8uTfW6udTcc2eY7h50Hu5Kx-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjns12qsA%253D%253D&md5=d0edfefcbb99be77d7c1dc064df74651</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1875-5364%2815%2930012-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1875-5364%252815%252930012-1%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.-C.%26aulast%3DZhao%26aufirst%3DL.-X.%26aulast%3DYu%26aufirst%3DS.-W.%26aulast%3DLou%26aufirst%3DH.-X.%26atitle%3DPre-treatment%2520with%2520puerarin%2520affects%2520pharmacokinetics%2520of%2520warfarin%252C%2520but%2520not%2520clopidogrel%252C%2520in%2520experimental%2520rats%26jtitle%3DChin.%2520J.%2520Nat.%2520Med.%26date%3D2015%26volume%3D13%26spage%3D257%26epage%3D263%26doi%3D10.1016%2FS1875-5364%2815%2930012-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Descamps, M.; Radisson, J.</span><span> </span><span class="NLM_article-title">Process for the preparation of an N-phenylacetic derivative of tetrahydrothieno(3,2-c)pyridine and its chemical intermediate</span>. US5204469,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=M.+Descamps&author=J.+Radisson&title=Process+for+the+preparation+of+an+N-phenylacetic+derivative+of+tetrahydrothieno%283%2C2-c%29pyridine+and+its+chemical+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDescamps%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520preparation%2520of%2520an%2520N-phenylacetic%2520derivative%2520of%2520tetrahydrothieno%25283%252C2-c%2529pyridine%2520and%2520its%2520chemical%2520intermediate%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Fox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennon, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCague, R.</span><span> </span><span class="NLM_article-title">A Convergent Synthesis of the 11-Oxa Prostaglandin Analogue AL-12182</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1227</span><span class="NLM_x">–</span> <span class="NLM_lpage">1236</span><span class="refDoi"> DOI: 10.1021/jo048035v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo048035v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=1227-1236&author=M.+E.+Foxauthor=M.+Jacksonauthor=I.+C.+Lennonauthor=R.+McCague&title=A+Convergent+Synthesis+of+the+11-Oxa+Prostaglandin+Analogue+AL-12182&doi=10.1021%2Fjo048035v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo048035v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo048035v%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DM.%2BE.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DLennon%26aufirst%3DI.%2BC.%26aulast%3DMcCague%26aufirst%3DR.%26atitle%3DA%2520Convergent%2520Synthesis%2520of%2520the%252011-Oxa%2520Prostaglandin%2520Analogue%2520AL-12182%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D1227%26epage%3D1236%26doi%3D10.1021%2Fjo048035v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Greck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piveteau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genet, J.-P.</span><span> </span><span class="NLM_article-title">Asymmetric synthesis of anti N-Boc-α-hydrazino-β-hydroxyesters from β-ketoesters by sequential catalytic hydrogenation and electrophilic amination</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1993</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1055/s-1993-22496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1055%2Fs-1993-22496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1993&publication_year=1993&pages=475-477&issue=7&author=C.+Greckauthor=L.+Bischoffauthor=F.+Ferreiraauthor=C.+Pinelauthor=E.+Piveteauauthor=J.-P.+Genet&title=Asymmetric+synthesis+of+anti+N-Boc-%CE%B1-hydrazino-%CE%B2-hydroxyesters+from+%CE%B2-ketoesters+by+sequential+catalytic+hydrogenation+and+electrophilic+amination&doi=10.1055%2Fs-1993-22496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1055%2Fs-1993-22496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1993-22496%26sid%3Dliteratum%253Aachs%26aulast%3DGreck%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DF.%26aulast%3DPinel%26aufirst%3DC.%26aulast%3DPiveteau%26aufirst%3DE.%26aulast%3DGenet%26aufirst%3DJ.-P.%26atitle%3DAsymmetric%2520synthesis%2520of%2520anti%2520N-Boc-%25CE%25B1-hydrazino-%25CE%25B2-hydroxyesters%2520from%2520%25CE%25B2-ketoesters%2520by%2520sequential%2520catalytic%2520hydrogenation%2520and%2520electrophilic%2520amination%26jtitle%3DSynlett%26date%3D1993%26volume%3D1993%26issue%3D7%26spage%3D475%26epage%3D477%26doi%3D10.1055%2Fs-1993-22496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bourdreux, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drouillat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greck, C.</span><span> </span><span class="NLM_article-title">Enantio- and diastereoselective syntheses of orthogonally protected anti-2-amino-1,3,4-butanetriols from an achiral β-keto ester</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1055/s-2005-871954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1055%2Fs-2005-871954" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=2086-2088&author=Y.+Bourdreuxauthor=B.+Drouillatauthor=C.+Greck&title=Enantio-+and+diastereoselective+syntheses+of+orthogonally+protected+anti-2-amino-1%2C3%2C4-butanetriols+from+an+achiral+%CE%B2-keto+ester&doi=10.1055%2Fs-2005-871954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-871954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-871954%26sid%3Dliteratum%253Aachs%26aulast%3DBourdreux%26aufirst%3DY.%26aulast%3DDrouillat%26aufirst%3DB.%26aulast%3DGreck%26aufirst%3DC.%26atitle%3DEnantio-%2520and%2520diastereoselective%2520syntheses%2520of%2520orthogonally%2520protected%2520anti-2-amino-1%252C3%252C4-butanetriols%2520from%2520an%2520achiral%2520%25CE%25B2-keto%2520ester%26jtitle%3DSynlett%26date%3D2005%26volume%3D13%26spage%3D2086%26epage%3D2088%26doi%3D10.1055%2Fs-2005-871954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Riess, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laschat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, V.</span><span> </span><span class="NLM_article-title">Evaluation of protecting groups for 3-hydroxyisoxazoles. Short access to 3-alkoxyisoxazole-5-carbaldehydes and 3-hydroxyisoxazole-5-carbaldehyde, the putative toxic metabolite of muscimol</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">1998</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span><span class="refDoi"> DOI: 10.1002/(SICI)1099-0690(199803)1998:3<473::AID-EJOC473>3.0.CO;2-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=473-479&issue=3&author=R.+Riessauthor=M.+Schoenauthor=S.+Laschatauthor=V.+Jaeger&title=Evaluation+of+protecting+groups+for+3-hydroxyisoxazoles.+Short+access+to+3-alkoxyisoxazole-5-carbaldehydes+and+3-hydroxyisoxazole-5-carbaldehyde%2C+the+putative+toxic+metabolite+of+muscimol&doi=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-0690%2528199803%25291998%253A3%253C473%253A%253AAID-EJOC473%253E3.0.CO%253B2-V%26sid%3Dliteratum%253Aachs%26aulast%3DRiess%26aufirst%3DR.%26aulast%3DSchoen%26aufirst%3DM.%26aulast%3DLaschat%26aufirst%3DS.%26aulast%3DJaeger%26aufirst%3DV.%26atitle%3DEvaluation%2520of%2520protecting%2520groups%2520for%25203-hydroxyisoxazoles.%2520Short%2520access%2520to%25203-alkoxyisoxazole-5-carbaldehydes%2520and%25203-hydroxyisoxazole-5-carbaldehyde%252C%2520the%2520putative%2520toxic%2520metabolite%2520of%2520muscimol%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D1998%26volume%3D1998%26issue%3D3%26spage%3D473%26epage%3D479%26doi%3D10.1002%2F%28SICI%291099-0690%28199803%291998%3A3%3C473%3A%3AAID-EJOC473%3E3.0.CO%3B2-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Ornstein, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleisch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borromeo, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugar, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">leander, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoepp, D. D.</span><span> </span><span class="NLM_article-title">Structure–Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2232</span><span class="NLM_x">–</span> <span class="NLM_lpage">2244</span><span class="refDoi"> DOI: 10.1021/jm950913h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950913h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2232-2244&author=P.+L.+Ornsteinauthor=M.+B.+Arnoldauthor=N.+K.+Allenauthor=T.+Bleischauthor=P.+S.+Borromeoauthor=C.+W.+Lugarauthor=J.+D.+leanderauthor=D.+Lodgeauthor=D.+D.+Schoepp&title=Structure%E2%80%93Activity+Studies+of+6-Substituted+Decahydroisoquinoline-3-carboxylic+Acid+AMPA+Receptor+Antagonists.+2.+Effects+of+Distal+Acid+Bioisosteric+Substitution%2C+Absolute+Stereochemical+Preferences%2C+and+in+Vivo+Activity&doi=10.1021%2Fjm950913h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm950913h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950913h%26sid%3Dliteratum%253Aachs%26aulast%3DOrnstein%26aufirst%3DP.%2BL.%26aulast%3DArnold%26aufirst%3DM.%2BB.%26aulast%3DAllen%26aufirst%3DN.%2BK.%26aulast%3DBleisch%26aufirst%3DT.%26aulast%3DBorromeo%26aufirst%3DP.%2BS.%26aulast%3DLugar%26aufirst%3DC.%2BW.%26aulast%3Dleander%26aufirst%3DJ.%2BD.%26aulast%3DLodge%26aufirst%3DD.%26aulast%3DSchoepp%26aufirst%3DD.%2BD.%26atitle%3DStructure%25E2%2580%2593Activity%2520Studies%2520of%25206-Substituted%2520Decahydroisoquinoline-3-carboxylic%2520Acid%2520AMPA%2520Receptor%2520Antagonists.%25202.%2520Effects%2520of%2520Distal%2520Acid%2520Bioisosteric%2520Substitution%252C%2520Absolute%2520Stereochemical%2520Preferences%252C%2520and%2520in%2520Vivo%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2232%26epage%3D2244%26doi%3D10.1021%2Fjm950913h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Croce, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzatti, E.</span><span> </span><span class="NLM_article-title">Stereoselective synthesis of 3-heteroaromatic-substituted alanines</span> <span class="citation_source-journal">Tetrahedron: Asymmetry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2635</span><span class="NLM_x">–</span> <span class="NLM_lpage">2642</span><span class="refDoi"> DOI: 10.1016/S0957-4166(00)00223-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;key=10.1016%2FS0957-4166%2800%2900223-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=2635-2642&author=P.+D.+Croceauthor=C.+La+Rosaauthor=E.+Pizzatti&title=Stereoselective+synthesis+of+3-heteroaromatic-substituted+alanines&doi=10.1016%2FS0957-4166%2800%2900223-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0957-4166%2800%2900223-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0957-4166%252800%252900223-8%26sid%3Dliteratum%253Aachs%26aulast%3DCroce%26aufirst%3DP.%2BD.%26aulast%3DLa%2BRosa%26aufirst%3DC.%26aulast%3DPizzatti%26aufirst%3DE.%26atitle%3DStereoselective%2520synthesis%2520of%25203-heteroaromatic-substituted%2520alanines%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2000%26volume%3D11%26spage%3D2635%26epage%3D2642%26doi%3D10.1016%2FS0957-4166%2800%2900223-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Baudy, R. B.; Butera, J. A.</span><span> </span><span class="NLM_article-title">Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as N-methyl-D-aspartate (NMDA) receptor antagonists</span>. WO 2004/092189,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>21 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=R.+B.+Baudy&author=J.+A.+Butera&title=Derivatives+of+2-%288%2C9-dioxo-2%2C6-diazabicyclo%285.2.0%29non-1%287%29-en-2-yl%29alkyl+phosphonic+acid+and+their+use+as+N-methyl-D-aspartate+%28NMDA%29+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaudy%26aufirst%3DR.%2BB.%26atitle%3DDerivatives%2520of%25202-%25288%252C9-dioxo-2%252C6-diazabicyclo%25285.2.0%2529non-1%25287%2529-en-2-yl%2529alkyl%2520phosphonic%2520acid%2520and%2520their%2520use%2520as%2520N-methyl-D-aspartate%2520%2528NMDA%2529%2520receptor%2520antagonists%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Serafinowska, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harnden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, D.</span><span> </span><span class="NLM_article-title">Synthesis and in Vivo Evaluation of Prodrugs of 9-[2-(Phosphonomethoxy) ethoxy]adenine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1372</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1021/jm00008a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1372-1379&author=H.+T.+Serafinowskaauthor=R.+J.+Ashtonauthor=S.+Baileyauthor=M.+R.+Harndenauthor=S.+M.+Jacksonauthor=D.+Sutton&title=Synthesis+and+in+Vivo+Evaluation+of+Prodrugs+of+9-%5B2-%28Phosphonomethoxy%29+ethoxy%5Dadenine&doi=10.1021%2Fjm00008a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a015%26sid%3Dliteratum%253Aachs%26aulast%3DSerafinowska%26aufirst%3DH.%2BT.%26aulast%3DAshton%26aufirst%3DR.%2BJ.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DHarnden%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DSutton%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520Prodrugs%2520of%25209-%255B2-%2528Phosphonomethoxy%2529%2520ethoxy%255Dadenine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1372%26epage%3D1379%26doi%3D10.1021%2Fjm00008a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00933">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_75110"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00933">10.1021/acs.jmedchem.5b00933</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_001.csv">CSV</a>)</p></li><li><p class="inline">Characterization of all target compounds not described in the main text, synthetic schemes for analogs <b>43</b> and <b>44</b>, and SDs and ranges for the data in <a class="ref internalNav" href="#tbl4">Table 4</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_001.csv">jm5b00933_si_001.csv (4.69 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00933/suppl_file/jm5b00933_si_002.pdf">jm5b00933_si_002.pdf (231.63 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00933%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00933" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c20ad9241234","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
